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Chapter 1 
General introduction 
Laurie M.G. de Kroon 
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Prologue 
Articular cartilage tissue covers bone surfaces in joints where it functions as a cushion 
between moving bones. Damage to this tissue does not heal spontaneously and may 
eventually culminate in the degenerative joint disease osteoarthritis (OA). To prevent 
degeneration of cartilage tissue, cartilage damage should be treated. A promising 
treatment is to regenerate cartilage using mesenchymal stem cells (MSCs) because 
these cells can differentiate into cartilage matrix-forming cells, also called 
chondrocytes, in the presence of appropriate stimulation factors. However, MSC-
derived chondrocytes differentiate into hypertrophic chondrocytes, thereby following 
a developmental process called endochondral ossification. Hypertrophic differentiation 
also occurs in articular chondrocytes of patients with OA. This hypertrophic phenotype 
leads the chondrocytes to degrade the formed cartilage matrix and deposit calcified 
matrix, which negatively influences the integrity of articular cartilage. Chondrogenic 
and hypertrophic differentiation are both regulated by a complex signaling mechanism 
that needs to be further delineated to improve cartilage formation by MSCs and to 
retain the articular cartilage phenotype. Transforming Growth Factor β (TGFβ) has a 
profound role in chondrogenesis and articular cartilage homeostasis. The contribution 
of TGFβ signaling components during generation and degeneration of articular 
cartilage was investigated in this thesis.  
As a background for the work described in this thesis, I will first provide more 
information on articular cartilage, osteoarthritis, regeneration of cartilage using MSCs 
and TGFβ signaling. Secondly, I will discuss the current knowledge on the role of TGFβ 
signaling components in generation and degeneration of cartilage. Finally, at the end 
of this chapter, I will give an outline of this thesis.  
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Articular cartilage 
Articular cartilage is a connective tissue covering subchondral bone in diarthrodial 
joints where it prevents friction and distributes forces between moving bones. It is 
classified as permanent hyaline cartilage as it maintains its function throughout life. 
Transient cartilage is the other class of hyaline cartilage and is present in growth plates 
and embryonic limbs where it transits from cartilage to bone during endochondral 
bone formation.
1
  
The articular cartilage matrix is synthesized and maintained by chondrocytes 
In cartilage only one cell population, the chondrocyte, is present and these cells make 
up about 2% of the total cartilage volume. Chondrocytes are responsible for deposition 
and maintenance of extracellular matrix (ECM). On a weight base, the ECM of articular 
cartilage is mainly composed of collagen fibrils, mostly collagen type II, and 
proteoglycans.
2,3
 Collagen fibrils constrain proteoglycans and provide cartilage’s tensile 
strength. Proteoglycans consist of a core protein to which highly negatively charged 
glycosaminoglycan chains (GAGs) are attached. Aggrecan is the largest of the 
proteoglycans and the most abundant by weight in cartilage.
4
 The negative charge of 
GAGs is counteracted by positive ions, causing a high osmotic pressure and the 
retention of water.
5
 Due to this constant attraction of water into the ECM, cartilage 
acts like a sponge. Namely, when cartilage is compressed, water is forced to 
uncompressed areas of the tissue. Moreover, some water is moved to the surface of 
cartilage tissue, where it functions as a lubricant to prevent friction. After release of 
compression, water is immediately attracted back into the tissue.
6
 This movement of 
water is important for the distribution of load over a greater surface of the tissue and 
helps to transport nutrients to chondrocytes. Articular cartilage is organized in distinct 
zones; the superficial zone, middle zone, deep zone and calcified zone (Figure 1). The 
orientation of ECM and distribution of chondrocytes are different in each zone, which 
provide articular cartilage its biomechanical properties.  
Lesions in articular cartilage often lead to osteoarthritis 
Chondrocytes maintain the composition of cartilage matrix by sensing changes via 
direct interaction with ECM components or by soluble factors released from the 
matrix.
7
 However, lesions in articular cartilage, as a result of ‘wear and tear’, 
inflammation or acute physical injury, are not sufficiently repaired by chondrocytes. It 
is believed that because cartilage is avascular, aneural and alymphatic, a wound 
healing response, as for instance observed in the skin, cannot occur. Consequently, 
articular cartilage has limited capacity to regenerate.
8-10
 As cartilage lesions are poorly 
10 
repaired, they can get worse over time.
11
 This may lead to progressive degeneration of 
articular cartilage, which is clinically identified as the degenerative joint disease; 
osteoarthritis (OA).
12,13
 Why these lesions progress to OA remains to be discovered. 
 
Figure 1. An overview of the different zones of articular cartilage. A section of (bovine) articular 
cartilage was stained with Safranin O, which stains cartilage matrix red. Fast Green was used as a 
counterstaining and stains bone and fibrotic tissue green/blue. The small white structures in the 
cartilage matrix are articular chondrocytes. 
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Osteoarthritis and regeneration of articular cartilage 
The loss of articular cartilage in OA causes narrowing of the joint space, rubbing of 
bones and a change in the biomechanical properties.
14
 The clinical symptoms of OA are 
joint pain and joint stiffness, which are associated with functional impairment and 
have a major impact on quality of life.
12,15,16
 The World Health Organization has 
estimated that worldwide 9.6% of men and 18.0% of women aged over 60 years have 
OA. About 80% of the patients with OA have limitations in movement and 25% cannot 
perform their major daily activities. By 2020, OA will be the fourth leading cause of 
disability worldwide.
17-20
 Current interventions, including physical therapy, medication 
or surgery mainly address pain, but they cannot reverse the degeneration of articular 
cartilage. A possible treatment to prevent or to treat OA is to repair lesions by 
regeneration of articular cartilage. 
Mesenchymal stem cells are promising for regeneration of cartilage tissue 
Tissue engineering has emerged as a potential therapeutic strategy to regenerate 
damaged articular cartilage. Mesenchymal stem cells (MSCs) are promising for tissue 
engineering applications because of their capacity to differentiate into chondrocytes 
(also called chondrogenic differentiation). This capacity has been originally ascribed to 
MSCs obtained from bone marrow.
21-29
 Additionally, MSCs isolated from other tissues 
including bone, periosteum, synovium and adipose tissues are capable of chondrogenic 
differentiation.
30-45
 Of all these cell sources, MSCs derived from bone marrow have 
been most extensively studied both in vitro and in vivo, meriting their use for 
regeneration of articular cartilage.
1,46-52
 Moreover, microdrilling, a surgical technique 
by which the damaged cartilaginous tissue is exposed to bone marrow, relies on the 
chondrogenic differentiation capacity of bone marrow-derived MSCs.
52,53
  
Cartilage formation by mesenchymal stem cells needs to be improved 
Despite MSC-derived chondrocytes can form cartilage tissue, expressing collagen type 
II and aggrecan, the obtained tissue is variable in composition, structure and durability. 
More importantly, it does not completely resemble the functional properties of 
articular cartilage.
9,54-58
 The proportions of different ECM components tend to be 
wrong, affecting the tissue’s tensile strength and load-bearing capacities.
59
 One of the 
problems is that chondrogenically differentiating MSCs express markers that represent 
chondrocyte hypertrophy, including collagen type X (COL10), matrix 
metalloproteinases (MMPs), runt-related transcription factor 2 (RUNX2) and alkaline 
phosphatase (ALP).
60-67
 Whereas these markers are not found in articular cartilage, as 
12 
it does not undergo hypertrophic maturation, they are expressed in transient cartilage 
that is formed during endochondral ossification.
68-70
  
Endochondral ossification is a process that occurs after chondrogenesis and is required 
for embryonic skeletal development, long bone formation in the growth plate and 
healing of bone fractures. During this process, chondrocytes undergo controlled 
phases of proliferation and hypertrophic maturation.
71
 Interestingly, there is a 
controversy what happens next to the hypertrophic chondrocytes.
72
 The current 
concept postulates that most hypertrophic chondrocytes undergo programmed cell 
death, apoptosis, prior to bone formation.
71-73
 However, recent investigations have 
demonstrated that hypertrophic chondrocytes can transform directly into bone cells.
74-
76
 Collectively, MSC-derived chondrocytes produce transient hyaline cartilage, which is 
prone to calcify, instead of permanent hyaline articular cartilage.  
Another problem with the use of MSCs for tissue engineering is that they are a very 
heterogeneous population of cells.
27
 Therefore, their capacity to chondrogenically 
differentiate may not only vary between donors, but also within one donor.
77,78
 To 
improve cartilage regeneration by MSCs, the molecular mechanisms that control 
chondrogenic and hypertrophic differentiation need to be further elucidated.
79
  
Natural chondrogenesis is a multistage process  
Chondrogenesis is the process of cartilage formation (Figure 2). This process has been 
primarily studied during the development of embryonic limbs in which it is regulated 
through different stages. In embryos, chondrogenesis begins with recruitment, 
migration and proliferation of MSCs.
80
 When the expanding pool of MSCs reaches a 
critical mass, condensation is triggered.
81
 During condensation, cells stop proliferating 
and start to aggregate.
82
 The exact molecular mechanism triggering condensation is 
not fully understood, but it is known that cell adhesion molecules are involved.
71
 
Adhesion molecules mediate cell–cell and cell–matrix interactions and regulate the 
expression of SRY-related high-mobility-group box 9 (SOX9); a transcription factor 
essential for chondrogenesis.
83,84
 In condensed MSCs, increased cellular interactions 
and SOX9 expression lead to chondrogenic differentiation of MSCs into 
chondroprogenitor cells (also called chondroblasts). During this early stage of 
chondrogenic differentiation, condensed MSCs stop expressing adhesion molecules, 
resume proliferation and start to produce cartilage matrix-specific proteins, such as 
aggrecan (ACAN) and collagen type II α1 (COL2A1).
85,86
 The chondroprogenitors further 
differentiate into mature chondrocytes followed by endochondral ossification 
(explained in more detail above).
86,87
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Figure 2. Schematic overview of chondrogenic and hypertrophic differentiation. To form 
articular cartilage, mesenchymal stem cells (MSCs) first differentiate into chondrocytes. The 
chondrogenic differentiation of MSCs and formation of cartilage by chondrocytes is termed 
chondrogenesis. During endochondral bone formation, chondrocytes undergo hypertrophic 
differentiation. Hypertrophic chondrocytes deposit calcified matrix and they release enzymes 
that degrade the cartilage matrix. 
In vitro chondrogenic differentiation of mesenchymal stem cells mimics natural 
chondrogenesis 
Current knowledge on cartilage tissue engineering using MSCs is primarily based on 
studying chondrogenesis in vitro.
23,52,88
 To induce chondrogenic differentiation in vitro, 
MSCs are centrifuged leading to the formation of a 3-dimensional (3D) pellet within 24 
hours as a result of enhanced cell–cell interactions (Figure 2). This process mimics the 
condensation stage of natural chondrogenesis. Since this in vitro model is relatively 
easy and allows one to investigate chondrogenic differentiation using standard 
laboratory techniques, it is currently the most frequently used model.
58,89
 Importantly, 
MSCs cultured in 3D pellets do not spontaneously differentiate into chondrocytes. 
They require additional signals, and transforming growth factor β (TGFβ) is a growth 
factor commonly used to induce chondrogenic differentiation of MSCs.
23,90
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Transforming Growth Factor β signaling  
Besides TGFβ can potently induce chondrogenic differentiation of MSCs, it can control 
the differentiation of chondrocytes, because TGFβ regulates the expression of genes 
that are involved in chondrogenic and hypertrophic differentiation. Regulation of gene 
expression by TGFβ is mediated by receptors at the cell surface and intracellular SMAD 
transcription factors. After providing a general overview of TGFβ signaling, we focus on 
the current knowledge of the role of TGFβ signaling components in chondrogenesis 
and in the onset of OA. 
TGFβ is a member of a large family of growth and differentiation factors 
TGFβ belongs to the transforming growth factor β superfamily, which is divided in two 
subfamilies. The TGFβ subfamily includes TGFβs, activins, nodal, inhibins, myostatin 
and mullarian inhibiting substance. The Bone Morphogenetic Protein (BMP) subfamily, 
includes BMPs, Growth and Differentiation Factors (GDFs) and Anti-Muellerian 
Hormone (AMH). Both subfamilies signal via type I and type II serine/threonine kinase 
receptors. There are 7 type I receptors (also called Activin receptor-Like Kinases; ALK1-
7) and 5 type II receptors (TGFBR2, BMPR2, ACVR2A, ACVR2B and AMHR2). In general, 
the TGFβ subfamily signals via ALK4, ALK5 or ALK7 and TGFBR2 or ACVR2A/B, which 
regulate target genes through the SMAD2/3 pathway. The BMP subfamily regulates 
gene transcription via ALK1, ALK2, ALK3 or ALK6 and BMPR2 or AMHR2, and the 
SMAD1/5/9 pathway.
91-94
  
TGFβ ligands are secreted in an inactive complex 
In 1985 two peptides, obtained from demineralized bovine bone, were found to induce 
the synthesis of cartilage-specific proteoglycan and collagen type II in embryonic rat 
MSCs. Therefore, both peptides were named cartilage-inducing factors (CIF) CIF-A and 
CIF-B.
95
 Hereafter, CIF-A was found to be identical to human TGFβ1 and CIF-B the same 
as TGFβ2.
96-98
 A year later TGFβ3 was identified and found to be mainly expressed in 
cell lines from mesenchymal origin.
99,100
  
TGFβ1, TGFβ2 and TGFβ3 are encoded by different genes and each isoform is located 
on a different chromosome.
101
 Although they share approximately 71-79% structural 
homology, their transcription is differentially regulated due to differences in their 
promoter sequences.
102
 Each TGFβ ligand is secreted as a large latent complex 
consisting of a latency-associated peptide (LAP) that is connected to a dimer of mature 
TGFβ peptides and latent TGFβ-binding protein (LTBP).
103-105
 TGFβ dimers not bound to 
LAP and LTBP are inefficiently secreted.
106
 After secretion, the large latent complex 
binds to and is stored in the ECM via the N-terminal region of LTBP.
107,108
 To activate its 
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receptor, the TGFβ dimer needs to be separated from LAP and LTBP. In vitro, this is 
facilitated by exposure to heat or a very low pH, which denatures LAP and LTBP 
without affecting the TGFβ dimer. In vivo, latent TGFβ can be released from LAP and 
LTBP by multiple mechanisms, for example by proteolytic cleavage, thrombospondin-
1-mediated disruption, reactive oxygen species (low pH) or interaction with 
integrins.
109
 The TGFβ dimer released from LAP and LTBP is also called ‘active TGFβ 
ligand’ as now it can initiate signaling via type I (TGFBR1 also called ALK5) and type II 
(TGFBR2) transmembrane serine/threonine kinase receptors at the cell’s surface. 
Active TGFβ ligands activate TGFβ receptors 
ALK5 and TGFBR2 have a similar domain structure including a relatively short 
extracellular ligand-binding domain, a single transmembrane helix and a cytoplasmic 
tail with a serine/threonine kinase domain. In basal state, TGFBR2 is phosphorylated, 
whereas ALK5 is not.
110
  
Since an active TGFβ ligand has higher affinity for TGFBR2 than for ALK5, it first binds 
to TGFBR2. Thereafter, ALK5 is recruited via unique extensions at the ligand–TGFBR2 
interface, leading to the formation of a heterotetrameric complex with one TGFβ 
dimer, two type I and two type II receptors. In this complex, the TGFβ dimer resembles 
two “hand-like” structures that are assembled in an antiparallel manner and are held 
together by a disulfide bond in the “wrist” region. The TGFβ dimer contacts ALK5 with 
its “fingertips” and TGFBR2 with the underside of its “fingers”.
111-113
 Also direct 
receptor–receptor interactions in the cytoplasm contribute to enhanced stability of the 
receptor–ligand complex.
111,113
 
In addition to the “traditional” ALK5 receptor, there is another TGFβ type I receptor; 
ALK1 (Figure 3). The expression of ALK1 has been shown for the first time on human 
endothelial cells, but more recently also on articular chondrocytes.
114-116
 ALK5 
mediates recruitment of ALK1 into a heterotetrameric complex.
117
 Since ALK1 cannot 
form a complex with the TGFβ dimer and TGFBR2 like ALK5 can, there is perhaps a 
third interaction required. This may be one of the co-receptors for TGFβ signaling; β-
glycan (also called type III receptor), endoglin, BMP and activin membrane-bound 
inhibitor (BAMBI), cripto, CD109 and Neuropilin-1, which can control the assembly of a 
ligand–receptor complex and modulate signaling of this complex. However, that 
remains to be elucidated.
112,113
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Figure 3. A simplified overview of TGFβ signaling. Active TGFβ ligands bind to type II 
serine/threonine receptors (TGFBR2) leading to heterotetrameric complex formation with 
activin receptor-like kinase 5 (ALK5) and/or ALK1 receptors. Within a receptor complex, ALK 
receptors are activated by TGFBR2. If only ALK5 receptors are present in a receptor complex, 
SMAD2 or SMAD3 proteins are phosphorylated. When a receptor complex contains both ALK5 
and ALK1 receptors, SMAD1, SMAD5 or SMAD9 proteins are phosphorylated. Phosphorylated 
SMAD2/3 and SMAD1/5/9 proteins first bind to SMAD4 and then translocate to the nucleus 
where they regulate transcription of specific genes. 
Following complex formation of type II and type I receptors, the constitutively active 
TGFBR2 phosphorylates a region of the cytoplasmic tail of ALK5 or ALK1 that contains 
glycine and serine residues (also called GS domain). Phosphorylation of the GS domain 
induces a conformational change that activates the kinase domain, located right 
underneath the GS domain. Once the kinase domains of type I receptors are 
phosphorylated by type II receptors, they can signal independently of the type II 
receptor.
118,119
 Furthermore, the phosphorylation of the GS domain enhances the 
binding affinity of intracellular proteins.
120
 In turn, multiple signaling pathways can be 
activated, including various branches of the mitogen-activated protein kinase (MAPK) 
pathways involving TGFβ-activated kinase 1 (TAK1 also known as MAP3K7), Rho-like 
GTPase signaling pathways, and phosphatidylinositol-3-kinase/AKT pathways.
121-123
 
However, the canonical pathway for TGFβ signaling is via SMAD proteins (SMADs). 
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Activated TGFβ receptors phosphorylate SMAD proteins 
The name SMAD is a contraction of the Caenorhabditis elegans protein Sma (from Sma 
gene identified by small body size of mutants)
124
 and Drosophila melanogaster protein 
Mad (mothers against decapentaplegic)
125
, coined by Liu et al. who identified sequence 
similarities between the genes of human SMAD1 and of Sma and Mad proteins.
126
 In 
mammals, the SMAD protein family consists of eight proteins SMAD1 to SMAD8 
(SMAD8 is also called SMAD9). Based on structural and functional considerations, 
SMADs are subdivided in receptor-regulated SMADs (R-SMADs), collaborating or 
common SMADs (co-SMADs) and inhibitory SMADs (I-SMADs). Among the R-SMADs 
are SMAD1, SMAD2, SMAD3, SMAD5 and SMAD9 (formerly known as SMAD8). Only 
one co-SMAD exists; SMAD4. I-SMADs include SMAD6 and SMAD7.  
R-SMADs and SMAD4 contain a amino(N)-terminal Mad-Homology 1 (MH1) domain, 
linker region and carboxyl (C)-terminal MH2 domain. I-SMADs only contain a linker 
region and MH2 domain.
127
 The MH1 domain contains a β-hairpin structure that is 
required for binding to desoxyribonucleïnezuur (DNA) or association with a subset of 
microRNA primary transcripts.
128,129
 The MH2 domain mediates protein–protein 
interaction, including type I receptors, transcription factors, anchor proteins and DNA-
binding co-factors, and oligomerization with other SMADs.
130
 Between the MH1 and 
MH2 domain lies the linker region, which is a flexible segment with phosphorylation 
sites for several kinases and binding sites for ubiquitin ligases. The linker region can 
control the nuclear translocation of SMADs and creates docking sites for positive and 
negative modulators of SMAD-mediated transcriptional activity.
131
  
Of all SMAD proteins, only R-SMADs can bind to the activated kinase domains of type I 
receptors. R-SMADs can be subdivided in two groups; SMAD2/3, which bind to ALK5, 
and SMAD1/5/9 that bind to ALK1 (Figure 3). Upon binding of a R-SMAD to the type I 
receptor, the kinase domains of the receptor phosphorylate two serine residues (also 
known as “SSXS motif”) at the C-terminal MH2 domain of the R-SMAD. This causes 
conformational changes leading to dissociation from the receptor and constitution of 
an acidic tail that binds a basic pocket in the MH2 domain of SMAD4 or to homologous 
MH2 domains.
132
 The phosphorylation of R-SMADs can be inhibited by I-SMADs 
(SMAD6 and SMAD7). Structural analyses showed that C-terminal phosphorylated R-
SMADs form homomeric or heteromeric complexes, which can consist of one SMAD4 
together with two SMAD2, two SMAD3, or one each of SMAD2 or SMAD3. The same 
holds true for SMAD1, SMAD5 and SMAD9.
133-135
 Subsequently, SMAD complexes 
translocate to the nucleus, where they behave as transcription factors as they regulate 
transcription of genes and can remodel chromatin.
136
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Phosphorylated SMAD proteins transduce the signal from the membrane to the 
nucleus where they regulate target gene transcription 
Phosphorylated SMAD proteins can enter the nucleus via an importin-mediated or 
nuclear pore protein-mediated mechanism. The N-terminal MH1 domain of SMAD1, 
SMAD2, SMAD3, and SMAD4 contains nuclear localization signal motifs, which are 
unmasked by phosphorylation. Through these motifs, SMADs can interact with 
importins leading to transportation into the nucleus. SMAD2, SMAD3 and SMAD4 can 
also be directly imported into the nucleus via a direct interaction with nuclear pore 
proteins.
137
 No data is available on nuclear import mechanisms of SMAD5 or SMAD9. 
Once inside the nucleus, activated R-SMAD–SMAD4 complexes can interact with 
various resident DNA-binding co-factors, co-activators and co-repressors.
138
  
SMAD4 and all R-SMADs, except for SMAD2, bind DNA directly.
129,139
 SMAD2 cannot 
bind DNA without SMAD4, because of an insert, encoded by exon 3, upstream of the 
DNA-binding β-hairpin.
140,141
  Binding to DNA is mediated by recognition of a specific 
DNA sequence motif, commonly referred to as SMAD-binding elements (SBE), within 
the promoters of target genes (Figure 3). Different SMAD complexes may interact with 
distinct motifs, but these interactions are not yet fully characterized.
136,142
 Since the 
affinity of R-SMADs for DNA is too low to support binding of a SMAD complex to a 
single SBE, R-SMADs require binding to multiple SBEs in order to activate transcription. 
Although many promoter regions of target genes contain one or more SBEs, still 
additional transcription factors are required to increase DNA-binding affinity. Many of 
these transcription factors are tissue-specific or even master regulators of 
differentiation, thereby they enhance the specificity of transcriptional responses.
136
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TGFβ signaling in cartilage generation 
TGFβ is well-known to potently induce chondrogenesis and control cartilage 
development.
90,143
 As can be appreciated from the previous section, the functions of 
TGFβ are mediated by multiple downstream signaling components. To provide an 
overview of the mechanism by which TGFβ regulates chondrogenesis, we reviewed the 
current knowledge on the role of TGFβ ligands, TGFβ receptors and SMAD proteins 
during chondrogenesis. 
TGFβ ligands:  
TGFβ1, TGFβ2 and TGFβ3 seem to differ in their efficiency to induce chondrogenesis  
TGFβ1, TGFβ2 and TGFβ3 use the same receptors and signaling pathways, yet there 
are striking phenotype differences between mice deficient for individual TGFβ ligands. 
The most interesting difference is that the skeletal morphology of Tgfb1 or Tgfb2 
knockout mice is abnormal, whereas it is normal in Tgfb3 knockout mice.
144-147
 
Replacing the gene for the mature domain of TGFβ1 into the TGFβ3 locus leads to 
partial, but not complete, rescue of the mutant phenotype.
148
 The functional 
differences between TGFβ isoforms may be caused by differential regulation of their 
expression as a result of variations in their promoter sequences.
102
 Since these results 
indicate that each TGFβ isoform has unique functions, it was investigated whether the 
TGFβ isoforms differ in their efficiency to induce in vitro chondrogenesis. One study 
demonstrated that TGFβ2 and TGFβ3 more effectively induce chondrogenic 
differentiation of human bone marrow-derived MSCs than TGFβ1
28
, whereas other 
studies showed no difference between TGFβ1 and TGFβ3.
39,149-151
 The opposite, that 
TGFβ1 is more effective than TGFβ3, has been shown as well in both human bone 
marrow-derived MSCs and amniotic fluid-derived MSCs.
152,153
 There are also 
contradictions between studies that investigated the effects of TGFβ isoforms on 
hypertrophy of MSC-derived chondrocytes and cartilage mineralization. Although two 
studies demonstrated no difference between TGFβ1 and TGFβ3, one study showed 
that human bone marrow-derived MSC pellets cultured with TGFβ3 have significantly 
more mineralized cartilage matrix than pellets cultured with TGFβ1.
28,149,151
 As a result 
of the contradictory observations, the question whether TGFβ1, TGFβ2 and TGFβ3 
differentially induce in vitro chondrogenesis and/or chondrocyte hypertrophy remains 
unanswered. It has been suggested that the functional variation among the TGFβ 
isoforms may be caused by differences in their conformations or in the kinetic 
assembly of the type I and II TGFβ receptors.
102,111
 For example, TGFβ2 binds to 
TGFBR2 with lower affinity than TGFβ1 and TGFβ3, therefore, preformed TGFBR2–
20 
TGFBR1 heteromeric complexes or co-receptors are required to assist TGFβ2 into 
assembling stable receptor complexes.
111
  
TGFβ receptors:  
TGFBR2, ALK5 and ALK1 are important for chondrocyte maturation 
As described above, TGFβ ligands can at least activate two distinct two type I 
receptors, ALK5 and ALK1, and TGFBR2 is a central mediator in activation of ALK5 and 
ALK1 by TGFβ. Deletion of Tgfbr2 or Alk5 in mice leads to defective yolk sac 
vasculogenesis and hematopoiesis culminating in embryonic lethality.
154,155
 Similarly, 
Alk1 knockout mice die at midgestation due to severe vascular abnormalities.
156
 
Therefore, to study the contribution of these TGFβ receptors during chondrogenesis, 
conditional deletion has been employed. Mice with conditional knockout of Tgfbr2 in 
neural crest stem cells by Wnt1-Cre exhibit cranial cartilage malformations.
157
 Deletion 
of Tgfbr2 in the murine limb mesenchyme by Prx1-Cre does not inhibit chondrogenic 
differentiation of limb bud cells. However, it does lead to short limbs and the absence 
of interphalangeal joints as no interzone is formed due to aberrant persistence of 
differentiated chondrocytes.
158,159
 Similarly, Alk5 knockout in skeletal progenitor cells 
using Dermo1-Cre does not affect differentiation of MSCs into chondrocytes, while it 
does result in short limbs and cartilage malformations.
160
 Unfortunately, mice with 
conditional deletion of Alk1 in the mesenchyme have not yet been generated. These 
findings indicate that, in vivo, TGFBR2 and ALK5 receptors are rather required for 
normal joint and skeleton development than for induction of chondrogenesis.  
The contribution of TGFBR2, ALK5 and ALK1 during in vitro chondrogenic 
differentiation of MSCs was investigated in a few studies. The expression of TGFBR2 
does not correlate with the chondrogenic differentiation potential of human adipose 
tissue-derived MSCs. The same study has demonstrated that overexpression of 
TGFBR2 in these cells does not enhance TGFβ-induced chondrogenesis. In contrast, co-
overexpression of ALK5 and TGFBR2 does lead to enhanced chondrogenic 
differentiation.
161
 Moreover, it has been shown that the reduced chondrogenic 
potential of human adipose tissue-derived MSCs can be ascribed to a lack of TGFBR1 
(gene of ALK5) expression.
162
 In the same cell type, TGFBR1 mRNA levels positively 
correlate with the chondrogenic differentiation capacity and overexpression of ALK5 
increased chondrogenesis induced by TGFβ.
161
 In line, chondrogenesis is accelerated in 
in vitro-cultured bone marrow-derived MSCs from mice with a point mutation in 
Tgfbr1, which causes partial activation of the receptor independent of ligand-
binding.
163
 On the other hand, treatment of human bone marrow-derived MSCs with 
the ALK5 inhibitors SD-208, SB505124 or SB431542 reduces TGFβ-induced 
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chondrogenic differentiation.
153,164,165
 Chondrogenesis is also blocked in murine bone 
marrow-derived MSCs treated with ALK5i; a small molecule inhibitor of ALK5.
166
 
Together, these results imply an important role for ALK5 during in vitro chondrogenic 
differentiation of MSCs.  
Regarding the role of ALK1, overexpression of kinase-inactive ALK1 receptors blocks 
spontaneous cartilage nodule formation in ATDC5 cells; a murine chondrogenic 
teratocarcinoma cell line. In contrast, the same study reported that overexpression of 
constitutively active ALK1, which phosphorylates downstream SMAD1/5/9 proteins 
without prior activation by TGFβ, fails to promote cartilage nodule formation in the 
ATDC5 cells.
167
 Apparently, in vitro chondrogenesis requires, besides ALK1, other 
factors. Based on the results described above this might be ALK5.  
SMAD proteins (signal transduction from receptor to the nucleus): 
The SMAD2/3 and SMAD1/5/9 pathways seem to be both required for induction of 
chondrogenesis 
ALK5 activates the SMAD2/3 pathway, whereas ALK1 activates the SMAD1/5/9 
pathway (Figure 3). It has been demonstrated that treatment of in vitro-cultured 
murine bone marrow-derived MSCs with SIS3; an inhibitor of SMAD3, blocks 
chondrogenic differentiation induced by TGFβ.
166
 TGFβ-induced chondrogenesis is also 
reduced when signaling via SMAD2/3 is downregulated by overexpression of 
microRNA-146a in human fetal femur-derived stem cells.
168
 Furthermore, 
downregulation of Smad1 by microRNA-199a overexpression inhibits chondrogenic 
differentiation of murine C3H10T1/2 cells; an embryonic mesenchymal cell line.
169
 We 
and others have previously demonstrated that inhibiting either the SMAD2/3 or 
SMAD1/5/9 pathway in human MSCs from different sources (bone marrow, synovium 
and embryonic stem cells) with small-molecule/chemical inhibitors blocks TGFβ-
induced chondrogenesis.
164,170-172
 Altogether, these results indicate that the SMAD2/3 
pathway and SMAD1/5/9 pathway are both required for induction of chondrogenic 
differentiation. However, the contribution of each pathway during chondrogenesis has 
not been fully clarified. 
The SMAD2/3 and SMAD1/5/9 pathways seem to have a different role during 
chondrogenesis 
There are indications that the SMAD2/3 pathway has a different role during in vivo 
chondrogenesis than the SMAD1/5/9 pathway. Mice with global deletion of Smad3 
have a normal skeleton and articular cartilage at birth. However, these mice develop 
postnatal dwarfism and their cartilage starts to degrade within one month after birth, 
resulting in a cartilage phenotype that resembles end-stage OA in humans.
173-176
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Moreover, fracture healing in 10 week-old Smad3 deficient mice is impaired, because 
expression of genes involved in chondrogenesis are suppressed.
177
 Also Smad9 
knockout mice are born with a normal skeleton, but whether Smad9 mutants develop 
cartilage abnormalities during adulthood has not yet been investigated.
178,179
 Similar to 
mice deficient for TGFβ ligands or receptors, Smad1, Smad2 or Smad5 knockout mice 
die prior to cartilage development.
180-184
 To study the role of these SMADs in 
chondrocyte differentiation, cartilage-specific (Col2-Cre) knockouts were generated. 
Mice with cartilage-specific loss of either Smad1, Smad2 or Smad5 are born with a 
normal skeleton and articular cartilage.
179,185
 However, Col2-Cre-Smad1/5 double 
mutants display severe chondrodysplasia at birth. Additional full body deletion of 
Smad9 does not lead to a more severe phenotype.
179
 Collectively, these observations 
indicate that SMAD1 and SMAD5 exhibit functional overlap, and SMAD9 plays a minor 
role in chondrogenesis. A recent study has demonstrated that Col2-Cre-Smad2 mice do 
not have skeletal defects at birth as is also the case for Smad3 knockout mice.
185
 
Crossing Col2-Cre-Smad2 with Smad3 knockout mice results in only subtle skeletal 
abnormalities at birth. Moreover, these double mutants develop progressive postnatal 
dwarfism, which is neither seen in Col2-Cre-Smad2 nor in Smad3 knockout mice. This 
suggests that SMAD2 and SMAD3 have compensatory roles in the regulation of axial 
skeletal growth after birth.
185
 Overall, these findings indicate that the SMAD1/5/9 
pathway has an important role during embryonic chondrogenesis, whereas the 
SMAD2/3 pathway is essential for postnatal maintenance of healthy cartilage. 
However, this is based on mice with cartilage-specific deletion of SMADs, meaning that 
the first stages of chondrogenesis already occurred. To more specifically study the 
contribution of the SMADs during in vivo MSC chondrogenesis, limb mesenchyme-
specific knockout mice are needed. Unfortunately, such mice are not (yet) available. 
Moreover, whether the SMAD2/3 and SMAD1/5/9 pathways have a different role in 
the induction of chondrogenesis of in vitro-cultured human (bone marrow-derived) 
MSCs remains to be investigated. In this thesis, we studied whether the two pathways 
have a distinct function during TGFβ-induced chondrogenic differentiation of human 
bone marrow-derived MSCs by knockdown and overexpression of ALK5 and ALK1 
receptors upstream of the two pathways.  
SMAD2 and SMAD3 seem to differentially mediate chondrogenesis 
In addition to differences between the SMAD2/3 and SMAD1/5/9 pathways, there are 
indications for functional differences between SMAD2 and SMAD3. Besides Smad2 
knockout mice have a different phenotype than Smad3 knockout mice, they can 
activate different promoters following activation by TGFβ.
139-141,186-192
 So far, one study 
investigated whether SMAD2 and SMAD3 have distinct functions in TGFβ-induced 
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chondrogenic differentiation of MSCs. Although both SMAD2 and SMAD3 equally 
associate with transcription factor SOX9, SMAD3 more strongly induces cartilage 
matrix deposition by human bone marrow-derived MSCs than SMAD2. Moreover, 
knockdown of SMAD3 blocks chondrogenesis, whereas SMAD2 knockdown has no 
effect.
193
 These findings suggest that SMAD2 and SMAD3 differentially mediate TGFβ-
induced chondrogenesis. 
SMAD4 is highly important for induction of chondrogenic differentiation 
SMAD4 is a co-factor commonly used by activated SMAD2/3 and SMAD1/5/9 proteins 
for translocation to the nucleus. As with most of the TGFβ signaling components, 
deficiency of this gene in mice results in prenatal death.
194,195
 Because of its central 
role in SMAD-dependent TGFβ signal transduction, the phenotype of Col2-Cre-Smad4 
mice was expected to resemble that of mice in which one or multiple R-SMADs is/are 
(cartilage-specific) knocked out. Strikingly, Col2-Cre-Smad4 mice do not exhibit skeletal 
defects at birth. Postnatally, these mice develop dwarfism as a result of disorganized 
chondrocyte differentiation in the growth plate.
196
 Since Col2-Cre-Smad1/5 knockout 
leads to a total arrest in chondrogenesis, it has been suggested that signaling via 
SMAD1/5 in skeletogenesis is largely independent of SMAD4.
197
 However, this only 
holds true for murine cells expressing Col2, which are already chondrocytes. More 
recent studies have shown that conditional inactivation of Smad4 in murine limb bud 
mesenchyme (by Prx1-Cre) blocks the condensation of MSCs, thereby preventing 
chondrogenic differentiation.
198,199
 Apparently, SMAD4 is essential for condensation of 
MSCs. 
  
24 
TGFβ signaling in articular cartilage degeneration and osteoarthritis 
For cartilage tissue engineering it is crucial to prevent hypertrophy of the obtained 
chondrocytes. Otherwise, the tissue engineered cartilage will calcify and turn into 
bone. Hypertrophic maturation of chondrocytes is not only a problem in cartilage 
tissue engineering, but also in the development of osteoarthritis.
200-202
 Interestingly, 
TGFβ and its downstream signaling mediators have been implicated in chondrocyte 
hypertrophy as well as in OA.  
TGFβ signaling is altered in osteoarthritis 
In cartilage obtained from human OA patients, gene and/or protein levels of TGFβ1, 
TGFBR2 and ALK5 are lower than in cartilage from healthy subjects.
203-205
 Reduced 
expression of multiple TGFβ signaling components is also evident in various animal 
models of OA.
206-211
 In contrast, enhanced expression of TGFβ ligands and receptors 
has been reported as well in both human and murine OA cartilage.
212-216
 Despite this 
contradiction, these results indicate changes in TGFβ signaling in articular cartilage 
during development of OA. This is supported by microarray studies showing that the 
TGFβ signaling pathway is enriched in murine and human OA cartilage.
210,211,215-217
 
Furthermore, we have previously demonstrated that the expression of both Alk5 and 
Alk1 decrease over time in cartilage from mice with experimental or spontaneous OA. 
Importantly, Alk5decreases more strongly than Alk1. As a result, the Alk1/Alk5 ratio 
increases during OA development.
115
 Moreover, Alk1 expression is upregulated in the 
mensical tear model of OA in rats.
209
 Taken together, these findings suggest that the 
expression of TGFβ signaling pathway components is altered in OA cartilage.  
Aberrant TGFβ signaling is associated with chondrocyte hypertrophy and 
osteoarthritis 
Multiple studies have shown that alterations in expression of TGFβ signaling 
components coincide with OA pathology. In humans, polymorphisms in TGFB1 and 
SMAD3 have been associated with OA symptoms.
218-225
 Additionally, mutations in 
SMAD3 cause early-onset OA (at a mean age of 42) in multiple joints.
226,227
 As 
described above, cartilage of Smad3 knockout mice exhibits human OA-like features, 
like hypertrophic chondrocytes, within one month after birth.
173-176
 In line, deletion of 
Smad3 in Col2-expressing murine chondrocytes results in enhanced hypertrophic 
differentiation these cells.
228-230
 This was also observed in mice with chondrocyte-
specific deletion (by Col2-Cre) of Smad4 or Tgfbr2.
196,231
 Moreover, Col2-Cre-Tgfbr2 
knockout mice develop a degenerative joint disease resembling human OA.
232
 
Consistent with this, overexpression of a truncated and kinase-defective Tgfbr2 in 
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murine skeletal tissue leads to accelerated chondrocyte hypertrophy and early-onset 
of OA.
233
 We have previously shown that, in human OA cartilage, ALK1 expression 
significantly correlates with expression of the chondrocyte hypertrophy marker 
MMP13, whereas ALK5 expression correlates with expression of ACAN and COL2A1.
115
 
Furthermore, protein expression of collagen type II in human chondrocytes is induced 
by ALK5, whereas expression is inhibited by ALK1.
116
 These results suggest that ALK5 
and ALK1 have opposing functions in human chondrocytes, which is also the case in 
human endothelial cells.
114,117
 This is further supported by observations in murine cells 
as knockdown of Alk5 in murine chondrocytes leads to increased Mmp13 expression, 
while knockdown of Alk1 decreases Mmp13 mRNA levels. In addition, whereas 
overexpression of Alk5 has no effect on Mmp13 expression, Alk1 overexpression 
results in enhanced Mmp13 expression.
115
 Together, these findings indicate that 
chondrocyte hypertrophy and OA are prevented by TGFβ signaling via TGFBR2, ALK5, 
SMAD3 and SMAD4, whereas OA pathology is induced via ALK1. Overall, there seems 
to be an important link between TGFβ signaling, chondrocyte hypertrophy and OA. 
Further research on this link may provide novel insights into the mechanism driving 
hypertrophic differentiation of articular chondrocytes in OA cartilage. 
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Aims and outline of this thesis 
TGFβ is highly involved in chondrogenesis, chondrocyte hypertrophy and the 
development of osteoarthritis. However, the role of downstream signaling 
components of TGFβ remains largely unknown. The aims of this thesis are: 
 to define the contribution of TGFβ receptors and TGFβ signaling proteins 
(SMADs) during chondrogenesis of bone marrow-derived MSCs (BMSCs). 
 to identify which genes related to TGFβ signaling (encoding TGFβ signaling 
components or regulated by TGFβ) are involved in chondrocyte hypertrophy 
and OA. 
TGFβ can regulate gene transcription via the SMAD2/3 pathway and, alternatively, via 
the SMAD1/5/9 pathway. The SMAD2/3 pathway has been shown to be important for 
chondrogenic differentiation of BMSCs, while the SMAD1/5/9 pathway has been 
implicated with chondrocyte hypertrophy. The ligands Activin and Nodal activate 
SMAD2/3 signaling, but are incapable of activating SMAD1/5/9 signaling. In chapter 2, 
we studied whether Activin and Nodal can induce chondrogenic differentiation of 
human BMSCs without inducing chondrocyte hypertrophy. 
In a previous study, inhibiting TGFβ-activated phosphorylation of either SMAD2/3 or 
SMAD1/5/9 with chemical inhibitors, blocked chondrogenic differentiation of human 
BMSCs. This suggests that both SMAD pathways are required for induction of 
chondrogenesis. TGFβ activates SMAD2/3 signaling via the ALK5 receptor and 
SMAD1/5/9 signaling via the ALK1 receptor. In chapter 3, we determined whether the 
two TGFβ receptors, ALK5 and ALK1, are expressed in human BMSCs and whether both 
receptors are required for TGFβ-induced chondrogenic differentiation. 
Activation of SMAD2 and SMAD3 proteins by ALK5 leads to complex formation with 
SMAD4. These SMAD complexes translocate to the nucleus where they regulate 
control transcription. Previous studies have shown that SMAD2, SMAD3 and SMAD4 
contribute to the regulation of TGFβ responses to varying extents and have distinct 
functions during in vivo cartilage development and homeostasis. By modulating the 
expression of SMAD2, SMAD3 and SMAD4 in human BMSCs, their specific role during 
in vitro chondrogenesis is investigated in chapter 4. 
TGFβ is not only involved in chondrogenic differentiation of MSCs, but also in 
hypertrophic differentiation of MSC-chondrocytes and articular chondrocytes. 
Chondrocyte hypertrophy is a process required for endochondral bone formation; a 
process in which a transient hyaline cartilage anlage transits to bone. In growth plate 
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cartilage this results in long bone formation, and in transient embryonic cartilage it 
leads to limb formation. Whereas chondrocyte hypertrophy is inhibited in healthy 
articular cartilage, it is induced in articular chondrocytes of patients with OA. The exact 
mechanism inducing the altered phenotype of OA chondrocytes is not completely 
known. Alterations in TGFβ signaling have been associated with some characteristics of 
OA, including expression of hypertrophy markers by articular chondrocytes and focal 
calcification of articular cartilage. In chapter 5, this link between TGFβ signaling, 
chondrocyte hypertrophy and OA is further explored by determining which TGFβ-
pathway and TGFβ-target genes are regulated in datasets of published microarray 
studies on surgically-induced OA in mice and chondrocyte hypertrophy. 
In chapter 6, we discussed the results of the studies described in this thesis. 
Furthermore, we provided our future perspectives on whether stable articular 
cartilage can be obtained using MSCs and chondrogenesis induced by TGFβ. The main 
findings of this thesis are summarized in chapter 7. 
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Abstract 
Objective: Previously, we demonstrated the importance of TGFβ-activated SMAD2/3 
signaling in chondrogenesis of bone marrow-derived mesenchymal stem cells (BMSCs). 
However, TGFβ also signals via the SMAD1/5/9 pathway, which is known to induce 
terminal differentiation of BMSCs. In this study we investigated whether other 
SMAD2/3-activating ligands, Activin and Nodal, can induce chondrogenic 
differentiation of BMSCs without inducing terminal differentiation.  
Design: Activation of SMAD2/3 signaling and chondrogenesis were evaluated in human 
BMSCs (N=3 donors) stimulated with TGFβ, Activin or Nodal. SMAD2/3 activation was 
assessed by determining phosphorylated-SMAD2 (pSMAD2) protein levels and 
SMAD2/3-target gene expression of SERPINE1. Chondrogenesis was determined by 
ACAN and COL2A1 transcript analysis and histological examination of proteoglycans 
and collagen type II.  
Results: Both Activin and TGFβ enhanced pSMAD2 and SERPINE1 expression compared 
to the control condition without growth factors, demonstrating activated SMAD2/3 
signaling. pSMAD2 and SERPINE1 had a higher level of expression following stimulation 
with TGFβ than with Activin, while Nodal did not activate SMAD2/3 signaling. Of the 
three ligands tested, only TGFβ induced chondrogenic differentiation as shown by 
strongly increased transcript levels of ACAN and COL2A1 and positive histological 
staining of proteoglycans and collagen type II.  
Conclusions: Even with concentrations up to 25 times higher than that of TGFβ, Activin 
and Nodal do not induce chondrogenic differentiation of BMSCs, thus neither of the 
two ligands are interesting alternative candidates for TGFβ to induce chondrogenesis 
without terminal differentiation. To obtain stable cartilage formation by BMSCs, future 
studies should decipher how TGFβ-induced terminal differentiation can be prevented. 
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Introduction 
Bone marrow-derived Mesenchymal stem cells (BMSCs) are promising for treatment of 
cartilage damage, because they can differentiate into chondrocytes. Unfortunately, 
BMSC-derived chondrocytes do not resemble the stable phenotype of articular 
cartilage-derived chondrocytes, because they undergo terminal chondrocyte 
differentiation.
1,2
 As this will result in mineralization of implanted tissue
3
, better insight 
into the molecular mechanisms that regulate BMSC differentiation is required.  
Transforming Growth Factor β (TGFβ) is commonly used to induce chondrogenic 
differentiation of BMSCs 
4
. TGFβ signals via complexes of type II and I serine/threonine 
kinase receptors; TGFBR2 and TGFBR1 (or Activin receptor-Like Kinase 5; ALK5). 
Following complex formation, SMAD2/3 signaling is activated which regulates 
transcription of downstream target  genes 
5
. We previously demonstrated the 
necessity of SMAD2/3 signaling in chondrogenesis, because inhibition of TGFβ-
activated SMAD2/3 signaling with chemical inhibitors blocked chondrogenic 
differentiation of BMSCs 
2
. Besides the canonical SMAD2/3 pathway, TGFβ signals via 
the SMAD1/5/9 pathway 
2,6
. Interestingly, blocking SMAD1/5/9 signaling in 
chondrogenically differentiated BMSCs inhibited terminal differentiation and 
mineralization without affecting cartilage matrix production, whereas blocking 
SMAD2/3 signaling in BMSC-derived chondrocytes inhibited further matrix deposition 
2
. These findings suggested that blocking TGFβ-activated SMAD1/5/9 signaling in 
BMSC-derived chondrocytes could prevent terminal differentiation. Therefore, we 
questioned whether other ligands known to activate SMAD2/3, but not SMAD1/5/9 
signaling, could induce chondrogenesis without subsequently inducing terminal 
differentiation. 
Like TGFβ, Activin and Nodal activate SMAD2/3 signaling, but via different receptor 
complexes; Activin via ACVR2A and ACVR1B (ALK4) 
7
, and Nodal via ACVR2B and 
ACVR1C (ALK7) 
8
. Activin and Nodal were reported to be incapable of activating 
SMAD1/5/9 signaling in multiple cell types 
8,9
, however, their capacity to induce 
chondrogenesis has not been clearly established. Activin was shown to enhance 
chondrogenesis, but also to inhibit cartilage matrix production in limb bud cells 
10,11
. In 
addition, Activin suppressed chondrocyte differentiation of murine chondroprogenitor 
cells 
12
. So far, no study has reported whether Nodal induces chondrogenesis. Our aim 
was to determine whether Activin and Nodal could activate SMAD2/3 signaling and 
induce chondrogenic differentiation of BMSCs without inducing terminal 
differentiation, like TGFβ. 
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Materials and methods 
Human BMSC Isolation and Expansion  
From 3 patients (age 10-12 years), pieces of iliac crest bone and marrow that were left 
over after cleft palate reconstruction surgery (approved by the ErasmusMC medical 
ethical committee; MEC-2014-106) were added to α-MEM containing 1.5 μg/mL 
fungizone, 50 μg/mL gentamicine, 10% fetal-calf-serum (all from Gibco, Waltham, MA, 
USA), 25 μg/mL ascorbic acid-2-phosphate (Sigma-Aldrich, St.Louis, MO, USA) and 
1 ng/mL FGF-2 (AbD Serotec, Kidlington, UK) for isolation of BMSCs by plastic-
adherence. When cells neared confluence, they were detached with 0.05% trypsin and 
re-seeded at 2300 cells/cm
2
. After 4 passages, cells were characterized by flow 
cytometry, confirming >97% positivity for BMSC-markers CD73, CD90, CD105 and 
CD166, and <0.5% for hematopoietic cell-marker CD45 (data not shown). BMSCs 
expanded for 4-5 passages were used for experiments. 
SMAD2/3 and SMAD1/5/9 Activation Following TGFβ, Activin or Nodal Stimulation 
Monolayer-cultured BMSCs were serum-starved overnight and maintained in serum-
free medium (unstimulated control) or stimulated for 1 or 24 hour(s) with recombinant 
human TGFβ1 (10 ng/mL = 0.78 nM), Activin A (10, 100 or 250 ng/mL = 0.77, 7.70 or 
19.3 nM) or Nodal (10, 100 or 250 ng/mL = 0.78, 7.81 or 19.5 nM). All ligands were 
purchased from R&D Systems (Minneapolis, MN, USA). Activation of SMAD2/3 and 
SMAD1/5/9 signaling was determined by western blot analysis of pSMAD2 and 
pSMAD1/5/9 in 1 hour-stimulated BMSCs and SMAD2/3-target gene expression of 
SERPINE1 in 24 hours-stimulated cells. 
Chondrogenic differentiation  
BMSC pellets were generated by centrifuging 200,000 cells at 200g for 8 min. Pellets 
were cultured in chondrogenic medium consisting of DMEM-high-glucose, 
1.5 μg/mL fungizone, 50 μg/mL gentamicin, 1 mM sodium pyruvate (Gibco), 1:100 ITS+ 
(BD Biosciences), 40 μg/mL L-proline and 100 nM dexamethasone (Sigma-Aldrich), 
supplemented with either TGFβ1, Activin or Nodal (all from R&D systems, same 
concentrations as above) or without supplementation (unstimulated control). Pellets 
were cultured for 10 days, renewing medium every 2-3 days.  
Gene Expression Analysis 
RNA was isolated with TRIzol® and treated with DNAse according to manufacturer’s 
protocol (Invitrogen, Waltham, MA, USA). Purity and concentration of isolated RNA 
were measured by spectrophotometry and samples with 260/280<1.6 were excluded. 
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200-500 ng RNA was converted into cDNA (Invitrogen). RT-qPCR measurements were 
performed with SYBR® Green MasterMix on a StepOnePlus™ system (Applied 
Biosystems) using primers listed in Table 1. Arbitrary Ct value of 40 was assigned to 
samples where no signal was detected. Gene expression was normalized to two 
reference genes; TBP and RPS27a. –ΔCt values were used for statistical analyses.  
 Primer sequences Details 
Gene Forward primer Reverse primer Product Efficiency 
RPS27a TGGCTGTCCTGAAATATTATAAGGT CCCCAGCACCACATTCATCA 90 bp 95 % 
TBP GCTTCGGAGAGTTCTGGGATTG GCAGCAAACCGCTTGGGATTA 134bp 106 % 
TGFBR2 CTGGTGCTCTGGGAAATGACA TCGCCCTCGATCTCTCAACA 138 bp 100 % 
ACVR2A AGGAAATTGGCCAGCATCCA GCCATTCCAGCATGTTTCTG 106 bp 110 % 
ACVR2B GCACGAGAACCTGCTACAGT GGGAGCCCTTGTCATGGAA 98 bp 106 % 
ACVR1B 
(ALK4) 
ATGCGAAAGGTTGTATGTGATCA ACCCGCAGTGCCTCATAACT 77 bp 105 % 
TGFBR1 
(ALK5)  
CGACGGCGTTACAGTGTTTCT CCCATCTGTCACACAAGTAAA 65 bp 102 % 
ACVR1C 
(ALK7) 
CCATCGTGAATGGCATCGT GGTCATTGGGCACCACATC 63 bp 101 % 
SERPINE1 GTCTGCTGTGCACCATCCCCCATC TTGTCATCAATCTTGAATCCCATA 213 bp 97 % 
ACAN GCCTGCGCTCCAATGACT  ATGGAACACGATGCCTTTCAC 104 bp 100 % 
COL2A1 CACGTACACTGCCCTGAAGGA CGATAACAGTCTTGCCCCACTT 65 bp 101 % 
Table 1. List of primers used for RT-qPCR. 
Histology 
Pellets were fixed in 4% formalin, embedded in paraffin and sectioned (6 μm). 
Proteoglycans were stained with 0.4% aqueous Thionin. For immunohistochemical 
staining of collagen type II, sections were pre-treated with 0.1% pronase and 
10 mg/mL hyaluronidase (Sigma-Aldrich), and incubated with 0.4 μg/mL mouse-anti-
collagen type II (#II-II6B3, DSHB, Iowa City, IA, USA) or 0.4 μg/mL mouse-IgG1 (#X0931, 
Dako, Glostrup, Denmark). Following incubation with alkaline phosphatase (AP)-
conjugated secondary antibody (1:50, #HK-321-UK, Biogenex, San Ramon, CA, USA), 
AP-activity was visualized with new-fuchsin substrate and positive staining appeared as 
a magenta colour. Sections were counterstained with haematoxylin. 
Western Blot   
Cells were lysed with lysis buffer (Cell-Signaling-Technology, Danvers, MA, USA) 
containing 1% protease inhibitor (Roche, Mannheim, Germany) and sonicated on ice. 
Per lane of a 10% bisacrylamide gel, 12 μg protein was loaded. After SDS-PAGE, 
proteins were transferred to a nitrocellulose membrane by wet transfer. Membranes 
were incubated overnight with rabbit-anti-pSMAD2 (1:1000, #3101L, Cell Signaling 
Technology) or rabbit-anti-pSMAD1/5/9 (1:1000, #9511L, Cell Signaling Technology), 
followed by incubation with anti-rabbit HRP-linked antibody (1:1500, #P0448, Dako). 
44 
Proteins were visualized by enhanced chemiluminescence. As loading control, GAPDH 
was detected by the Odyssey CLx system (LI-COR, Lincoln, NE, USA) after incubation 
with mouse-anti-GAPDH (1:10,000; #G8795, Sigma-Aldrich) and donkey-anti-mouse-
IRDye®680RD (1:10,000, #925-68072, LI-COR).  
Statistical Analysis  
Statistical analyses were performed using SPSS version 22 (IBM, Armonk, NY, USA). 
Normal distribution was tested using the Shapiro-Wilk test. Data were analyzed with 
the generalized mixed models procedure considering ‘conditions’ as fixed parameter 
and ‘donors’ as random factor. Pairwise comparisons based on estimated marginal 
means were used. Multiple comparisons between unstimulated control and other 
conditions were corrected using Bonferroni’s procedure. P<0.05 was considered 
statistically significant. 
Results 
BMSCs express the type II and type I receptors of TGFβ, Activin and Nodal 
Since complexes of type II and type I receptors are required for activation of SMAD2/3 
signaling 
5
, we evaluated their expression in BMSCs (N=3 donors). Both the type II 
(TGFBR2, ACVR2A, ACVR2B) and type I receptors (TGFBR1, ACVR1B, ACVR1C) were 
detected with small variation between donors (Fig. 1A – 1C), indicating that the 
required receptors were present in BMSCs prior to chondrogenic induction and 
therefore not a limiting factor for Nodal, Activin and TGFβ signaling.  
 
Figure 1. The receptors of TGFβ, Activin and Nodal are expressed in BMSCs. In in vitro-
expanded human BMSCs (N=3 donors), gene expression of the receptors of (A) TGFβ: TGFBR2 
and TGFBR1, (B) Activin: ACVR2A and ACVR1B and (C) Nodal: ACVR2B and ACVR1C was detected 
using RT-qPCR. Gene expression was normalized to RPS27a and TBP (mean Ct value between 19-
20). Mean ± S.D. of 3 donors are shown with each data point representing the mean of triplicate 
in vitro-expanded BMSC samples per donor.      
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TGFβ and Activin activate SMAD2/3 signaling whereas Nodal does not  
To determine whether TGFβ, Activin and Nodal activated SMAD2/3 signaling in BMSCs, 
we analyzed expression of phosphorylated-SMAD2 protein (pSMAD2) and SERPINE1 
mRNA. Since the effective dose of Activin and Nodal to activate SMAD2/3 signaling in 
BMSCs was unknown, we evaluated the effect of 10, 100 and 250 ng/mL.  
The highest detected level of pSMAD2 was observed in BMSCs stimulated with TGFβ 
(Fig. 2A). Whereas Activin dose-dependently enhanced pSMAD2 expression, Nodal had 
no effect on pSMAD2 as compared to control (Fig. 2A). Consistent with these findings, 
 
 
Figure 2. TGFβ and Activin, but not Nodal, induce SMAD2 phosphorylation and SMAD2/3-
target gene expression. SMAD2/3 activation was determined in human BMSCs (N=3 donors) 
that were either not stimulated (Ctrl) or stimulated with TGFβ, Activin or Nodal at indicated 
concentrations. After 1 hour, cells were lysed for Western blot analysis of pSMAD2 using GAPDH 
as loading control (A), and after 24 hours RNA was isolated for SMAD2/3-target gene expression 
analysis of SERPINE1 (B). Western blot results of one representative donor (out of 3) are shown. 
Gene expression was normalized to RPS27a and TBP (mean Ct value between 19-20). Mean ± 
S.D. of 3 donors are shown with each data point representing the mean of triplicate BMSC 
samples per donor. Statistical differences between Ctrl and TGFβ, Activin or Nodal stimulation 
were determined using generalized mixed models and pairwise comparisons based on estimated 
marginal means. *** P˂0.001. 
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both TGFβ and Activin enhanced SERPINE1 expression (Fig. 2B; p=6.27E-26 for TGFβ; 
p=5.64E-4 for 10 ng/mL Activin; p=6.70E-9 for 100 ng/mL Activin; p=3.56E-10 for 250 
ng/mL Activin), whereas Nodal did not (Fig. 2B; p=1.00 for all doses). Although Activin 
induced SERPINE1 expression, it never reached the same level of TGFβ-induced 
SERPINE1 (Fig. 2B). In addition, we show that, in contrast to TGFβ, Activin and Nodal 
did not enhance phosphorylation of SMAD1/5/9 proteins (Fig. 3). 
Taken together, these findings show that SMAD2/3 signaling and subsequent 
downstream SERPINE1 expression in human BMSCs were activated by TGFβ and 
Activin, but not by Nodal.  
 
Figure 3. Unlike TGFβ, Activin and Nodal do not activate SMAD1/5/9 signaling in BMSCs. 
Activation of SMAD1/5/9 signaling was determined in human BMSCs (N=3 donors) that were 
either not stimulated (Ctrl) or stimulated with TGFβ, Activin or Nodal at indicated concentrations 
for 1 hour. Cells were lysed for Western blot analysis of pSMAD1/5/9 using GAPDH as loading 
control. Results of one representative donor (out of 3) are shown. 
Activin and Nodal do not induce cartilage formation  
We next investigated whether Activin and Nodal were capable of inducing 
chondrogenic differentiation of BMSCs. Even though the selected concentrations of 
Nodal did not activate SMAD2/3 signaling, we tested its chondrogenic induction 
capacity as it had not been investigated previously.   
TGFβ highly upregulated gene expression levels of ACAN (Fig. 4A; p=8.01E-20) and 
COL2A1 (Fig. 4B; p=6.02E-28). Activin slightly enhanced ACAN expression, but only at 
the highest dose of 250ng/mL (Fig. 4A; p=1.03E-2). Furthermore, 10 ng/mL as well as 
250 ng/mL Activin increased COL2A1 mRNA levels (Fig. 4B; p=3.19E-4 for 10 ng/mL; 
p=1.93E-2 for 250 ng/mL). None of the three Activin doses induced ACAN and COL2A1 
expression as high as TGFβ did. Compared to control, Nodal had no effect on 
expression of ACAN (Fig. 4A; p=1.00 for all doses) and COL2A1 (Fig. 4B; p=1.00 for all 
doses). 
The effects of TGFβ, Activin and Nodal on cartilage-specific gene expression were 
reflected by deposition of proteoglycans and collagen type II. Only BMSC pellets  
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Figure 4. In contrast to TGFβ, Activin and Nodal do not induce chondrogenic differentiation. 
Human BMSCs (N=3 donors with 3 pellets per donor) were pellet-cultured in chondrogenic 
medium either without growth factor (Ctrl) or with TGFβ, Activin or Nodal at indicated 
concentrations. After 10 days, triplicate pellets were harvested for cartilage-specific gene 
expression analysis of (A) ACAN and (B) COL2A1, and histological examination of (C) 
proteoglycans and collagen type II. For histology, each image shows a representative pellet 
section (out of 3 pellets per donor) per condition. Scale bar indicates 250 µm. Gene expression 
was normalized to RPS27a and TBP (mean Ct value between 19-20). n.d.= not detected. 
Statistical differences between Ctrl and TGFβ, Activin or Nodal stimulation were determined 
using generalized mixed models and pairwise comparisons based on estimated marginal means. 
*** P˂0.001; *P<0.05.  
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stimulated with TGFβ stained highly positive for proteoglycans and collagen type II 
(Fig. 4C). Although Activin slightly enhanced expression of cartilage-specific genes, 
neither proteoglycans nor collagen type II were detected (Fig. 4C). Also Nodal-
stimulated pellets were devoid of cartilage matrix. These results demonstrate that, 
unlike TGFβ, Activin and Nodal did not induce chondrogenesis of BMSCs. 
Discussion 
The aim of this study was to determine whether Activin and Nodal could activate 
SMAD2/3 signaling in BMSCs and, unlike TGFβ, induce chondrogenic differentiation 
without inducing terminal differentiation. We show that the receptors of TGFβ, Activin 
and Nodal were expressed in BMSCs and that TGFβ as well as Activin activated 
SMAD2/3 signaling, whereas Nodal did not. In contrast to TGFβ, Activin and Nodal 
dosages up to 25 times higher than that of TGFβ did not induce chondrogenic 
differentiation of BMSCs. 
TGFβ is well-known to induce chondrogenesis of BMSCs. Previously, we showed that 
activation of SMAD2/3 signaling by TGFβ is crucial for chondrogenic induction, 
however, TGFβ also activated SMAD1/5/9 signaling which is involved in terminal 
differentiation 
2
. Since Activin and Nodal had been reported to activate SMAD2/3 
signaling without activating SMAD1/5/9 signaling in multiple cell lines 
7-9
, we 
hypothesized these ligands could be alternative candidates for TGFβ to induce 
chondrogenesis of BMSCs without terminal differentiation. We demonstrate that, in 
human BMSCs, SMAD2/3 signaling was activated by Activin, but surprisingly not by 
Nodal. Although it was described that 250 to 4000 ng/ml of Nodal could activate 
SMAD2/3 signaling in murine P19 embryonal carcinomal cells 
8
, we did not observe the 
same effect in human BMSCs (data not shown). Despite we detected mRNA of Nodal 
receptor ALK7, the Ct value was relatively high (about 32), whereas the Ct value of 
TGFβ receptor ALK5 was approximately 26. Although this can be influenced by primer 
efficiency, this does hint towards an actual lower expression of Nodal receptors, which 
can have subsequent effects on possibilities for actual signaling and downstream gene 
activation. Why Nodal did not induce SMAD2/3 signaling and chondrogenesis may also 
be explained by dependency of Nodal on co-expression of Cripto; a member of the 
epidermal growth factor-Cripto/FRL1/Cryptic protein family, as formerly shown in 
embryonic cells 
9
. As we are first in determining the effects of Nodal on adult BMSCs, 
further investigation is necessary to gain insight into the role of Nodal in 
chondrogenesis of BMSCs. 
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To date, the chondrogenic induction capacity of Activin remained unclear. In contrast 
to a study showing that Activin inhibited aggrecan expression in murine ATDC5 cells 
(chondroprogenitor cell line) 
12
, we show that Activin induced aggrecan expression in 
human BMSCs. This discrepancy might be caused by differences between ATDC5 cells 
and BMSCs, for instance ATDC5 cells could undergo chondrogenesis with only insulin 
supplementation 
13
, whereas BMSCs could not 
4
. Although the molar dose of Activin 
was up to 25 times higher than that of TGFβ, Activin neither activated SMAD2/3 
signaling nor induced formation of cartilage proteins as intense as TGFβ. Previously, 
low TGFβ doses (<1 ng/mL), known to result in less intense SMAD2/3 activation than 
with 10 ng/mL 
14
, did not induce chondrogenesis 
4
, indicating that chondrogenic 
induction may depend on the intensity of SMAD2/3 activation. SMAD3 has been 
shown to be important for activation of SOX9; a master transcription factor for 
chondrogenesis 
15
 and we observed that silencing of SMAD2/3 expression in TGFβ-
stimulated BMSCs inhibits chondrogenic differentiation (unpublished data, manuscript 
under preparation). Moreover, a recent study demonstrated that in HepG2 cells 
(human hepatocarcinoma cell line) the maximum efficacy of Activin to activate 
SMAD2/3 signaling is 36% lower than that of TGFβ 
16
, suggesting that Activin is not able 
to activate SMAD2/3 proteins as efficiently as TGFβ. Therefore, possibly Activin did not 
stimulate cartilage matrix formation, because it could not activate a similar level of 
SMAD2/3 signaling as TGFβ did. In addition, since we recently found that both 
SMAD2/3 and SMAD1/5/9 pathways seem required for TGFβ-induced chondrogenesis 
of human BMSCs 
2,6
, the absence of SMAD1/5/9 pathway stimulation by Activin (Fig. 3) 
might be responsible for absence of chondrogenic differentiation.  
This study is first in comparing the chondrogenic induction capacity between known 
SMAD2/3-activating ligands; TGFβ, Activin and Nodal. As only TGFβ induced 
chondrogenic differentiation of BMSCs, neither Activin nor Nodal are suitable 
alternatives for TGFβ to induce chondrogenesis without terminal differentiation. 
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Abstract 
Objective: Bone marrow-derived mesenchymal stem cells (BMSCs) are promising for 
cartilage regeneration because BMSCs can differentiate into cartilage tissue-producing 
chondrocytes. Transforming Growth Factor β (TGFβ) is crucial for inducing 
chondrogenic differentiation of BMSCs and is known to signal via Activin receptor-Like 
Kinase (ALK) receptors ALK5 and ALK1. Since the specific role of these two TGFβ 
receptors in chondrogenesis is unknown, we investigated whether ALK5 and ALK1 are 
expressed in BMSCs and whether both receptors are required for chondrogenic 
differentiation of BMSCs.  
Design: ALK5 and ALK1 gene expression in human BMSCs was determined with RT-
qPCR. To induce chondrogenesis, human BMSCs were pellet-cultured in serum-free 
chondrogenic medium containing TGFβ1. Chondrogenesis was evaluated by aggrecan 
and collagen type IIα1 RT-qPCR analysis, and histological stainings of proteoglycans 
and collagen type II. To overexpress constitutively active (ca) receptors, BMSCs were 
transduced either with caALK5 or caALK1. Expression of ALK5 and ALK1 was 
downregulated by transducing BMSCs with shRNA against ALK5 or ALK1.  
Results: ALK5 and ALK1 were expressed in in vitro-expanded as well as in pellet-
cultured BMSCs from five donors, but mRNA levels of both TGFβ receptors did not 
clearly associate with chondrogenic induction. TGFβ increased ALK5 and decreased 
ALK1 gene expression in chondrogenically differentiating BMSC pellets. Neither caALK5 
nor caALK1 overexpression induced cartilage matrix formation as efficient as induced 
by TGFβ. Moreover, short hairpin-mediated downregulation of either ALK5 or ALK1 
resulted in a strong inhibition of TGFβ-induced chondrogenesis.  
Conclusions: ALK5 as well as ALK1 are required for TGFβ-induced chondrogenic 
differentiation of BMSCs, and TGFβ not only directly induces chondrogenesis, but also 
modulates ALK5 and ALK1 receptor signaling in BMSCs. These results imply that 
optimizing cartilage formation by mesenchymal stem cells will dependent on activation 
of both receptors. 
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Introduction 
Articular cartilage is a connective tissue covering bone surfaces within synovial joints 
and its main functions are distributing forces and preventing friction between moving 
bones. Chondrocytes are the only cell population present in articular cartilage and are 
responsible for production, maintenance and organization of the cartilage matrix.
1
 
Once articular cartilage becomes damaged by an injury or joint disease, it is not 
regenerated. In the long run, articular cartilage defects get worse and patients suffer 
from joint pain and dysfunction.
2
 Therefore, innovative treatments to regenerate 
cartilage tissue are highly necessary. However, to date, a procedure in which articular 
cartilage tissue is formed closely resembling native tissue’s structure and properties 
still needs to be developed.
3,4
 
To heal damaged cartilage, bone marrow-derived mesenchymal stem cells (BMSCs) are 
promising due to their capacity to differentiate into chondrocytes. 
5-11
 Unfortunately, 
thus far, results from BMSC-based therapies have been suboptimal due to variable 
levels of cartilage tissue formation and poor functional properties of the repair tissue 
formed.
12-15
 To solve these issues regarding the functionality of BMSC-derived 
cartilage, we need to better understand the molecular mechanisms that control 
chondrogenic differentiation of BMSCs. Ultimately, this might lead to formation of 
cartilage tissue which yields similar properties as native cartilage and restores joint 
functionality. 
Transforming growth factor β (TGFβ), originally described as Cartilage-Inducing 
Factor
16
, is required for chondrogenic differentiation of human BMSCs.
5-9,11
 TGFβ 
signals via type I and II serine/threonine kinase receptors 
17
. Upon binding of TGFβ 
ligands to type II receptors, heteromeric complexes are formed with type I receptors.
18-
20
 Within a complex, type II receptors phosphorylate the kinase domain of type I activin 
receptor-like kinase receptors (ALKs) which then recruit and phosphorylate SMAD 
proteins. Phosphorylated SMAD proteins translocate to the nucleus, where they 
associate with transcriptional co-activators and co-repressors to modulate target gene 
expression in a cell type-specific manner.
21-23
 
Although in most cell types TGFβ signaling is conveyed through ALK5, multiple studies 
have identified ALK1 as an alternative type I receptor for TGFβ.
24-30
 ALK5 is known to 
phosphorylate SMAD2 and SMAD3 proteins (SMAD2/3), and ALK1 phosphorylates 
SMAD1, SMAD5 and SMAD8 proteins (SMAD1/5/8).
22,31
 Previously, our group 
demonstrated that both SMAD pathways are important in chondrogenic 
differentiation of BMSCs as blocking TGFβ-induced phosphorylation of either SMAD2/3 
54 
or SMAD1/5/8 with chemical inhibitors prevented BMSC chondrogenesis.
32
 However, 
the specific role of ALK5 and ALK1 receptors in chondrogenic induction of BMSCs with 
TGFβ remains unknown. As TGFβ is crucial for BMSC chondrogenesis and is known to 
activate ALK5 as well as ALK1 receptors, our aim was to elucidate whether ALK5 and 
ALK1 are required for TGFβ-induced chondrogenic differentiation of human BMSCs. 
Materials and methods 
Cell isolation and expansion: 
Human fetal bone marrow-derived mesenchymal stem cells 
Primary human fetal BMSCs from one donor (donor F1) were purchased from ScienCell 
Research Laboratories (Carlsbad, CA, USA). Cells were culture-expanded in 
Mesenchymal Stem Cell Growth Medium (Lonza, Basel, Switzerland) supplemented 
with 1% Penicillin-Streptomycin-Glutamine (Gibco/Thermo Fisher Scientific, Waltham, 
MA, USA) until subconfluency and stored in liquid nitrogen at passage 5. Per 
experiment, fetal BMSCs were defrosted and expanded for another 2 to 4 passages.  
Human adult bone marrow-derived mesenchymal stem cells 
After obtaining written informed consent from patients (n=5), bone marrow aspirates 
were collected during total hip arthroplasty for osteoarthritis. This procedure was 
approved by the medical ethical committees of the Erasmus Medical Center, 
Rotterdam (#METC 2004-142) and Albert Schweitzer Hospital, Dordrecht (#METC 
2011.07). Primary human adult BMSCs were isolated from the marrow aspirate from 5 
donors (Donor A1 – A5) by plastic adherence. Adult BMSCs were seeded in α-MEM 
(Gibco) containing 10% pre-selected fetal calf serum (FCS; Lonza), 50 μg/mL 
gentamicine, 1.5 μg/mL fungizone (both from Gibco), 10
−4
 M L-Ascorbic acid 2-
phosphate  (Sigma-Aldrich, St. Louis, MO, USA) and 1 ng/mL Fibroblast Growth Factor-
2 (AbD Serotec, Kidlington, United Kingdom). Non-adherent cells were removed after 
24 hours and adherent cells were further culture-expanded until subconfluency. 
Experiments were performed using adult BMSCs in passage 2 to 4. 
Chondrogenic differentiation of human adult and fetal BMSCs 
BMSCs were centrifuged at 200 x g for 8 minutes and the obtained cell pellets (0.2×10
6
 
cells/pellet) were cultured for up to 21 days in 0.5 mL serum-free chondrogenic 
medium which consisted of DMEM-high glucose-GlutaMAX™, 1.5 mg/mL fungizone, 50 
mg/mL gentamicin, 1.0 mg/mL sodium pyruvate (all from Gibco), 6.25 µg/mL insulin, 
6.25 µg/mL transferrin, 6.25 ng/mL selenious acid, 5.35 µg/mL linoleic acid, 
1.25 mg/mL bovine serum albumin, 0.4 mg/mL L-proline, 10
−4
 M L-Ascorbic acid 2-
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phosphate, 10
−7
 M dexamethasone (all from Sigma-Aldrich) and 10 ng/mL TGFβ1 (for 
adult BMSCs; R&D Systems, Minneapolis, MN, USA and fetal BMSCs; Biolegend, San 
Diego, CA, USA). In parallel, pellets were cultured in chondrogenic medium without 
TGFβ1 supplementation in order to determine the effects of TGFβ on ALK5 and ALK1 
expression. This was done with cells from donors A1 and F1 because only from these 
two donors a sufficient number of cells was available. Medium was renewed 2 or 3 
times a week. Triplicate pellets were harvested for mRNA expression analysis and 
histological examination. 
Overexpression of caALK5 and caALK1 
Adenoviruses for constitutively active (ca) caALK5, caALK1 or LacZ were kindly 
provided by Dr. P. ten Dijke (Leiden University Medical Center, the Netherlands), and 
their preparation was described by Nakao et al. and Itoh et al.
22,33
  
Viral overexpressions were performed in BMSCs from fetal donor F1, because a high 
number of cells was available. Moreover, BMSCs from this donor chondrogenically 
differentiated within 7 days which is preferred to reliably test the effect of viral 
transductions, as adenoviruses cannot integrate into the cell’s genome. Furthermore, 
donor F1 was tested negative for HIV which is an important requirement for lentiviral 
transductions. Due to ethical concerns, the HIV-status could not be tested in donors 
A1-A5. 
Prior to cell pellet preparation, fetal BMSCs cultured in monolayer were transduced in 
serum-free DMEM-high glucose-GlutaMAX™ (Gibco) with adenovirus overexpressing 
caALK5 or caALK1 or LacZ (control) at a multiplicity of infection (MOI) of 150 pfu/cell 
for 3 hours. Cells were washed and pellet-cultured in serum-free chondrogenic 
medium for 7 days. In the presence of TGFβ, fetal BMSC pellets chondrogenically 
differentiated within 7 days as determined by ACAN and COL2A1 RT-qPCR analysis and 
histological examination of proteoglycans and collagen type II. To test whether 
constitutively active ALK5 or ALK1 receptor signaling induced chondrogenic 
differentiation, BMSCs either transduced with caALK5 or caALK1 were not stimulated 
with TGFβ and LacZ-transduced BMSCs were stimulated with TGFβ.  
To verify the overexpression of caALK5 and caALK1 in BMSC pellets one day after 
transduction, mRNA levels of ALK5 (=TGFBR1) and ALK1 (=ACVRL1) were determined 
by RT-qPCR. In order to confirm that caALK5 induced SMAD2 phosphorylation 
(pSMAD2) and that caALK1 induced SMAD1/5/8 phosphorylation (pSMAD1/5/8), 
expression of pSMAD2 and pSMAD1/5/8 proteins were analyzed by Western blot in 
one day-cultured BMSC pellets transduced with caALK5, caALK1 or LacZ. Expression of 
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pSMAD2 and pSMAD1/5/8 was compared between LacZ-transduced pellets (not 
exposed to TGFβ) and pellets transduced either with caALK5 or caALK1. 
shRNA-mediated downregulation of ALK5 and ALK1 expression 
MISSION® TRC-Hs1.5 shRNA clones (Sigma-Aldrich) targeting ALK5 (TRCN0000039773) 
or ALK1 (TRCN0000000355) and Empty Vector Control (SHC001) constructed in the 
pLKO.1-Puro plasmid vector were kindly provided as purified plasmid DNA by Dr. P. ten 
Dijke (Leiden University Medical Center, the Netherlands). Lentiviruses were packaged 
with one of the aforementioned pLKO.1-puro plasmid vectors as described below. 
HEK293T cells (ATCC, Manassas, VA, USA) were co-transduced with 42.7 µg pLKO.1-
puro plasmid, 31.8 µg gag/pol packaging plasmid (pMDL-g/p-RRE), 10.7 µg rev 
expression plasmid (RSV-REV) and 15.0 µg VSV-G expression plasmid (pHIT-G) by 
calcium phosphate precipitation for 16 hours. Co-transductions were carried out in 
DMEM-high glucose-GlutaMAX™ (Gibco) containing 10% FCS (Perbio Science, 
Erembodegem, Belgium), 0.01 mM cholesterol (Sigma-Aldrich) and 1% pyruvate 
(Gibco). This medium (=supernatant) was renewed 16 hours after transduction, and 1% 
Penicillin-Streptomycin-Glutamine (Gibco) was added. After 24 and 48 hours from the 
medium renewal, the supernatant was collected and filtered through a 0.45 µm pore 
polyvinylidene fluoride Durapore filter (Millipore, Bedford, MA, USA). To concentrate 
lentiviral particles, 20% sucrose (Sigma-Aldrich) in PBS was pipetted under the 
supernatant and centrifuged at 134,350 x g for 2 hours (Sorvall WX80+, Thermo Fisher 
Scientific). After re-suspending the pellet in 210 µL sterile PBS, the concentration of 
lentiviral particles was determined according to the INNOTEST® HIV p24 Antigen 
monoclonal antibody assay (Fujirebio Europe, Gent, Belgium) and lentivirus titers were 
expressed as pg of p24/µL.  
Fetal BMSCs, cultured in monolayer, were transduced for 24 hours with 1 pg p24 
(lentivirus) per cell of either ALK5-shRNA, ALK1-shRNA or empty vector control in 
Mesenchymal Stem Cell Growth Medium (Lonza) supplemented with 1% Penicillin-
Streptomycin-Glutamine (Gibco) and 100 µg/mL protamine sulfate (Sigma-Aldrich). 
Following lentiviral transduction, cells were washed, trypsinized (0.25% trypsin; Gibco) 
and pellet-cultured in serum-free chondrogenic medium containing TGFβ1. After 7 
days, chondrogenic induction was evaluated by determining expression of cartilage-
specific genes (ACAN and COL2A1) and proteins (proteoglycan and collagen type II). In 
pellets cultured for 1 or 7 days, TGFBR1 and ACVRL1 mRNA levels were analyzed by RT-
qPCR to evaluate the efficiency of shRNA-mediated downregulation of ALK5 and ALK1.  
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RNA extraction and real-time quantitative polymerase chain reaction 
Total cellular RNA was extracted from fetal BMSCs with TRI Reagent® (Sigma-Aldrich) 
according to manufacturer’s protocol and contaminating DNA was removed by DNAse 
treatment (Invitrogen/Thermo Fisher Scientific). Adult BMSCs were homogenized in 
RNA-Bee (Tel-Test, Friendswood, TX, USA) and RNA was further purified using an 
RNeasy MicroKit (Qiagen, Hilden, Germany) with on-column DNA digestion. The 
concentration and purity of isolated RNA were measured on a NanoDrop® 
spectrophotometer (Isogen Life Science, Utrecht, the Netherlands). 500ng of total RNA 
was converted into cDNA using Reverse Transcriptase (Invitrogen) according to 
manufacturer’s instructions. Real-Time Quantitative Polymerase Chain Reaction (RT-
qPCR) measurements were performed on a StepOnePlus™ Real-Time PCR System using 
SYBR Green Master mix (both from Applied Biosystems/Thermo Fisher Scientific). 
Primers are listed in Table 1.  
Gene expression analysis  
The Ct value of each primer was determined at a fixed threshold level of fluorescence 
and the amplification efficiency of all primers was between 90% and 110% (Table 1). 
Gene expression was normalized to expression of ribosomal protein 27a (RPS27a), 
which was stably expressed between conditions and over time. Normalized gene 
expression levels in control conditions were set as 100%. –ΔCt values were used for 
statistical analyses. 
 Primer sequences Details 
Gene Forward primer Reverse primer Product Slope 
RPS27a TGGCTGTCCTGAAATATTATAAGGT CCCCAGCACCACATTCATCA 90bp 3.4 
TGFBR1 
(ALK5)  
CGACGGCGTTACAGTGTTTCT CCCATCTGTCACACAAGTAAA 65bp 3.3 
ACVRL1 
(ALK1) 
CCATCGTGAATGGCATCGT GGTCATTGGGCACCACATC 63bp 3.2 
ACAN GCCTGCGCTCCAATGACT  ATGGAACACGATGCCTTTCAC 104bp 3.3 
COL2A1 CACGTACACTGCCCTGAAGGA CGATAACAGTCTTGCCCCACTT 65bp 3.3 
Table 1. List of primers used for RT-qPCR. 
Histology 
Pellets were fixed in 4% formalin in PBS for 24 hours followed by paraffin embedding. 
Sections (6 µm thick) were mounted on Super Frost glass slides (Thermo Fisher 
Scientific). Proteoglycans were stained with 0.1% aqueous Safranin O and sections 
were counterstained with 0.1% aqueous Fast Green (both from Brunschwig Chemie, 
Amsterdam, the Netherlands). To stain collagen type II using immunohistochemistry, 
sections were pre-treated with 0.1% pronase (Sigma-Aldrich) in PBS at 37°C for 30 
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minutes followed by 30 minutes-incubation with 1% hyaluronidase (Sigma-Aldrich) in 
PBS at 37°C for antigen retrieval. Sections were rinsed with PBS and non-specific 
binding sites were blocked with 10% normal goat serum (SouthernBiotech, 
Birmingham, AL, USA) in PBS containing 1% BSA (PBS-1%BSA). After 30 minutes, 
sections were incubated either with 0.4 μg/mL anti-collagen II primary antibody 
(mouse monoclonal IgG1, raised against chicken collagen type II; II-II6B3 cell culture 
supernatant, Developmental Studies Hybridoma Bank, Iowa City, IA, USA) in PBS-
1%BSA or incubated with 0.4 μg/mL mouse-IgG1 as negative control (#X0931, Dako, 
Glostrup, Denmark) in PBS-1%BSA at room temperature for 60 minutes. Subsequently, 
sections were rinsed with PBS and anti-collagen type II antibody was detected using 
alkaline phosphatase-conjugated secondary antibody kit (1:50 in PBS-1%BSA; #HK-321-
UK, Biogenex, San Ramon, CA, USA) according to manufacturer’s protocol. Alkaline 
phosphatase activity, representing presence of collagen II protein, stained magenta 
after incubating sections with New Fuchsine substrate (Chroma, Köngen, Germany). 
Finally, sections were counterstained with hematoxylin (Sigma-Aldrich), air-dried and 
mounted with VectaMount™ (Vector Laboratories, Burlingame, CA, USA). 
Western blot analysis 
Phosphorylated SMAD2 (pSMAD2) and phosphorylated SMAD1/5/8 (pSMAD1/5/8) 
protein expression was analyzed by Western blot. Total proteins were isolated from 
fetal BMSC pellets using Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA, USA) 
with 1% protease inhibitor (Roche Diagnostics, Basel, Switzerland). Lysates were 
sonicated on ice using a Bioruptor® (Diagenode, Denville, NJ, USA). Sonified samples 
were centrifuged at 4°C at 16,000 x g for 15 minutes. In supernatant, the protein 
concentration was determined using the bicinchoninic acid assay (Thermo Fisher 
Scientific). 14 μg of protein lysate was loaded on a 10% bisacrylamide gel for SDS-
PAGE. Hereafter, proteins were transferred to a nitrocellulose membrane (GE 
Healthcare, Little Chalfont, United Kingdom) by wet transfer in Towbin buffer (4°C) at 
275 mA for 2 hours. Membranes were blocked with 5% non-fat dry milk (pSMAD2) or 
with 5% BSA (pSMAD1/5/8) in 0.1% Tween in Tris-buffererd saline (TBST). 
Subsequently, membranes were incubated overnight at 4°C with either rabbit-anti-
pSMAD2 (1:1000; #3101L, Cell Signaling Technology) or rabbit-anti-p-Smad1/5/8 
(1:1000; #9511L, Cell Signaling Technology) in 5% or 2% non-fat dry milk in TBST, 
respectively. After washing in TBST, membranes were incubated with anti-rabbit 
horseradish peroxidase (HPR)-linked secondary antibody (1:1500; #P0448, Dako) in 
TBST containing 5% non-fat dry milk (pSMAD2) or 2% non-fat dry milk (pSMAD1/5/8) 
at room temperature for 1 hour. Proteins were visualized by detection of the HRP-
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signal using enhanced chemiluminescence (ECL) Prime Western Blotting Detection 
Reagent kit (GE Healthcare) following manufacturer’s protocol.  
To assess equal protein loading on pSMAD-stained membranes, GAPDH expression 
was analyzed. Membranes were blocked with Odyssey® Infrared Imaging System 
Blocking Buffer (LI-COR, Lincoln, NE, USA) for 1 hour, followed by incubation with 
mouse-anti-GAPDH antibody (1:10,000; #G8795, Sigma-Aldrich) in Odyssey blocking 
buffer at room temperature for 1 hour. After washing with PBS containing 0.1% Tween 
(PBST), membranes were incubated with donkey-anti-Mouse antibody conjugated with 
IRDye® 800CW (LI-COR) at room temperature for 30 minutes. GAPDH expression was 
detected using an Odyssey CLx Infrared Imaging System (LI-COR) and signal intensity 
was quantified with Image Studio™ Lite (Version 3.1, LI-COR). 
Data analysis 
Quantitative data are represented as mean ± standard deviation. Statistical analyses 
were performed using GraphPad Prism version 5.03 for Windows (GraphPad Software, 
San Diego, CA, USA). The normality and variance were evaluated by the Shapiro-Wilk 
test and Levene’s Test of Homogeneity. Normally distributed data with equal variance 
were analyzed by an independent student’s t test or one-way ANOVA with Bonferroni 
post hoc test. Level of significance was set at P<0.05. 
Results 
Levels of ALK5 and ALK1 expression in BMSCs are not associated with chondrogenic 
differentiation capacity 
Transforming Growth Factor-β is known to signal either via ALK5 or ALK1 receptors, 
which intracellularly activate SMAD2/3 and SMAD1/5/8 signaling respectively. We first 
confirmed gene expression of ALK5 (TGFBR1) and ALK1 (ACVRL1) in in vitro-expanded 
BMSCs (n=5) and observed that their expression levels varied between donors (Fig. 1). 
We next investigated whether the mRNA levels of ALK5 and ALK1 at onset of 
chondrogenic differentiation (first 7 days of pellet culture) were related to the 
chondrogenic capacity of BMSCs at day 21. Moreover, gene expression of aggrecan 
(ACAN; Fig. 2A) and collagen type IIα1 (COL2A1; Fig. 2B) was analyzed during onset of 
chondrogenesis. The overall chondrogenic capacity of each donor was determined by 
histological examination of proteoglycans and collagen type II deposition (Fig. 2C) in 
pellets cultured for 21 days. Chondrogenic markers (Fig. 2C) were highest expressed in 
pellets of donors A1, A2, A3 and F1 (defined as ‘highly chondrogenic’) and lowest in 
donors A4 and A5 (defined as ‘poorly chondrogenic’). At onset of chondrogenesis,  
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Figure 1. ALK5 and ALK1 are expressed in human bone marrow-derived mesenchymal stem 
cells (BMSCs). In human BMSCs, obtained from four adult donors (A1 – A4) and one fetal donor 
(F1), gene expression levels of ALK5 (=TGFBR1) (A) and ALK1 (=ACVRL1) (B) were analyzed using 
RT-qPCR. Gene expression was normalized to reference gene RPS27a. Each data point 
represents one measurement. 
ALK5 gene (TGFBR1) expression pattern was similar in donors A1 and A5, with a high 
expression at the start of culture and an increase over time (Fig. 2D). The other 4 
donors displayed lower TGFBR1 expression than donors A1 and A5 and stable or 
decreasing expression over the 7 days of culture (Fig. 2D). ALK1 mRNA (ACVRL1) levels 
remained rather stable over time in donors A1, A3, A5 and F1, while in donors A2 and 
A4 we generally observed a lower expression compared to the other donors (Fig. 2E). 
These data indicate that ALK5 and ALK1 are expressed in human BMSCs, but the mRNA 
levels of both TGFβ receptors no clearly associate with the chondrogenic capacity of 
BMSCs. 
Figure 2 (next page). Gene expression levels of ALK5 (TGFBR1) and ALK1 (ACVRL1) are not 
associated with the chondrogenic capacity of human BMSCs. To induce chondrogenesis, BMSCs 
(passage 2 – 4) from adult donors A1 – A5 and fetal donor F1 were pellet-cultured in 
chondrogenic medium and stimulated with TGFβ. Cartilage-specific gene expression of aggrecan 
(ACAN) (A) and collagen type IIα1 (COL2A1) (B) was determined in BMSCs cultured for 0, 1, 4, 7 
and 21 days using RT-qPCR. Cartilage-specific protein depositions of proteoglycans (C; upper 
panel) and collagen type II (C; lower panel) were stained in sections of 21 days-cultured pellets. 
To stain proteoglycans, sections were stained with Safranin O (red/orange) and Fast Green (blue) 
was used as counterstaining. Collagen type II was stained immunohistochemically (pink) and 
hematoxylin (purple) was used as counterstaining. Representative images of consecutive pellet 
sections per donor are shown and the scale bar represents 500 µm. TGFBR1 (D) and ACVRL1 (E) 
expression levels were measured in BMSC monolayer (day 0) and pellets cultured for 1, 4 and 7 
days. Gene expression was normalized to reference gene RPS27a. Data points represent mean ± 
SD of triplicate BMSC pellets per donor per time point. 
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TGFβ increases ALK5 and decreases ALK1 gene expression in BMSCs 
As an increase in TGFβ levels and in the number of receptors might result in enhanced 
sensitivity of cells to TGFβ 
34
, we investigated whether TGFβ modulated TGFBR1 (ALK5) 
and ACVRL1 (ALK1) expression in BMSC pellets in donors A1 and F1 cultured for 1, 4 or 
7 days. Compared to unstimulated pellets, TGFβ significantly induced TGFBR1 
expression in pellets from donor A1 and donor F1 at day 1, 4, and 7 (Table 2). More 
specifically, TGFβ enhanced transcript levels of TGFBR1 in donor F1 about 2-fold at all 
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time points measured, whereas in donor A1 TGFβ continuously increased TGFBR1 
mRNA levels over time; 2.55-fold at day 1, 3.31-fold at day 4 and 7.58-fold at day 7. 
Contrary to TGFBR1 expression, ACVRL1 appeared to be significantly downregulated by 
TGFβ in both donors tested (Table 2). The inhibiting effect of TGFβ on ACVRL1 
expression was more pronounced on day 4 than on day 1 in donor A1 (from -1.93-fold 
at day 1 to -3.30-fold at day 4) as well as in donor F1 (from -2.38-fold at day 1 to -3.32-
fold at day 4). At day 7, ACVRL1 mRNA levels were stronger decreased by TGFβ in 
donor A1 (-3.98-fold) than in donor F1 (-2.72-fold). Altogether, our data show that 
TGFβ regulates gene expression of its ALK5 and ALK1 receptors in chondrogenically 
differentiating BMSCs by enhancing TGFBR1 and decreasing ACVRL1 expression. 
 TGFBR1 fold change (Mean ± SD) ACVRL1 fold change (Mean ± SD) 
Day Donor A1 P-value Donor F1 P-value Donor A1 P-value Donor F1 P-value 
1 2.55 ± 0.39 0.010 1.98 ± 0.22 0.001 -1.93 ± 0.21 0.040 -2.38 ± 0.30 0.001 
4 3.31 ± 0.27 0.001 2.24 ± 0.12 <0.001 -3.30 ± 0.51 0.003 -3.32 ± 0.74 0.001 
7 7.58 ± 0.26 <0.001 2.34 ± 0.19 0.005 -3.98 ± 1.06 0.001 -2.72 ± 0.20 <0.001 
 
Table 2. TGFβ increases TGFBR1 (ALK5) and decreases ACVRL1 (ALK1) in human BMSC pellets. 
The effect of TGFβ on TGFBR1 and ACVRL1 was evaluated in BMSC pellets from donor A1 and 
donor F1 cultured in chondrogenic medium with TGFβ or without (=unstimulated) for 1, 4 or 7 
days. Gene expression was normalized to reference gene RPS27a. Data are expressed as fold 
change relative to unstimulated pellets and the mean ± SD of triplicate BMSC pellets per donor 
per time point are shown. 
Overexpression of caALK5 or caALK1 receptors does not induce chondrogenic 
differentiation as efficient as TGFβ 
Since it was unknown whether TGFβ induces chondrogenesis through activation of its 
ALK5 or ALK1 receptor, we tested whether overexpression of either constitutively 
active (ca) caALK5 or caALK1 receptors induced chondrogenic differentiation of BMSCs.  
In one day-cultured pellets we confirmed overexpression of TGFBR1 following caALK5 
transduction (Fig. 3A) and ACVRL1 overexpression following caALK1 transduction (Fig. 
3B). Whereas overexpression of caALK1 did not change TGFBR1 expression (Fig. 3A), 
caALK5 overexpression reduced mRNA levels of ACVRL1 (Fig. 3B). We also verified that 
caALK5 and caALK1 receptors phosphorylated their downstream signaling proteins 
SMAD2/3 (Fig. 3C) and SMAD1/5/8 (Fig. 3D) without prior activation by TGFβ and 
dimerization with type II receptors.  
Figure 2B Figure 2A 
Figure 2C 
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Figure 3. BMSCs overexpressing either constitutively active (ca) caALK5 or caALK1 express 
enhanced levels of phosphorylated SMAD2/3 and SMAD1/5/8 proteins, respectively. Human 
fetal BMSCs (donor F1) were transduced with adenoviral caALK5, caALK1 or LacZ as control and 
pellet-cultured in chondrogenic medium for 1 day. Transduction efficiency of caALK5 and caALK1 
was evaluated after gene expression analysis of TGFBR1 (A) and ACVRL1 (B). Gene expression 
was normalized to reference gene RPS27a and data are expressed as fold change relative to 
normalized gene levels in LacZ-transduced BMSCs. Bars represent mean ± SD from triplicate 
pellets of 1 representative experiment (out of 3), **P<0.01; ***P<0.001. Constitutively active 
receptor signaling of ALK5 and ALK1 was evaluated by Western blot analyses of phosphorylated 
SMAD (pSMAD) proteins; pSMAD2/3 (C) and pSMAD1/5/8 (D) using GAPDH as loading control. 
Next, we determined whether overexpression of either caALK5 or caALK1 induced 
chondrogenic differentiation of human fetal BMSCs similar to chondrogenesis induced 
by TGFβ. Chondrogenic differentiation was evaluated by comparing expression of 
cartilage matrix-specific genes (ACAN and COL2A1) and proteins (proteoglycans and 
collagen type II) between caALK5- or caALK1-transduced pellets cultured in the 
absence of TGFβ and the control condition (LacZ-transduced pellets stimulated with 
TGFβ). Compared to the LacZ control stimulated with TGFβ, caALK5-transduced pellets 
expressed ACAN 99.6% lower (Fig. 4A) and COL2A1 99.9% lower (Fig. 4B). In caALK1-
transduced pellets ACAN was 92.7% (Fig. 4A) and COL2A1 was 99.6% (Fig. 4B) lower 
expressed than in LacZ-transduced pellets exposed to TGFβ. Consistent with these 
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findings, caALK5-transduced pellets did not stain positive for proteoglycans (Fig. 4C; 
upper panel) or collagen type II (Fig. 4C; lower panel), and caALK1-transduced pellets 
stained weakly positive for the two cartilage-specific proteins. In contrast, LacZ-
transduced pellets displayed intense staining of proteoglycans and collagen type II 
after 7 days stimulation with TGFβ (Fig. 4C), confirming that only in this condition 
BMSCs differentiated and deposited a high amount of cartilage matrix. Taken together, 
these data indicate that neither constitutively active ALK5 nor constitutively active 
ALK1 induce chondrogenic differentiation of BMSCs as efficient as TGFβ. 
 
Figure 4. Constitutively active (ca) caALK5 and caALK1 receptors do not induce BMSC 
chondrogenesis as efficiently as TGFβ does. Human fetal BMSCs (donor F1) transduced with 
adenoviral caALK5, caALK1 or LacZ as control were pellet-cultured in chondrogenic medium for 7 
days. Only LacZ-transduced pellets were exposed to TGFβ to compare if either caALK5 or caALK1 
induced chondrogenesis as efficiently as induced by TGFβ. Chondrogenesis was evaluated by 
cartilage-specific gene expression analysis of ACAN (A) and COL2A1 (B) and by staining 
proteoglycans with Safranin O/Fast Green (C; upper panel) and collagen type II with 
immunohistochemistry (C; lower panel). Representative images of consecutive pellet sections 
per condition are shown and the scale bar represents 500 µm. Gene expression was normalized 
to reference gene RPS27a and data are expressed as % relative to normalized gene levels in 
LacZ-transduced pellets stimulated with TGFβ. Bars represent mean ± SD from quadruplet 
pellets of 1 representative experiment (out of 3), ***P<0.001. 
 65 
Downregulation of either ALK5 or ALK1 expression in BMSCs inhibits TGFβ-induced 
chondrogenic differentiation 
To further determine the role of ALK5 and ALK1 receptors in chondrogenesis initiated 
by TGFβ, we investigated whether downregulation of either ALK5 or ALK1 expression 
abrogated TGFβ-induced chondrogenic differentiation of BMSCs. ALK5 and ALK1 were 
downregulated by transducing human fetal BMSCs, cultured in monolayer, with a 
lentivirus overexpressing either ALK5 short hairpin RNA (ALK5-shRNA) or ALK1-shRNA. 
Following transduction, BMSCs were pellet-cultured in chondrogenic medium. 
At day 1 and 7 of chondrogenic induction we verified the efficiency of shRNA-mediated 
downregulation by gene expression analysis of TGFBR1 and ACVRL1. Compared to the 
control condition at both time points, TGFBR1 expression was about 50% 
downregulated by ALK5-shRNA (Fig. 5A) and ACVRL1 expression was about 50% 
downregulated by ALK1-shRNA (Fig. 5B). In addition, TGFBR1 mRNA levels were not 
affected by ALK1-shRNA (Fig. 5A), but ACVRL1 was higher expressed in the ALK5-shRNA 
condition than in the control condition at day 7 (Fig. 5B).The effect of shRNA-mediated 
ALK5 and ALK1 downregulation on TGFβ-induced chondrogenic differentiation of 
BMSCs was determined by ACAN and COL2A1 gene expression analysis and examining 
deposition of proteoglycans and collagen type II in pellets stimulated with TGFβ for 7 
days. Compared to control vector-transduced pellets stimulated with TGFβ, ALK5-
shRNA reduced expression levels of ACAN by 98.8% (Fig. 5C) and COL2A1 by 99.9% 
(Fig. 5D), resulting in the same low ACAN and COL2A1 mRNA levels as in the 
unstimulated control condition. ALK1-shRNA reduced ACAN expression by 62.6% (Fig. 
5C) and COL2A1 expression by 87.2% (Fig. 5D) compared with the TGFβ-stimulated 
control condition. Furthermore, we observed that control vector-transduced pellets 
exposed to TGFβ stained strongly positive for proteoglycans (Fig. 5E; upper panel) and 
collagen type II (Fig. 5E; lower panel), whereas TGFβ-stimulated pellets overexpressing 
ALK1-shRNA were only weakly positive for both cartilage matrix molecules. Moreover, 
pellets consisting of ALK5-shRNA-transduced BMSCs did not stain positive for 
proteoglycans nor for collagen type II, despite stimulation with TGFβ (Fig. 5E). Thus, 
shRNA-mediated downregulation of ALK5 or ALK1 results in an abrogation of TGFβ-
induced chondrogenic differentiation of BMSCs. 
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Figure 5. shRNA-mediated downregulation of either ALK5 or ALK1 inhibits TGFβ-induced 
chondrogenic differentiation of BMSCs. Human fetal BMSCs (donor F1) were transduced with 
lentiviral ALK5-shRNA, ALK1-shRNA or empty vector as control (Ctrl vector) and pellet-cultured in 
chondrogenic medium containing TGFβ. Short hairpin RNA-mediated downregulation of ALK5 
and ALK1 was determined by gene expression of TGFBR1 (A) and ACVRL1 (B) in pellets cultured 
for 1 or 7 days. The effect of ALK5-shRNA and ALK1-shRNA on TGFβ-induced chondrogenesis was 
evaluated by transcript analysis of ACAN (C) and COL2A1 (D) and by staining proteoglycans with 
Safranin O/Fast Green (E; upper panel) and collagen type II with immunohistochemistry (E; 
lower panel) in pellets cultured for 7 days. Representative images of consecutive pellet sections 
per condition are shown and the scale bar represents 500 µm. Gene expression was normalized 
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to reference gene RPS27a and data are expressed as % relative to normalized mRNA levels in 
control vector-transduced pellets stimulated with TGFβ. Bars represent mean ± SD of quadruplet 
pellets from 1 representative experiment (out of 3), ns = not significant; **P<0.01; ***P<0.001.  
Discussion 
In this study we investigated the involvement of ALK5 and ALK1 receptors in TGFβ-
induced chondrogenic differentiation of BMSCs. We show that TGFβ modulated gene 
expression of its receptors in BMSCs by increasing ALK5 whilst decreasing ALK1, 
although mRNA levels of ALK5 and ALK1 did not associate with the chondrogenic 
differentiation capacity. Overexpression of either caALK5 or caALK1 receptors did not 
induce chondrogenesis as efficient as induced by TGFβ, and downregulating either 
ALK5 or ALK1 blocked cartilage formation in TGFβ-stimulated BMSCs. Taken together, 
these findings indicate that both ALK5 and ALK1 are required for TGFβ-induced 
chondrogenic differentiation of human BMSCs. 
Although TGFβ is well-known to induce chondrogenic differentiation, no study has 
determined whether TGFβ induces chondrogenesis through activation of its ALK5 or 
ALK1 receptor. Therefore, in the present study we overexpressed either constitutively 
active ALK5 or constitutively active ALK1 and downregulated mRNA expression of the 
two TGFβ receptors in BMSCs. The characteristic of constitutively active ALK receptors 
is that they phosphorylate downstream SMAD proteins without prior activation by 
TGFβ, which allowed us to determine whether TGFβ induces chondrogenic 
differentiation through activation of its ALK5 or ALK1 receptor. Despite ALK5 is 
considered to be the 'classical' TGFβ receptor, overexpression of caALK5 did not induce 
chondrogenesis. Previously, caALK1 overexpression was reported to fail to promote 
cartilage nodule formation in ATDC5 cells (chondrogenic mouse teratocarcinoma cell 
line).
35
 Here, we demonstrate that caALK1 overexpression slightly induced cartilage 
matrix formation in BMSCs, albeit not comparable to TGFβ-induced matrix formation. 
Together these results suggest that, to induce chondrogenesis, activation of either 
ALK5 or ALK1 is insufficient. Since the abundance and timespan of SMAD 
phosphorylation has been demonstrated to influence the cell’s responses
36,37
, one has 
to take into account that SMAD phosphorylation might be initiated with different 
kinetics by exogenous TGFβ than by overexpression of constitutively active receptors.  
As neither caALK5 nor caALK1 overexpression induced chondrogenic differentiation in 
single overexpression experiments, this suggests that both receptors are required to 
induce chondrogenesis. When co-transducing cells with two constructs, we cannot 
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ensure double targeting of all single cells which is crucial for drawing conclusions on 
the impact of dual receptor overexpression on chondrogenesis. Instead, we 
determined the requirement of both receptors for chondrogenic differentiation by 
downregulating either ALK5 or ALK1 expression with short hairpin RNA. We show that 
knocking down either one of the two TGFβ receptors prevented chondrogenic 
induction by TGFβ, confirming that without the presence of both receptors 
chondrogenesis will not occur. Similar to our observation when we specifically 
downregulated ALK5, also inhibition of ALK5 with a small molecule (ALK5i) was 
reported to prevent chondrogenesis.
38
 Although small molecule inhibitors might have 
off-target effects
39
, the results of Elkasrawy et al.
38
 and our study proof a crucial role 
for ALK5 in chondrogenic differentiation of BMSCs. Additionally, the importance of 
ALK5 in chondrogenesis is supported in vivo as mice with conditional knockout of ALK5 
in skeletal progenitor cells had impaired endochondral bone formation; a process 
wherein mesenchymal stem cells first differentiate into chondrocytes which then 
terminally differentiate and eventually are replaced by bone cells.
40
 Regarding the 
involvement of ALK1 in chondrogenesis, overexpression of kinase-inactive ALK1 
receptors was previously found to block spontaneous cartilage nodule formation in a 
murine chondrogenic cell line.
35
 We show here that shRNA-mediated downregulation 
of ALK1 in human BMSCs strongly reduced TGFβ-induced chondrogenic differentiation, 
further supporting that besides ALK5 also ALK1 is required for chondrogenesis. 
To the best of our knowledge, this study is first to demonstrate ALK5 and ALK1 gene 
expression in in vitro expanded human BMSCs as well as in chondrogenically 
differentiating human BMSC pellet cultures. We show that TGFβ, besides inducing 
chondrogenic differentiation of BMSCs, regulated expression of its receptors by 
enhancing ALK5 expression whilst downregulating ALK1 expression, skewing the 
balance between its two receptors towards ALK5. This is in line with previous reports 
demonstrating that TGFβ enhanced ALK5 gene expression in human smooth muscle 
cells, pancreatic epithelial cells and lung fibroblasts.
41-43
 However, also the opposite 
was shown as TGFβ downregulated ALK5 mRNA and protein levels in human articular 
chondrocytes
44
, suggesting that the effects of TGFβ on ALK5 expression might be 
culture condition- or cell type-dependent. So far, the effect of TGFβ on ALK1 was 
investigated in only two studies. Whereas TGFβ did not change ALK1 expression in 
neurons
45
, TGFβ reduced ALK1 mRNA levels in human endothelial cells, which is similar 
to our observation in human BMSCs.
46
 Moreover, in line with the observed effect of 
TGFβ on ALK1 receptor expression, we also demonstrate that caALK5 overexpression 
reduced ALK1 mRNA levels whereas downregulation of ALK5 enhanced ALK1 gene 
expression. In addition to a change in balance between ALK5 and ALK1 receptor levels 
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by TGFβ, we show that the mRNA levels of ALK5 and ALK1 varied between different 
BMSC donors during onset of chondrogenesis. Previously, ALK5 gene expression was 
shown by us to correlate with expression of ACAN and COL2 in human OA cartilage.
24
 
Although the chondrogenic capacity of different BMSC donors was diverse in our 
study, we could not find an association between ALK5 or ALK1 gene expression levels 
and the chondrogenic differentiation capacity of BMSCs. Since both TGFβ receptors 
appeared necessary for chondrogenesis of BMSCs, the importance of balance, timing 
of expression and activity of ALK5 and ALK1 deserves more attention in future studies.  
In our study we used human BMSCs from both adult and fetal origin. Recently, Brady 
et al. found that TGFβ3 could induce chondrogenesis in adult BMSC pellets, whereas 
TGFβ3 as well as TGFβ1 did not initiate chondrogenic differentiation of fetal BMSC 
pellet cultures.
47
 The authors suggested that, apparently, adult and fetal BMSCs use 
different signaling mechanisms for inducing chondrogenic differentiation. In our 
experiments, however, both adult and fetal BMSC pellets did form cartilage matrix 
molecules following stimulation with TGFβ1 and the mRNA levels of ALK5 and ALK1 as 
well as their response to TGFβ1 was similar. Because our observation is not in line with 
the findings from Brady et al., further investigation is necessary to exactly determine 
the dependency of chondrogenesis on TGFβ and whether this is related to source and 
developmental stage of human BMSCs. 
Our study provides new insights regarding the involvement of ALK5 and ALK1 in 
chondrogenesis induced by TGFβ. This new knowledge helps to better understand the 
molecular events that control chondrogenic differentiation of mesenchymal stem cells, 
which is important for developing procedures to optimize cartilage repair. 
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Abstract 
To improve cartilage formation by bone marrow-derived mesenchymal stem cells 
(BMSCs), the signaling mechanism governing chondrogenic differentiation requires 
better understanding. We previously showed that the transforming growth factor-β 
(TGFβ) receptor ALK5 is crucial for chondrogenesis induced by TGFβ. ALK5 
phosphorylates SMAD2 and SMAD3 proteins, which then form complexes with SMAD4 
to regulate gene transcription. By modulating the expression of SMAD2, SMAD3 and 
SMAD4 in human BMSCs, we investigated their role in TGFβ-induced chondrogenesis. 
Activation of TGFβ signaling, represented by SMAD2 phosphorylation, was decreased 
by SMAD2 knockdown and highly increased by SMAD2 overexpression. Moreover, 
TGFβ signaling via the alternative SMAD1/5/9 pathway was strongly decreased by 
SMAD4 knockdown. TGFβ-induced chondrogenesis of human BMSCs was strongly 
inhibited by SMAD4 knockdown and only mildly inhibited by SMAD2 knockdown. 
Remarkably, both knockdown and overexpression of SMAD3 blocked chondrogenic 
differentiation. Chondrogenesis appears to rely on a delicate balance in the amount of 
SMAD3 and SMAD4 as it was not enhanced by SMAD4 overexpression and was 
inhibited by SMAD3 overexpression. Furthermore, this study reveals that TGFβ-
activated phosphorylation of SMAD2 and SMAD1/5/9 depends on the abundance of 
SMAD4. Overall, our findings suggest a more dominant role for SMAD3 and SMAD4 
than SMAD2 in TGFβ-induced chondrogenesis of human BMSCs. 
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Introduction 
Joint injuries frequently cause articular cartilage lesions that do not heal well in adults 
as articular cartilage has poor regenerative capacity. Since bone marrow-derived 
mesenchymal stem cells (BMSCs) can chondrogenically differentiate, they are 
promising for cell-based regeneration of damaged articular cartilage. Chondrogenic 
differentiation is potently induced by transforming growth factor-β (TGFβ) 
1-3
. 
However, cartilage tissue formed by BMSC-derived chondrocytes does not completely 
resemble native articular cartilage as these cells tend to lose the chondrogenic 
phenotype due to hypertrophic differentiation 
4-8
. Therefore, understanding how 
mediators of TGFβ signal transduction govern chondrogenesis will be crucial to 
improve cartilage regeneration by BMSCs.  
Binding of TGFβ to its type II serine/threonine receptor TGFBR2 activates the type I 
receptor TGFBR1, also termed activin receptor-like kinase 5 (ALK5), to intracellularly 
phosphorylate receptor-regulated SMAD proteins (R-SMADs). Activated R-SMADs form 
complexes with co-factor SMAD4 and these complexes translocate to the nucleus 
where they regulate gene transcription 
9
. Previously, we demonstrated that either 
blocking the kinase activity or downregulating the expression of ALK5 in human BMSCs 
inhibits chondrogenesis 
6,10
, indicating an important role for TGFβ signaling via ALK5 in 
chondrogenic differentiation of BMSCs.  
ALK5 can activate two R-SMADs, SMAD2 and SMAD3, which share similar structures 
including a Mad-Homology 1 (MH1) domain, linker region and MH2 domain 
9,11
. 
Despite their similarities, SMAD2 and SMAD3 have a differential role in TGFβ signal 
transduction 
12-15
. Whereas Smad2 knockout mice die during gastrulation 
16,17
, Smad3 
knockout mice develop cartilage and survive for several months after birth 
18-20
. 
Moreover, SMAD3, but not SMAD2, is involved in enhanced transcriptional activity of 
SRY (Sex Determining Region Y)-Box 9 (SOX9); a master regulator of chondrogenesis, in 
human mesenchymal stem cells 
21,22
. In contrast to SMAD3, SMAD2 lacks the MH1 
domain. Therefore, SMAD2 cannot bind DNA without complex formation with SMAD4, 
which may explain the differential effects of SMAD2 and SMAD3 
23-27
. However, 
whether SMAD2 and SMAD3 have a different function during TGFβ-induced 
chondrogenic differentiation of human BMSCs remains largely unknown. Also the 
specific role of SMAD4 in chondrogenesis of human BMSCs has not been investigated. 
In mice, deletion of Smad4 causes early embryonic death 
28,29
. Therefore, tissue-
specific Smad4 knockout mice have been generated. Conditional deletion of Smad4 in 
the limb bud mesenchyme of mice leads to an absence of cartilage elements 
prefiguring the limb skeleton 
30,31
, indicating that SMAD4 is required for cartilage 
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formation. Furthermore, chondrocyte-specific Smad4 knockout mice exhibit dwarfism 
and impaired growth plate organization 
32
. Similarly, Smad3 knockout mice have 
forelimb malformations, are smaller than wild-type mice and they develop 
spontaneous joint degeneration resembling the degenerative joint disease 
osteoarthritis in humans 
18,19
. In humans, mutations in SMAD3 lead to skeletal 
anomalies and early-onset of osteoarthritis 
33-36
. Moreover, SMAD3 is required for 
TGFβ-mediated suppression of hypertrophic differentiation of human articular 
chondrocytes 
37,38
. Although SMAD3 does not appear directly required for embryonic 
cartilage and joint development, SMAD3 seems to be important for maintaining a 
stable cartilage phenotype by preventing cartilage degeneration. 
Since SMAD2, SMAD3 and SMAD4 have been shown to differentially regulate TGFβ 
signaling and to have distinct functions during in vivo cartilage development and 
maintenance, we investigated their role in TGFβ-induced signaling and chondrogenesis 
of human BMSCs. We knocked down and overexpressed either SMAD2, SMAD3 or 
SMAD4 in human fetal BMSCs and determined the effects on TGFβ-activated SMAD 
phosphorylation and induction of chondrogenic differentiation. 
Materials and methods 
Culturing of human fetal bone marrow-derived mesenchymal stem cells  
Human fetal BMSCs (#SCC7500, Lot#6890, ScienCell Research Laboratories, Carlsbad, 
CA, USA) were expanded in Mesenchymal Stem Cell Growth Medium (MSCGM™; 
Lonza, Basel, Switzerland) supplemented with 1% Penicillin-Streptomycin-Glutamine 
(Gibco, Carlsbad, CA, USA). Cells were cultured in a 37°C-incubator with 5% CO2. After 
reaching 80% confluence, cells were passaged using 0.05% trypsin-EDTA (Gibco) and 
re-seeded (~6,000 cells/cm
2
) in MSCGM. After 4 passages, cells were stored in liquid 
nitrogen. Per experiment, fetal BMSCs were defrosted and expanded in MSCGM for 
another 2 or 3 passages. 
Induction of chondrogenic differentiation  
BMSC pellets were obtained by centrifuging 200,000 cells at 300 x g for 8 minutes in 
polystyrene V-bottom tubes (Greiner Bio-One, Alphen a/d Rijn, Netherlands). Pellets 
were cultured for 1, 7 or 14 days in 0.5 mL of serum-free chondrogenic medium, which 
consisted of DMEM-high glucose-GlutaMAX, 1% Penicillin-Streptomycin-Glutamine 
(both from Gibco), 6.25 µg/mL Insulin, 6.25 µg/mL Transferrin, 6.25 ng/mL selenious 
acid 5.35 µg/mL linoleic acid, 1.25 mg/mL bovine serum albumin, 1.0 mg/mL sodium 
pyruvate, 0.4 mg/mL L-proline, 50 µg/mL sodium L-ascorbate, 10
−7
 M dexamethasone 
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(all from Sigma-Aldrich), and 10 ng/mL TGFβ1 (Biolegend, San Diego, CA, USA). This 
medium was renewed 3 times per week. 
Short hairpin-mediated knockdown of SMAD2, SMAD3 or SMAD4  
MISSION® TRC-Hs1.5 shRNA clones targeting SMAD2 (TRCN0000040036), SMAD3 
(TRCN0000330056) or SMAD4 (TRCN0000010321), and Non-Mammalian shRNA 
control (SHC002) constructed in the pLKO.1-Puro plasmid vector were obtained from 
Sigma-Aldrich. Lentiviruses were packaged as described previously 
10
. Briefly, HEK293T 
cells (ATCC, Manassas, VA, USA) were co-transduced with plasmids of Rev, Gag, Pol, 
VSV-G (Plasmid Factory, Bielefeld, Germany) and a pLKO.1-Puro plasmid vector by 
calcium phosphate precipitation in DMEM (Gibco) containing 10% FCS (Perbio Science, 
Erembodegem, Belgium), 0.01 mM cholesterol (Sigma-Aldrich) and 1% pyruvate 
(Gibco). Medium was renewed at day 1, 2 and 3 post-transduction, collecting the 
medium at day 2 and 3. Collected medium was filtered through a 0.45 µm filter and 
centrifuged at 134,350 x g for 2 hours (Sorvall WX80+, ThermoFisher Scientific). 
Lentivirus concentration was determined with the INNOTEST® HIV p24 Antigen assay 
(Fujirebio Europe, Gent, Belgium) and expressed as pg of p24/µL. 
At 20% confluence, BMSCs were infected with 1 pg p24 per cell in MSCGM (Lonza) 
supplemented with 100 µg/mL protamine sulfate (Sigma-Aldrich) for 1 day. After 
culture-expanding infected cells for 2 days, pellets were prepared to induce 
chondrogenesis. 1 day after pellet preparation, the efficiency of shRNA-mediated 
knockdown of SMAD2, SMAD3 and SMAD4 was analyzed by RT-qPCR and Western 
blot. 
Adenoviral-mediated overexpression of SMAD2, SMAD3 or SMAD4  
Adenoviruses for SMAD2, SMAD3 and SMAD4 were kindly provided by Dr. P. ten Dijke 
(Leiden University Medical Center, the Netherlands). Cells at 80% confluence were 
incubated for 3 hours with adenovirus (multiplicity of infection of 1 pfu/cell) 
overexpressing either SMAD2, SMAD3, SMAD4 or LacZ (control). Following 
transduction, cells were washed and centrifuged to obtain pellets for chondrogenic 
induction. Overexpression of SMAD2, SMAD3 and SMAD4 was verified at gene (RT-
qPCR) and protein (Western blot) level in BMSCs cultured for 1 day in chondrogenic 
medium. 
Western blot analysis of (phosphorylated) SMAD proteins  
To evaluate the effects of SMAD knockdown and overexpression on activation of TGFβ 
signaling, cells transduced either with lentivirus (SMAD-shRNA) or adenovirus (SMAD 
overexpression) were seeded in chondrogenic medium without TGFβ. After 18 hours, 
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cells were stimulated with 10 ng/mL TGFβ1 (Biolegend) for 1 hour and cell lysates were 
prepared as described below to determine pSMAD2 and pSMAD1/5/9 expression.  
To determine protein abundance, cells were lysed (duplicate per condition) using lysis 
buffer (Cell-Signaling-Technology, Danvers, MA, USA) containing 1% protease inhibitor 
(Roche, Mannheim, Germany) and lysates were sonicated on ice. Protein 
concentration was determined using bicinchoninic acid assay. Duplicate samples per 
condition were pooled and 10 μg protein lysate was subjected to 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose 
membranes and overnight at 4°C incubated with an antibody (1:1,000) recognizing 
SMAD2 (#40855, Abcam, Cambridge, UK), SMAD3 (#28379, Abcam), SMAD4 (#AF2097, 
R&D systems, Minneapolis, MN, USA), pSMAD2 (#3101L, Cell Signaling Technology) or 
pSMAD1/5/9 (#9511L, Cell Signaling Technology). Subsequently, membranes were 
incubated with HRP-linked antibody (1:1,500) against rabbit-IgG (#P0448, Dako, 
Glostrup, Denmark) or against goat-IgG (#P0449, Dako) for 1 hour at room 
temperature. To evaluate equal protein loading between conditions, GAPDH 
expression was determined. Membranes were overnight incubated with an antibody 
(1:20,000) recognizing GAPDH (#G8795, Sigma-Aldrich), followed by 1 hour-incubation 
with HRP-linked antibody (1:1,500) against mouse-IgG (#P0260, Dako). Proteins were 
visualized by enhanced chemiluminescence using Prime Western Blotting Detection 
Reagent and a ImageQuant LAS4000 machine (GE Healthcare). Densitometry was 
performed using ImageJ software (release 1.46r; National Institute of Health, 
Bethesda, Maryland, USA). 
RNA extraction and gene expression analysis  
Pellets (n=3 per condition at each time point) were collected in TRIzol® (Sigma-Aldrich) 
and disrupted using MagNA Lyser instrument (Roche). After total RNA was isolated 
according to manufacturer’s protocol (Sigma-Aldrich), RNA samples were treated with 
DNAse (Invitrogen) to remove contaminating genomic DNA. RNA concentration and 
purity were measured using a NanoDrop® spectrophotometer (Isogen Life Science, 
Utrecht, the Netherlands). 0.5 µg RNA was reverse transcribed in cDNA with M-MLV 
Reverse Transcriptase (Invitrogen). Gene expression was measured by real-time 
Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) on a 
StepOnePlus™ System using SYBR Green Master mix (Applied Biosystems) and the 
primers listed in Table 1. CT values were determined at a fixed threshold level of 
fluorescence and efficiency of all primers was between 90% and 110% (Table 1). Data 
were normalized to the mean CT value of Ribosomal protein 27a (RPS27A) and TATA-
box binding protein (TBP). The following genes were used as markers of 
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chondrogenesis; Aggrecan (ACAN), Collagen type IIα1 (COL2A1) and SRY (Sex 
Determining Region Y)-Box 9 (SOX9). In addition, markers of chondrocyte hypertrophy; 
collagen type 10 α1 (COL10A1) and runt-related transcription factor 2 (RUNX2), were 
measured. 
Gene Forward primer Reverse primer Product 
RPS27A TGGCTGTCCTGAAATATTATAAGGT CCCCAGCACCACATTCATCA 90 bp 
TBP GCTTCGGAGAGTTCTGGGATTG GCAGCAAACCGCTTGGGATTA 134 bp 
SMAD2 CCGACACACCGAGATCCTAAC AGGAGGTGGCGTTTCTGGAAT 127 bp 
SMAD3 CATCGAGCCCCAGAGCAATA GTGGTTCATCTGGTGGTCACT 88 bp 
SMAD4 CCAATCATCCTGCTCCTGAGT CCAGAAGGGTCCACGTATCC 130 bp 
ACAN GCCTGCGCTCCAATGACT ATGGAACACGATGCCTTTCAC 104 bp 
COL2A1 CACGTACACTGCCCTGAAGGA CGATAACAGTCTTGCCCCACTT 65 bp 
SOX9 TGGGCAAGCTCTGGAGACTT CCCGTTCTTCACCGACTTCCT 140 bp 
COL10A1 TTTTACGCTGAACGATACCAAATG CTGTGTCTTGGTGTTGGGTAGTG 66 bp 
RUNX2 GCAAGGTTCAACGATCTGAGA TTCCCGAGGTCCATCTACTG 141 bp 
Table 1. List of primers used for RT-qPCR. 
Histology  
To macroscopically evaluate pellet size of 14-days cultured pellets, pictures were taken 
using a microscope (Wild M3B, Heerbrugg, Switzerland). Subsequently, pellets were 
fixed in 4% formalin for 14 hours, embedded in paraffin and sectioned (6 μm). Sections 
were stained with 0.1% aqueous Safranin O (Brunschwig Chemie, Amsterdam, the 
Netherlands), resulting in red-staining of negatively-charged GAGs. As counter-
staining, 0.1% aqueous Fast Green (Brunschwig Chemie) was used to stain the 
cytoplasm blue/green.  
For immunohistochemical staining of collagen type II, sections were pre-treated with 
1 mg/mL pronase and 10 mg/mL hyaluronidase (Sigma-Aldrich), and then incubated 
with 0.4 μg/mL antibody specific for collagen type II (#II-II6B3, Developmental Studies 
Hybridoma Bank, Iowa City, IA, USA) or 0.4 μg/mL mouse-IgG1 (#X0931, Dako, 
Glostrup, Denmark). Following incubation with alkaline phosphatase (AP)-conjugated 
secondary antibody (1:50, #HK-321-UK, Biogenex, San Ramon, CA, USA), AP-activity 
was visualized (magenta color) by incubation with new-fuchsin substrate. Sections 
were counterstained with haematoxylin (purple) to visualize nuclei. 
Glycosaminoglycans and DNA content measurements  
Pellets cultured for 1, 7 or 14 days were digested overnight at 60°C in 100 µL papain 
digestion buffer (pH=6.4) containing 0.1% papain, 10 mM EDTA-disodium salt (both 
from Merck), 100 mM sodium acetate, and 5 mM L-Cysteine·HCL (both from Sigma-
Aldrich). Following digestion, samples were diluted 1:8 in water to measure the GAG 
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content or samples were diluted 1:6 in Tris-EDTA (TE) buffer to measure DNA content. 
The GAG content was measured by adding 200 µL dimethylmethylene blue (DMB) 
solution (0.05 mM DMB, 41 mM NaCl, 45 mM glycin and pH=3.0) to 40 µL papain-
digested sample (pre-diluted 1:8 in water) and absorbance was measured at 590 nm 
using an iMark Reader (Bio-Rad). To determine the DNA content, PicoGreen® stock 
solution (ThermoFisher Scientific) was diluted 1:200 in TE buffer (10 mM Tris-HCl, 1 
mM EDTA and pH=7.5) and 50 µL of this solution was mixed with 50 µL papain-
digested sample (pre-diluted 1:6 in TE buffer). After 5 minutes dark incubation at room 
temperature, fluorescence was measured at 485/520 nm (excitation/emission) with a 
CLARIOstar (BMG Labtech, Offenburg, Germany) using DNA obtained from human 
HEK293T cells to set the standard curve. 
Data analysis  
Data represent mean + standard deviation of 6 pellets (from two experiments with 
triplicate pellets per experiment) per condition per time point. Statistical analyses 
were performed using SPSS version 22 (IBM, Armonk, NY, USA). Normality and 
variance were verified with the Shapiro-Wilk test and Levene’s Test, respectively. 
Statistical differences between control and experimental conditions per time point 
were determined with two-tailed independent T-tests. Level of significance was set at 
P<0.05. 
Results 
Efficient knockdown and overexpression of SMAD2, SMAD3 and SMAD4 
To study the role of SMAD2, SMAD3 and SMAD4 in TGFβ-induced SMAD 
phosphorylation and chondrogenesis of human BMSCs, their expression was 
modulated in human fetal BMSCs using short hairpin RNA (shRNA)-mediated 
knockdown and adenoviral (ad)-mediated overexpression. 
We confirmed efficient shRNA-mediated knockdown of SMAD2 (Fig. 1A,B), SMAD3 
(Fig. 1C,D) and SMAD4 (Fig. 1E,F) at the mRNA and protein level. In addition, we 
observed that SMAD2 (Fig. 1A) and SMAD3 (Fig. 1C) mRNA levels, but not their protein 
levels (Fig. 1B,D), were increased in SMAD4-shRNA compared to Ctrl-shRNA. Although 
gene expression of SMAD3 (Fig. 1C) and SMAD4 (Fig. 1E) was similar between SMAD2-
shRNA and Ctrl-shRNA, their protein expression (Fig. 1D,F) was decreased in SMAD2-
shRNA. Next, we verified adenoviral overexpression of SMAD2 (Fig. 2A,B), SMAD3 (Fig. 
2C,D) and SMAD4 (Fig. 2E,F) at gene and protein level. Notably, only SMAD4 protein 
(Fig. 2F) was slightly reduced in ad-SMAD2 compared to ad-LacZ. Thus, these data 
confirm efficient knockdown and overexpression of SMAD2, SMAD3 and SMAD4. 
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Figure 1. Short hairpin RNA-mediated knockdown of SMAD2, SMAD3 and SMAD4 expression. 
Following lentiviral transduction with either SMAD2-shRNA, SMAD3-shRNA, SMAD4-shRNA or 
non-mammalian shRNA control (Ctrl-shRNA), human fetal BMSCs were cultured in chondrogenic 
medium for 1 day. Short hairpin RNA-mediated knockdown was evaluated by determining gene 
(RT-qPCR; A, B, E) and protein (Western blot; B, D, F) expression of SMAD2 (A, B), SMAD3 (C, D) 
and SMAD4 (E, F). Protein levels were normalized to GAPDH and expressed as relative to Ctrl-
shRNA. Gene expression was normalized to the mean CT value of RPS27a and TBP. Data are 
expressed as % relative to normalized mRNA levels in Ctrl-shRNA. Bars represent mean + S.D. of 
triplicate pellets from 2 experiments. **=P<0.01; ***=P<0.001 compared to Ctrl-shRNA. 
TGFβ-activated phosphorylation of R-SMADs is altered by knockdown and 
overexpression of SMAD2, SMAD3 or SMAD4 
TGFβ signaling appears to be a straightforward cascade in which the ALK5 receptor 
phosphorylates SMAD2 and SMAD3, which upon binding to SMAD4 translocate to the 
nucleus where they regulate gene transcription 
9
. However, this system is more 
complex as multiple mechanisms have been discovered that control TGFβ signal 
transduction 
39
. Since it remained unknown whether R-SMAD phosphorylation 
depends on the amount of SMAD2 and SMAD3 present, we investigated whether 
modulating the expression of SMAD2 and SMAD3 affected TGFβ-activated 
phosphorylation of R-SMADs. We only show the effects on phosphorylated SMAD2 
(pSMAD2) due to difficult detection of pSMAD3. First, we verified that TGFβ induced 
pSMAD2 in Ctrl-shRNA cells (Fig. 3A) and in ad-LacZ cells (Fig. 3B) compared to no  
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Figure 2. Adenoviral-mediated overexpression of SMAD2, SMAD3 and SMAD4. Human fetal 
BMSCs were transduced with adenovirus overexpressing SMAD2 (ad-SMAD2), ad-SMAD3, ad-
SMAD4 or ad-LacZ as control, followed by culturing in chondrogenic medium for 1 day. To 
confirm overexpression, gene (RT-qPCR; A, C, E) and protein (Western blot; B, D, F) expression of 
SMAD2 (A, B), SMAD3 (C, D) and SMAD4 (E, F) were measured. Protein levels were normalized 
to GAPDH and expressed as relative to ad-LacZ. Gene expression data are presented as –ΔCT 
compared to the mean CT value of RPS27a and TBP. Bars represent mean + S.D. of triplicate 
pellets from 2 experiments. ***=P<0.001 compared to ad-LacZ. 
stimulation. TGFβ-activated SMAD2 phosphorylation was reduced in the SMAD2-
shRNA condition (Fig. 3A) and it was enhanced in ad-SMAD2 (Fig. 3B). No effect on 
pSMAD2 was observed with SMAD3-shRNA (Fig. 3A) or ad-SMAD3 (Fig. 3B). Moreover, 
to determine if co-factor SMAD4 is involved in TGFβ-activated R-SMAD 
phosphorylation, the expression of SMAD4 was modulated. We found that pSMAD2 
was lower in SMAD4-shRNA than in Ctrl-shRNA (Fig. 3A) and was similar between ad-
SMAD4 and ad-LacZ (Fig. 3B).  
Next to SMAD2/3, TGFβ can activate SMAD1/5/9, and both these R-SMAD signaling 
pathways are important for chondrogenic induction 
6,10
. Moreover, the TGFβ receptor 
ALK5 is required for TGFβ-activated phosphorylation of SMAD2/3 and SMAD1/5/9 
40
. 
Hence, we hypothesized there could be competition between SMAD2/3 and 
SMAD1/5/9 for phosphorylation by ALK5. We confirmed SMAD1/5/9 phosphorylation 
(pSMAD1/5/9) in response to TGFβ stimulation compared to no stimulation in 
Ctrl-shRNA (Fig. 3C) and ad-LacZ (Fig. 3D). TGFβ-induced pSMAD1/5/9 was higher in 
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SMAD2-shRNA and SMAD3-shRNA than in Ctrl-shRNA (Fig. 3D). Although SMAD1/5/9 
phosphorylation was similar between ad-SMAD2 and ad-LacZ, it was slightly reduced in 
ad-SMAD3 (Fig. 3D). Next, we studied the involvement of SMAD4 in TGFβ-activated 
SMAD1/5/9 phosphorylation. We observed that in the SMAD4-shRNA condition TGFβ 
stimulation did not lead to induction of pSMAD1/5/9 (Fig. 3C), whereas TGFβ-induced 
pSMAD1/5/9 was comparable between ad-SMAD4 and ad-LacZ (Fig. 3D). 
Taken together, these data demonstrate that activation of the SMAD2/3 and 
SMAD1/5/9 signaling pathways by TGFβ was affected by modulating SMAD2, SMAD3 
or SMAD4 expression, indicating that the levels of TGFβ-induced phosphorylated R-
SMADs depend on the amount of R-SMAD2/3 and co-SMAD4. 
 
Figure 3. TGFβ-activated phosphorylation of R-SMADs is affected by knockdown and 
overexpression of SMAD2, SMAD3 and SMAD4. The effects of shRNA-mediated knockdown and 
adenoviral-mediated overexpression of SMAD2, SMAD3 and SMAD4 on TGFβ-induced 
phosphorylation of SMAD2 (pSMAD2; A, B) and pSMAD1/5/9 (C, D) were determined using 
Western blot. To confirm TGFβ-induced phosphorylation of SMAD2 and SMAD1/5/9, Ctrl-shRNA 
cells and ad-LacZ cells were either not stimulated (-) or stimulated (+) with TGFβ in chondrogenic 
medium. Protein levels were normalized to GAPDH and expressed as relative to unstimulated 
Ctrl-shRNA or ad-LacZ. 
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Knocking down either SMAD3 or SMAD4 strongly inhibits chondrogenesis 
We determined the contribution of SMAD2, SMAD3 and SMAD4 during TGFβ-induced 
chondrogenic differentiation by knocking down the expression of these SMADs and 
culturing the BMSCs in pellets in chondrogenic medium containing TGFβ. After 1, 7 and 
14 days we evaluated expression of chondrogenesis-specific genes ACAN, COL2A1 and 
SOX9, formation of cartilage matrix and the macroscopic appearance of the BMSC 
pellets. 
In 1, 7 and 14 days-cultured BMSC pellets, ACAN (Fig. 4A), COL2A1 (Fig. 4B) and SOX9 
(Fig. 4C) were similarly expressed in the SMAD2-shRNA and Ctrl-shRNA condition, 
except for a significant decrease in COL2A1 expression at day 1 in SMAD2-shRNA 
(p=0.007). Although ACAN and SOX9 expression were mildly affected by SMAD3-
shRNA, transcription of COL2A1 was significantly inhibited by SMAD3-shRNA at day 1 
(p=0.007), day 7 (p<0.001) and day 14 (p=0.029). Furthermore, a strong and significant 
inhibition of ACAN, COL2A1 and SOX9 expression was observed in SMAD4-shRNA at all 
time points (p<0.01 for all genes and time points).  
Next, we analyzed cartilage matrix deposition by determining the presence of 
glycosaminoglycans (GAGs) and collagen type II protein. In addition, we measured the 
pellet size. Compared to control, TGFβ-induced deposition of GAGs was not inhibited 
by SMAD2-shRNA at day 14 (Fig. 4D), whereas it was significantly inhibited by SMAD3-
shRNA (p=0.010 at day 7; p<0.001 at day 14). The same was observed after correcting 
the GAG content for the amount of DNA per pellet (Fig. 4E; Supplementary Fig. S1). 
Despite stimulation with TGFβ, no GAGs were formed in pellets of BMSCs transduced 
with SMAD4-shRNA (Fig. 4D,E). Consistent with this, analyzing the presence of GAGs 
and collagen type II protein in 14 days-cultured pellets by histology revealed that both 
cartilage components were similarly present in SMAD2-shRNA and Ctrl-shRNA, 
whereas they were reduced in SMAD3-shRNA and even absent in SMAD4-shRNA (Fig. 
4F). These observations were reflected by the size of the pellets after 14 days of 
culturing. Compared to Ctrl-shRNA pellets, SMAD2-shRNA pellets had the same size, 
SMAD3-shRNA pellets were smaller and SMAD4-shRNA pellets were smallest (Fig. 4G).  
Once BMSCs have differentiated into chondrocytes, they undergo hypertrophic 
maturation, which is characterized by enhanced expression of collagen type X α1 
(COL10A1) and runt-related transcription factor 2 (RUNX2) 
4-8
. We observed that 
COL10A1 and RUNX2 mRNA levels were similar between SMAD2-shRNA, SMAD3-
shRNA and Ctrl-shRNA in 7 and 14 days-cultured pellets (Supplementary Fig. S2A,B). In 
contrast, compared to Ctrl-shRNA, COL10A1 expression was lower in the 
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Figure 4. Chondrogenesis is mildly inhibited by SMAD2-shRNA, is strongly inhibited by SMAD3-
shRNA and completely blocked by SMAD4-shRNA. Human fetal BMSCs were transduced 
(lentivirus) either with SMAD2-shRNA, SMAD3-shRNA, SMAD4-shRNA or Ctrl-shRNA and 
subsequently pellet-cultured for 1, 7 or 14 days in chondrogenic medium with TGFβ. The effect 
of shRNA-mediated knockdown of SMAD2, SMAD3 and SMAD4 on chondrogenesis was 
determined by RT-qPCR analysis of the chondrogenesis-specific genes; ACAN (A), COL2A1 (B) and 
SOX9 (C), deposition of glycosaminoglycans (GAGs) per pellet (D) and per µg DNA (E), histological 
examination of GAGs by Safranin O (Saf.O) staining and collagen type II by 
immunohistochemistry in sections of 14 days-cultured pellets (F), and macroscopic evaluation of 
14 days-cultured pellets (G). In (F) representative images of consecutive pellet sections per 
condition are shown and the scale bar represents 500 µm. Gene expression data are presented 
as –ΔCT compared to the mean CT value of RPS27a and TBP. Bars represent mean + S.D. of 
triplicate pellets from 2 experiments. *=P<0.05; **=P<0.01; ***=P<0.001 compared to Ctrl-
shRNA. 
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SMAD4-shRNA than in the Ctrl-shRNA condition (Supplementary Fig. S2A), while 
SMAD4-shRNA had no significant effect on RUNX2 expression (Supplementary Fig. 
S2B). 
Altogether, these results indicate that shRNA-mediated knockdown of SMAD2 had a 
minor inhibitory effect on TGFβ-induced chondrogenic differentiation of human 
BMSCs. However, SMAD3 knockdown strongly reduced cartilage deposition, and 
SMAD4 knockdown completely blocked chondrogenesis. 
SMAD3 overexpression results in a strong inhibition of chondrogenesis 
Since knockdown of SMAD2, SMAD3 and SMAD4 inhibited chondrogenesis, we 
investigated whether overexpression of these SMADs might enhance TGFβ-induced 
chondrogenic differentiation of human BMSCs.  
Expression of ACAN (Fig. 5A), COL2A1 (Fig. 5B) and SOX9 (Fig. 5C) was comparable 
between the control condition (ad-LacZ) and ad-SMAD2, ad-SMAD3 and ad-SMAD4 
after 1 day of pellet culturing. In 7 days-cultured pellets ACAN, COL2A1 and SOX9 were 
slightly lower expressed in ad-SMAD2 than in ad-LacZ (ACAN: p=0.016; COL2A1: 
p<0.001; SOX9: p=0.047). However, after 14 days only ACAN expression was 
significantly decreased in ad-SMAD2 compared to ad-LacZ (p=0.038). At all time points 
expression of ACAN, COL2A1 and SOX9 was significantly reduced by ad-SMAD3 (p<0.05 
for all genes), whereas their expression was not affected by ad-SMAD4. 
Deposition of GAGs (Fig. 5D) was significantly decreased in pellets of BMSCs 
transduced with ad-SMAD2 compared to control after 7 days (p=0.009) and 14 days 
(p=0.003). However, this significant reduction was not observed when the GAG 
content was corrected for the DNA content (Fig. 5E; Supplementary Fig. S3). Pellets of 
ad-SMAD3-transduced BMSCs had a significantly lower amount of GAGs per pellet (Fig. 
5D: p<0.001 at day 7; p=0.006 at day 14) and per µg DNA (Fig. 5E; Supplementary Fig. 
S3; p=0.007 at day 7; p<0.001 at day 14) than the control condition. At all time points, 
GAG deposition (Fig. 5D,E) was similar between ad-SMAD4 and ad-LacZ. Histological 
analysis of 14 days-cultured pellets revealed that the abundance of GAGs and collagen 
type II protein (Fig. 5F) was similar between ad-SMAD2, ad-SMAD4 and ad-LacZ, 
whereas their abundance was strongly reduced in the ad-SMAD3 condition. In line with 
these observations, pellets of ad-SMAD2-transduced BMSCs were slightly smaller than 
control pellets, whereas pellets of ad-SMAD3-transduced BMSCs were much smaller 
(Fig. 5G). The pellet size was comparable between the ad-SMAD4 and ad-LacZ 
condition (Fig. 5G).  
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Figure 5. Chondrogenesis is strongly inhibited by SMAD3 overexpression, whereas it is mildly 
inhibited by SMAD2 overexpression and unaffected by SMAD4 overexpression. Human fetal 
BMSCs transduced either with adenoviral SMAD2 (ad-SMAD2), ad-SMAD3, ad-SMAD4 or ad-LacZ 
as control were pellet-cultured for 1, 7 or 14 days in chondrogenic medium with TGFβ. The 
effect of SMAD overexpression on chondrogenesis was determined by RT-qPCR analysis of the 
chondrogenesis-specific genes; ACAN (A), COL2A1 (B) and SOX9 (C), deposition of 
glycosaminoglycans (GAGs) per pellet (D) and per µg DNA (E), histological examination of GAGs 
by Safranin O (Saf.O) staining and collagen type II by immunohistochemistry in sections of 14 
days-cultured pellets (F), and macroscopic evaluation of 14 days-cultured pellets (G). In (F) 
representative images of consecutive pellet sections per condition are shown and the scale bar 
represents 500 µm. Gene expression data are presented as –ΔCT compared to the mean CT value 
of RPS27a and TBP. Bars represent mean + S.D. of triplicate pellets from 2 experiments. 
*=P<0.05; **=P<0.01; ***=P<0.001 compared to ad-LacZ. 
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In addition, we found that chondrocyte hypertrophy markers, COL10A1 and RUNX2, 
were similarly expressed between ad-LacZ and ad-SMAD4 after 7 and 14 days 
(Supplementary Fig. S4A,B). Although COL10A1 expression was lower in ad-SMAD2 
than in ad-LacZ at day 7, the two conditions were comparable at day 14 
(Supplementary Fig. S4A). At both time points, RUNX2 mRNA levels were similar 
between ad-SMAD2 and ad-LacZ (Supplementary Fig. S4B). Strikingly, in the ad-SMAD3 
condition COL10A1 mRNA was lower (Supplementary Fig. S4A), whereas RUNX2 mRNA 
was higher than in the ad-LacZ condition (Supplementary Fig. S4B). 
Our data demonstrate that TGFβ-induced chondrogenesis was slightly inhibited by 
SMAD2 overexpression and not affected by SMAD4 overexpression, whereas it was 
strongly inhibited by SMAD3 overexpression. 
Discussion 
The pro-chondrogenic effect of TGFβ on human BMSCs is well-known, however, the 
contribution of the downstream signaling molecules SMAD2, SMAD3 and SMAD4 
during chondrogenesis has been less well investigated. By using human fetal BMSCs as 
a model for TGFβ-induced chondrogenic differentiation, we demonstrate here that 
modulating SMAD2 expression had a minor effect on chondrogenesis. In contrast, 
knockdown as well as overexpression of SMAD3 strongly inhibited cartilage formation 
and SMAD4 knockdown completely blocked chondrogenesis. 
To the best of our knowledge, the specific role of SMAD2 and SMAD3 during 
chondrogenic differentiation of human BMSCs has been studied in one study so far, 
which demonstrated that modulating SMAD2 expression does not affect 
chondrogenesis 
22
. In contrast, we observed a slight reduction in cartilage formation 
when SMAD2 was knocked down or overexpressed. We also found that SMAD2 
knockdown led to reduced protein levels of SMAD3 and SMAD4, whereas Furumatsu et 
al. did not report an effect of SMAD2 knockdown on SMAD3 and SMAD4 expression 
22
. 
Since knockdown of either SMAD3 or SMAD4 inhibited chondrogenesis, reduced 
SMAD3 and SMAD4 abundance might explain why chondrogenesis was slightly 
inhibited by SMAD2 knockdown. Our finding that TGFβ-induced chondrogenic 
differentiation of human BMSCs is more strongly inhibited by SMAD3 knockdown than 
by SMAD2 knockdown is in line with the aforementioned study 
22
. While we employed 
continuous knockdown by viral transduction with shRNA, Furumatsu and co-workers 
employed transient knockdown by transfection with siRNA 
22
. We, thus, verified that 
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continuous knockdown of SMAD2 and SMAD3 had effects on chondrogenesis similar to 
transient knockdown.  
Whereas the previous study has shown that SMAD3 overexpression accelerated 
chondrogenesis 
22
, in our study SMAD3 overexpression blocked chondrogenic 
differentiation of human BMSCs. This discrepancy might be caused by a difference in 
chondrogenic media composition (details of medium components were not reported), 
cell source (fetal or adult origin, bone marrow or other tissue derived) or amount of 
overexpression (western blots of overexpressed SMAD3 were not shown). In addition, 
we found that the DNA content per pellet decreased over time in cells overexpressing 
SMAD3 (Supplementary Fig. S3). In multiple cell types, it has been shown that 
overexpression of SMAD3 leads to an inhibition of proliferation 
41-43
. Importantly, 
proliferation of BMSCs early during chondrogenic differentiation is required for 
chondrogenesis 
44
. Therefore, SMAD3 overexpression might have inhibited 
chondrogenesis, because it blocked proliferation. Overall, this indicates that constantly 
high levels of SMAD3 in BMSCs do not accelerate cartilage matrix formation. Since 
both knockdown and overexpression of SMAD3 inhibited chondrogenic differentiation, 
chondrogenesis seems to rely on well-balanced levels of SMAD3. 
The present study, for the first time, investigated the role of SMAD4 during 
chondrogenic differentiation of human BMSCs. Previous studies in mice have 
demonstrated that mesenchyme-specific deletion of Smad4 leads to an absence of the 
limb skeleton as a result of impaired mesenchymal condensation 
30,31
; a process 
required for initiating chondrogenesis 
45
. In our study, SMAD4 knockdown did not 
interfere with pellet formation, implying that human BMSCs can form pellets even with 
a low amount of SMAD4. Although BMSCs transduced with SMAD4-shRNA formed 
pellets, they did not undergo chondrogenic differentiation. This observation is in line 
with a previous study demonstrating that BMSCs isolated from Smad4 knockout
 
mice 
show reduced expression of Sox9 
30
. Additionally, we found that SMAD4 knockdown 
inhibited TGFβ-induced SMAD1/5/9 phosphorylation and expression of COL2A1; a 
direct transcriptional target of SOX9 
46
. In murine chondroprogenitor cells, complex 
formation between Smad4 and phosphorylated Smad1/5 proteins is required for 
transactivation of the Col2a1 promoter 
47
. This might explain why chondrogenesis did 
not occur when we knocked down SMAD4 . Furthermore, we previously demonstrated 
that the SMAD2/3 as well as the SMAD1/5/9 pathways are required for TGFβ-induced 
chondrogenesis of human BMSCs 
6,10
. In the present study activation of both pathways 
was reduced by SMAD4 knockdown, thereby possibly explaining the absence of 
cartilage formation. Altogether, these findings underline the importance of SMAD4 
during TGFβ-induced chondrogenic differentiation of human BMSCs. 
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Following chondrogenesis, BMSC-derived chondrocytes display signs of hypertrophic 
differentiation. This is undesired for the formation of articular cartilage, as 
hypertrophic chondrocytes produce cartilage that will mineralize and ossify when 
implanted in vivo 
7
. We found that modulating SMAD2 expression did not have an 
effect on expression of hypertrophic differentiation markers, neither did SMAD4 
overexpression. SMAD3 overexpression and SMAD4 knockdown did result in lower 
COL10A1 expression. In these conditions, however, next to hypertrophy markers, the 
markers of chondrogenesis were also much lower expressed than in the control 
condition, following the principle that reduced chondrogenesis leads to reduced 
hypertrophic differentiation. Whereas COL10A1 expression was lower by SMAD3 
overexpression, RUNX2 expression was slightly, but significantly, higher. This was 
surprising, because SMAD3 is required for repression of RUNX2 expression and 
chondrocyte hypertrophy 
38,48-51
. Possibly, as a result of decreased chondrogenesis 
RUNX2 expression failed to go down during the early phase of chondrogenesis or 
RUNX2 expression levels might depend on the abundance of SMAD3, but this requires 
further investigation. Overall, our results failed to show effects specifically on 
hypertrophic differentiation of BMSC-derived chondrocytes without effects on the 
induction of chondrogenesis. 
Besides the effects on chondrogenic and hypertrophic differentiation, this study 
investigated the effect of modulating SMAD2, SMAD3 and SMAD4 expression on TGFβ 
signal transduction. After activation by TGFβ, the ALK5 receptor phosphorylates 
SMAD2/3 proteins 
9
. We show that SMAD2 phosphorylation was reduced by 
knockdown of SMAD2, while it highly increased by SMAD2 overexpression. These 
findings suggests that TGFβ-activated phosphorylation depends on the number of R-
SMADs present in the cytoplasm rather than, for instance, on the kinase activity or 
number of ALK5 receptors.  
We previously showed that TGFβ does not only induce phosphorylation of SMAD2/3, 
but also of SMAD1/5/9 in BMSCs 
6,10,52
. Although SMAD1/5/9 cannot be directly 
phosphorylated by the TGFβ receptor ALK5, TGFβ-activated SMAD1/5/9 
phosphorylation requires the intracellular kinase domains of ALK5 
40
. Moreover, ALK5 
is the only receptor through which TGFβ can induce phosphorylation of SMAD2/3 
53,54
. 
Consistent with a study showing enhanced pSMAD1/5/9 in SMAD3 knockout 
chondrocytes 
51
, we demonstrate increased pSMAD1/5/9 when SMAD3 or SMAD2 
were knocked down. This supports the idea that TGFβ-induced phosphorylation of 
SMAD1/5/9 requires the ALK5 receptor and is independent of other receptors that can 
activate SMAD1/5/9 
55,56
. 
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Although SMAD4 is an important co-factor for translocation of activated R-SMADs to 
the nucleus 
57
, it has not been implicated in controlling the phosphorylation of R-
SMADs. Patients with Myhre syndrome have mutations in SMAD4 that lead to 
decreased ubiquitination of SMAD4 protein, resulting in accumulation of SMAD4 
58-61
. 
In skin fibroblasts from these patients, pSMAD2/3 and pSMAD1/5/9 were enhanced 
compared to healthy controls 
58,61
. Contrary to this, in our study SMAD4 
overexpression had no effect on R-SMAD phosphorylation. On the other hand, SMAD4 
knockdown reduced TGFβ-induced phosphorylation of SMAD2 and completely 
prevented SMAD1/5/9 phosphorylation. Based on these observations, we speculate 
that SMAD4 is required for R-SMAD phosphorylation, or prevents R-SMADs from de-
phosphorylation 
62,63
 or ubiquitination 
64,65
, which adds a regulatory mechanism that 
controls TGFβ signal transduction. 
To conclude, this study reveals that TGFβ-activated phosphorylation of R-SMADs in 
BMSCs does not only depend on the levels of SMAD2 and SMAD3, but also on the 
presence of SMAD4. Moreover, our findings suggest that SMAD3 and SMAD4 are more 
important than SMAD2 for TGFβ-induced chondrogenic differentiation of human 
BMSCs. However, as cartilage formation was not enhanced by overexpression of 
SMAD4 and even inhibited by SMAD3 overexpression, induction of chondrogenic 
differentiation seems to rely on a delicate balance in the amount of SMAD3 and 
SMAD4. This also implies that continuously enhanced SMAD3 expression levels may 
not be a suitable strategy to improve chondrogenesis. Despite its exploratory nature, 
this study offers novel insights into the signaling mechanism governing the induction of 
chondrogenic differentiation of human BMSCs. Further research is required to 
delineate the function of SMAD4 in TGFβ-induced phosphorylation of R-SMADs and 
the mechanisms behind the detrimental effects of SMAD3 overexpression on 
chondrogenesis. 
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Supplementary figures 
 
Supplementary Figure S1. The DNA content per pellet is lower in SMAD3-shRNA and SMAD4-
shRNA than in Ctrl-shRNA. Human fetal BMSCs were transduced (lentivirus) either with SMAD2-
shRNA, SMAD3-shRNA, SMAD4-shRNA or Ctrl-shRNA. Subsequently, BMSCs were pellet-cultured 
for 7 and 14 days in chondrogenic medium with TGFβ. The DNA content per pellet was 
measured using Picogreen. Bars represent mean + S.D. of triplicate pellets from 2 experiments. 
**=P<0.01; ***= P<0.001 compared to Ctrl-shRNA. 
 
Supplementary Figure S2. Effect of knockdown of SMAD2, SMAD3 or SMAD4 on chondrocyte 
hypertrophy markers. The effect of shRNA-mediated knockdown of SMAD2, SMAD3 and SMAD4 
on gene expression of markers for hypertrophic differentiation of chondrocytes; collagen type 
10 α1 (COL10A1) (A) and runt-related transcription factor 2 (RUNX2) (B), was measured by RT-
qPCR in 7 and 14 days-cultured human fetal BMSC pellets. Gene expression data are presented 
as –ΔCT compared to the mean CT value of RPS27a and TBP. Bars represent mean + S.D. of 
triplicate pellets from 2 experiments. ***=P<0.001 compared to Ctrl-shRNA.  
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Supplementary Figure S3. The DNA content per pellet is reduced by SMAD3 overexpression. 
Human fetal BMSCs were transduced either with ad-SMAD2, ad-SMAD3, ad-SMAD4 or ad-LacZ 
as control. Subsequently, BMSCs were pellet-cultured for 7 and 14 days in chondrogenic medium 
with TGFβ. The DNA content per pellet was measured using Picogreen. Bars represent mean + 
S.D. of triplicate pellets from 2 experiments. **=P<0.01 compared to ad-LacZ. 
 
Supplementary Figure S4. Effect of overexpression of SMAD2, SMAD3 or SMAD4 on 
chondrocyte hypertrophy markers. The effect of adenoviral (ad)-mediated overexpression of 
SMAD2, SMAD3 and SMAD4 on gene expression of markers for hypertrophic differentiation of 
chondrocytes; collagen type 10 α1 (COL10A1) (A) and runt-related transcription factor 2 (RUNX2) 
(B), was measured by RT-qPCR in 7 and 14 days-cultured human fetal BMSC pellets. Gene 
expression data are presented as –ΔCT compared to the mean CT value of RPS27a and TBP. Bars 
represent mean + S.D. of triplicate pellets from 2 experiments. *=P<0.05; **=P<0.01; 
***=P<0.001 compared to ad-LacZ. 
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Abstract 
Objective: Osteoarthritis (OA) is a joint disease characterized by progressive 
degeneration of articular cartilage. Some characteristics of OA, including expression of 
hypertrophy markers by articular chondrocytes and focal calcification of articular 
cartilage, resemble endochondral ossification processes observed during skeletal 
development. Alterations in transforming growth factor β (TGFβ) signaling have been 
associated with OA as well as with chondrocyte hypertrophy. Our aim was to identify 
novel candidate genes implicated in OA pathogenesis by determining which TGFβ-
related genes are regulated during murine OA as well as chondrocyte hypertrophy. 
Methods: A list of TGFβ-related genes including TGFβ signaling pathway components 
and TGFβ-target genes was generated. Regulation of TGFβ-related genes was assessed 
in a microarray of murine OA after destabilization of the medial meniscus (DMM). 
Subsequently, expression of genes, regulated in the DMM model, was evaluated in two 
microarray datasets on chondrocyte hypertrophy in mice; one dataset from different 
zones of the growth plate and another dataset from transient embryonic cartilage and 
the interzone. 
Results: A total of 106 from 580 TGFβ-related genes were differentially expressed in 
articular cartilage of DMM-operated mice compared to sham-control. From the 106 
genes regulated in murine OA, 43 genes were similarly regulated during chondrocyte 
hypertrophy in the growth plate and/or transient embryonic cartilage. From these 43 
genes, we found that 18 genes have already been associated with OA. Therefore, the 
remaining 25 genes are new candidate genes involved in OA pathogenesis. In addition 
to the murine datasets, we found in supplementary data of published microarrays that 
15 of the 25 genes are regulated in articular cartilage of human OA patients. 
Conclusion: By focusing on TGFβ-related genes during OA and chondrocyte 
hypertrophy in mice, we identified 18 known and 25 new candidate genes potentially 
implicated in OA. We propose that 15 of these candidates warrant further 
investigation as therapeutic target for OA as they are also regulated in articular 
cartilage of OA patients. 
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Introduction 
Osteoarthritis (OA) is characterized by degeneration of articular cartilage and the 
clinical symptoms are joint pain and functional impairment 
1,2
. Chondrocytes in 
articular cartilage of OA patients exhibit phenotypic changes that resemble 
hypertrophic differentiation of chondrocytes in the growth plate 
3-8
 and during 
endochondral bone formation in the embryo 
9-11
. Since articular cartilage has limited 
repair capacity, it is essential to prevent cartilage degeneration at an early stage. To 
accomplish this, the pathogenic mechanisms initiating OA need to be further 
elucidated.  
The transforming growth factor-β (TGFβ) signaling pathway has been implicated in OA 
pathogenesis and in hypertrophic differentiation of chondrocytes 
12-15
. Signaling via 
this pathway is initiated when TGFβ ligands form a complex with type I (TGFBR1, also 
termed activin receptor-like kinase 5 or ALK5) and type II (TGFBR2) serine/threonine 
kinase receptors. Activated receptor complexes phosphorylate downstream SMAD2 or 
SMAD3 proteins, which then form a complex with SMAD4. These SMAD complexes 
translocate to the nucleus where they regulate expression of target genes 
16,17
. In 
humans, polymorphisms in the signal sequence region of TGFB1 and SMAD3 have been 
associated with multiple OA symptoms 
18-22
. Moreover, mutations in SMAD3 lead to 
early-onset of OA in multiple articular joints 
23,24
. In mice, deficiency of Smad3 or 
Tgfbr2 results in a degenerative joint disease resembling human OA 
25,26
. A similar 
phenotype is observed in mice overexpressing a truncated kinase-defective Tgrbr2 
27
. 
Previously, we have shown that protein expression of Tgfb3 and phosphorylated 
Smad2 is reduced in two murine models for OA 
28
. We and others have also found an 
age-related loss of Tgfbr1 in murine and bovine articular cartilage 
29-31
. Importantly, a 
decrease in Tgfbr1 in murine and human articular chondrocytes not only correlates 
with OA development, but also with elevated expression of markers for chondrocyte 
hypertrophy 
32
. Besides TGFβ signaling is involved in OA development, it has a 
fundamental role in skeletal development 
33
. Chondrocyte-specific deletion of Tgfbr2, 
Tgfbr1, Smad3 or Smad4 leads to enhanced hypertrophic differentiation of 
chondrocytes in the growth plate and articular cartilage 
34-40
. Moreover, Tgfb2 
knockout mice display severe abnormalities in bone formed by endochondral 
ossification 
41
. Together, these data indicate an important link between TGFβ, 
chondrocyte hypertrophy and OA. 
For the identification of molecular targets that may be involved in early onset and 
progression of osteoarthritis, microarray analyses have been performed on murine 
models for OA (early onset, trauma-induced) rather than on human OA cartilage (end-
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stage disease) 
42-45
. However, a hypothesis-driven approach focusing on a subset of 
genes based on OA pathobiology has not been attempted. Since altered TGFβ signaling 
associates with chondrocyte hypertrophy and OA, we hypothesized that defining the 
regulation of genes involved in or regulated by the TGFβ signaling pathway in early OA 
and chondrocyte hypertrophy would result in the identification of novel targets 
implicated in OA pathogenesis. In this study, we generated a list of TGFβ-related genes, 
which included genes encoding components of the TGFβ signaling pathway (from the 
Kyoto Encyclopedia of Genes and Genomes; KEGG) 
46
 and genes shown to be regulated 
by TGFβ (i.e. TGFβ-target genes) in three independent microarray studies 
47-49
. We 
determined which of these TGFβ-related genes are regulated in a murine model for 
early OA as well as during chondrocyte hypertrophy in murine growth plates and/or 
transient embryonic cartilage using available microarray datasets 
11,42,50
. Genes 
identified by this approach were further explored in the literature to evaluate whether 
our approach identified genes known to be involved in OA pathology and to determine 
which genes might be novel candidates implicated in OA pathogenesis. 
Methods  
List of TGFβ-related genes 
A list of genes related to TGFβ signaling was compiled by including murine genes of the 
TGFβ signaling pathway derived from the KEGG database 
46
 and genes shown to be 
regulated by TGFβ in three published microarray studies: 1x in vivo and 3x in vitro 
47-49
. 
Takahashi et al. analyzed gene expression (Murine Genome Array U74Av2; Affymetrix) 
in unstimulated and TGFβ1-stimulated (10 ng/mL for 9 hours) chondrocytes from the 
H4 murine cell line 
47,51
. Sohn et al. performed microarray analysis (GeneChip Mouse 
Genome 430 2.0 Array; Affymetrix) on murine embryonic (E11.5) sclerotome cells 
cultured in micromass in absence or presence of TGFβ1 (5 ng/mL for 8 hours), and on 
vertebra isolated from wild-type and Tgbr2 knock-out mice 
48
. Ramaswamy et al. 
evaluated gene expression (GeneChip Bovine Genome Array; Affymetrix) in micromass 
cultures of chondrocytes (isolated from articular cartilage of 3 cows) that were 
cultured in absence or presence of TGFβ1 (5 ng/mL for 8 hours) 
49
. Bovine gene probes 
(Affymetrix) were translated to mouse orthologs. After merging the results of the three 
published microarray studies 
47-49
, one list of 501 genes regulated by TGFβ (up and 
down) was obtained. 
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Published microarray datasets of murine OA cartilage, growth plate zones and 
developing embryonic joints 
Microarray dataset of murine OA cartilage 
A detailed description of the performed microarray experiment can be found in 
42
. 
Briefly, OA was induced in 10-week-old male C57BL/6 mice by surgical destabilization 
of the medial meniscus (DMM) of the right knee. As control, a sham operation (where 
the medial menisco-tibial ligament was exposed, but not transected) was performed 
on the left knee. At 1, 2 and 6 weeks after surgery, tibial epiphyses were isolated (n=4 
mice per time point), decalcified, embedded and snap-frozen. Cryosections were 
stained with toluidine blue to locate developing OA lesions (loss of toluidine blue 
staining and cartilage fibrillations) in non-calcified medial tibial plateau articular 
cartilage for laser-microdissection (Arcturus Bioscience). Anatomic and histologic 
landmarks were used to laser-microdissect noncalcified articular cartilage from sham-
operated mice. After pooling laser-microdissected sections from each individual 
mouse, total RNA was isolated using TRIzol reagent (Invitrogen) following 
manufacturer’s protocol and RNA was amplified in two rounds using the MessageAmp 
II aRNA Amplification Kit (Ambion) to obtain over 30 µg amplified RNA per mouse joint. 
Microarray expression profiling was performed on amplified RNA from cartilage of 
individual DMM- or sham-operated mouse joints, using duplicate microarrays (Cy3/Cy5 
dye swap with replicate RNA samples). Labeled RNA was hybridized to 44k whole 
genome oligo microarray (G4122A; Agilent). The arrays were scanned on a G2565BA 
DNA microarray Scanner (Agilent) and Agilent Feature Extraction software version 
9.5.3 was used to extract the features. The microarray data have been validated by 
real-time quantitative PCR (qPCR) on amplified RNA 
42
. 
Microarray dataset of murine growth plate zones 
Details regarding the performed microarray experiment are described elsewhere 
11
. In 
brief, femoral growth plates were isolated from long bones of 14-day old female Swiss 
white mice (n=2), immersed in Tissue-Tek OCT embedding compound (Sakura 
Finetechnical, Tokyo, Japan) and snap-frozen in isopentane. Using microdissection, 
approximately 2,000 chondrocytes (per layer) were isolated from the proliferative (PR), 
pre-hypertrophic (PH) and hypertrophic (H) layer of the growth plate using an 
ophthalmic scalpel (Feather, Osaka, Japan). Total RNA was extracted using PicoPure 
RNA isolation kit (Arturus Bioscience, Mountain View, CA), treated with DNase to 
remove contaminating genomic DNA (Qiagen, Hilden, Germany) and linearly amplified 
using MessageAmp aRNA kit (Ambion, Austin, TX) according to manufacturer’s 
protocol. Amplified RNA was labeled with Cy3/Cy5 fluorophores, then hybridized to 
44k whole genome oligo microarrays (G4122A; Agilent Technologies) and scanned on 
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an Axon 4000B scanner. Features were extracted using GenePix Pro software (version 
4.1; Axon Instruments, Union City, CA, USA). The microarray data have been validated 
by qPCR on amplified RNA 
11
.  
Microarray dataset of murine embryonic cartilage and interzone layers 
Details regarding the performed microarray experiment are described elsewhere 
50
. 
Hind limbs from murine embryos of CD-1 IGS mice (n=3) recovered on gestational day 
15.5 (E15.5) were isolated. Hind limbs were snap-frozen in liquid nitrogen, embedded 
in frozen section medium (Neg-50, ThermoFisher, Walldorf, Germany) and sectioned 
along the sagittal axis. Laser capture microdissection (PALM Microbeam system; Carl 
Zeiss Microscopy GmbH) was used to isolate femorotibial intermediate interzone (II), 
femorotibial outer interzone (OI), and femoral and tibial transient embryonic cartilage 
(EC). During embryonic limb formation, transient embryonic cartilage undergoes 
hypertrophy to form long bones 
9-11
. The interzone is critical for joint formation and 
consists of two outer zone layers adjacent to the epiphyseal end of the future bones 
and an intermediate zone. The outer interzone undergoes endochondral ossification, 
forming the subchondral bone, whereas the intermediate interzone will form articular 
cartilage 
50
. Three independent biological replicates were collected of II and OI, and 
two replicates of EC. Each replicate originated from 1 out of 3 individual embryos from 
different litters. Cells were lysed and total RNA was isolated using RNeasy Micro Kit 
following manufacturer’s instructions (Qiagen Sciences, Inc. Germantown, MD). The 
integrity, purity and quantity of RNA were determined using Agilent Bioanalyzer 2100 
(RNA 6000 Pico LabChip® kit; Agilent Technologies, Waldbronn, Germany). 
Subsequently, RNA was amplified and labeled with fluorescent Cyanide 3-CTP (Cy3) 
using the Agilent Low Input Quick Amp Labelling kit (Agilent Technologies). Labeled 
cRNA was hybridized to Agilent Whole Mouse Genome Oligo Microarrays (Agilent 
Sureprint G3 mouse 8x60L Microarray; Agilent Technologies), according to the Agilent 
60-mer microarray processing protocol. Subsequently, fluorescent signal intensities 
were detected using Agilent’s Microarray Scanner System and processed using Agilent 
Feature Extraction Software. The microarray data have been validated by qPCR on 
amplified RNA 
50
. 
Analysis of published microarray datasets 
Published microarray datasets of the murine DMM (destabilization of the medial 
meniscus) model for OA 
42
, 14 days-old mouse femoral growth plates 
11
 and developing 
murine embryonic joints 
50
 were imported and processed using Genespring 13.1 Multi-
Omic software (Agilent Technologies, Santa Clara, CA, USA). After uploading 
experiments as single color experiments, normalization using the 75th percentile shift 
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was performed. Data separation was confirmed by PCA plot analysis. Samples of the 
murine OA dataset were grouped into sham and DMM cohorts at 1, 2 and 6 weeks 
after surgery. Samples of the growth plate dataset were grouped into microdissected 
material originating from the PR, PH and H zone. The dataset originating from the 
developing joints of murine embryos at gestational day 15.5 (E15.5), just prior to 
cavitation, was clustered into laser dissected femorotibial material from the II, OI and 
EC. Moderated T-test and volcano plots were used to determine cut-off values for fold 
change and statistical significance (fold change ≥ 3 and P ≤ 0.01). 
Results 
TGFβ-related genes 
To obtain a complete list of TGFβ-related genes, we merged the KEGG TGFβ pathway 
murine gene list, containing 85 genes, with the list of 501 genes previously shown to 
be regulated by TGFβ in murine or bovine chondrogenic cells 
47-49
. After merging the 
two lists, 6 genes overlapped. Therefore, the list of TGFβ-related genes contained 580 
genes (Supplementary Table 1). We further analyzed these TGFβ-related genes in 
datasets of published microarray studies in order to identify novel candidate genes 
potentially implicated in OA pathogenesis.  
TGFβ-related genes regulated in a murine OA model 
We first determined which TGFβ-related genes were regulated in murine articular 
cartilage after DMM-induced OA compared to sham-operation at the same time point. 
From the 580 TGFβ-related genes, 106 genes were regulated in DMM compared to 
sham at week 1, 2 and/or 6 (Fig. 1; Supplementary Table 2). The largest number of 
genes that were differentially expressed between DMM and sham was at 2 weeks 
post-surgery, where early focal degeneration of the medial tibial plateau cartilage was 
observed on histology. The number of regulated genes was lowest at 6 weeks after 
DMM surgery, when cartilage fibrillations and loss of aggrecan were evident. Of the 
106 DMM-regulated TGFβ-related genes, 86 were upregulated (Fig. 1A) and 20 were 
downregulated (Fig. 1B) in murine OA cartilage at week 1, 2 and/or 6 post-surgery.  
TGFβ-related genes regulated in OA and chondrocyte hypertrophy  
To identify genes implicated in both hypertrophic differentiation of chondrocytes and 
early OA, we determined which of the TGFβ-related genes that were regulated in 
DMM-induced OA were similarly regulated during chondrocyte hypertrophy. Two 
microarray datasets on chondrocyte hypertrophy in mice were used. 
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Figure 1: TGFβ-related genes regulated in a murine model for OA. Microarray analysis was 
performed on cartilage of mice in which OA was induced by surgical destabilization of the medial 
meniscus (DMM) of one knee and sham operation of the other knee at 1, 2 and 6 weeks post-
surgery. Expression of 580 TGFβ-related genes was compared between DMM and sham by a 
moderated T-test. Venn diagrams illustrate genes that were upregulated (A) or downregulated 
(B) in DMM versus sham (fold change ≥ 3 and P ≤ 0.01). 
Microarray data from the proliferative (PR), pre-hypertrophic (PH) and hypertrophic 
(H) zone of the growth plate from Belluoccio et al. 
11
 were filtered for the TGFβ-related 
genes regulated in DMM. We found that 25 of the 86 genes upregulated in damaged 
cartilage following DMM were also higher expressed in the hypertrophic zone 
compared to prehypertrophic or proliferative zones (Table 1). Furthermore, the 
expression of 5 out of 20 genes that were downregulated in the DMM model was also 
reduced in the hypertrophic zone compared to prehypertrophic or proliferative zones 
(Table 1). 
In addition to chondrocytes in the growth plate, chondrocytes in transient embryonic 
cartilage also undergo hypertrophic maturation 
9-11
. Next to the growth plate dataset, 
we used a dataset on embryonic joint formation to determine which of the TGFβ-
related genes that were regulated in DMM were also regulated in chondrocyte 
hypertrophy. Jenner et al. have shown that genes relevant to chondrocyte hypertrophy 
are predominantly expressed in transient embryonic cartilage (EC), to a lesser extent in 
the outer interzone (OI) and lowest in the intermediate interzone (II) 
50
. Therefore, we 
compared gene expression between EC and both interzone layers. Nine out of the 86 
TGFβ-related genes that were upregulated in cartilage of DMM-operated mice were 
also upregulated in EC than in the two interzone layers (OI and II; Table 2). Of the 20 
genes that were downregulated in DMM, 7 genes were downregulated in EC compared 
to OI and II (Table 2). 
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Gene symbol Higher in H than in PH zone Higher in H than in PR zone 
Fold change P-value Fold change P-value 
Agpat9  − − 7.56  1.93E-08  
Agpat9  − − 6.45  1.87E-06  
Ank  9.77  9.20E-09  5.11  2.62E-07  
Arhgap24  3.21  7.62E-04  − − 
Bmp6  − − 7.28  1.98E-07 
Cd44  6.77  2.12E-06  5.12  3.73E-06  
Cd44  5.07  3.85E-08  4.61  1.13E-07  
Cdkn2b  − − 4.16  6.59E-07  
Dcn  3.08  3.29E-03  − − 
Ddit4l  − − 27.37  3.32E-08  
Ddit4l  − − 13.19  1.77E-07  
Ddit4l  − − 8.63  3.94E-07  
Dnajb9  − − 3.31  4.55E-07  
Dnajb9  − − 5.02  2.08E-07  
Fn1  3.64  1.29E-06  17.61  1.49E-05  
Inhba  8.09  7.48E-07  15.83  8.09E-07  
Jag1  11.73  1.83E-04  − − 
Kitl  4.48  1.35E-04  10.74  2.53E-04  
Map1b  − − 4.29  5.04E-07  
Nr2f2  3.19  3.78E-04  4.10  1.68E-07  
Nr2f2  4.16  7.94E-06  − − 
Pcdh17  4.01  2.30E-06  5.43  2.37E-06  
Pdgfra  7.64  4.74E-07  3.31  5.09E-06  
Pmepa1  4.38  3.02E-07  − − 
Ptgs2  13.26  2.62E-09  49.11  1.58E-09  
Ptgs2  22.82  4.94E-10  187.12  9.16E-08  
Rgcc  − − 7.53  2.97E-08  
Serpine1  − − 10.13  1.67E-04  
Slit2  3.74  4.87E-04  9.27  8.91E-04  
Slit2  3.89  5.04E-07  18.03  2.96E-08  
Smad7  − − 6.94  1.52E-07  
Timp3  − − 7.09  1.36E-06  
Tnnt2  − − 3.82  1.65E-03  
Gene symbol Lower in H than in PH zone Lower in H than in PR zone 
Fold change  P-value  Fold change  P-value  
Hhip  − − 5.95  2.50E-08  
Myrip  − − 10.95  4.88E-07  
Ncapg  − − 4.37  3.82E-06  
Ogn  3.43  5.50E-06  18.38  1.06E-08  
Thbs4  5.23  1.12E-08  3.95  8.78E-08  
Analyses based on Moderated T-test: Fold change ≥ 3 and P ≤ 0.01 
–  =not significantly regulated 
Table 1: Differential expression of TGFβ-related genes, regulated in murine OA, between the 
hypertrophic (H) and pre-hypertrophic (PH) or proliferative (PR) zone of murine growth plates.  
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Finally, the results from TGFβ-related genes in the DMM model and regulation in 
either the hypertrophic zone of the growth plate (Table 1) or in transient embryonic 
cartilage (Table 2) were merged. Cdkn2b overlapped between the 25 genes 
upregulated in the hypertrophic zone and 9 genes upregulated in EC, resulting in a 
total of 33 genes upregulated in murine OA and chondrocyte hypertrophy (Fig. 2). 
Between the 5 genes downregulated in the hypertrophic growth plate zone and 7 
genes downregulated in EC, Hhip and Thbs4 overlapped. Hence, a total of 10 genes 
were downregulated in OA and hypertrophic chondrocytes (Fig. 2). Overall, 43 of 106 
TGFβ-related genes were regulated in the same direction in both DMM-induced OA as 
well as chondrocyte hypertrophy. 
Gene symbol Higher in EC than in OI Higher in EC than in II 
Fold change P-value Fold change P-value 
6330415B21Rik  −  −  6.86  2.76E-04  
Asb4  8.32  6.56E-04  9.01  7.42E-05  
Bmp7  −  −  10.30  5.97E-03  
Cdkn2b  −  −  3.32  4.66E-03  
Dtna  −  −  3.83  3.23E-03  
Gna14  −  −  7.52  7.55E-03  
Ltbp1  −  −  3.22  7.46E-03  
Papss2  3.96  3.84E-03  8.19  2.87E-05  
Prkg2  6.58  2.49E-03  6.80  1.49E-04  
Gene symbol Lower in EC than in OI Lower in EC than in II 
Fold change  P-value  Fold change  P-value  
Adamtsl2  5.06  6.00E-03  −  − 
Ccnjl  − − 7.43  1.30E-04  
Gas6  −  −  4.87  7.24E-03  
Hhip  3.92  9.55E-03  −  −  
Hhip  11.52  1.94E-03  −  −  
Scara3  3.97  5.17E-03  −  −  
Thbs4  7.98  3.07E-04  23.66  6.33E-06  
Wipf3  4.87  1.35E-03  −  −  
Analyses based on Moderated T-test: Fold change ≥ 3 and P ≤ 0.01 
–  =not significantly regulated 
Table 2: Differential expression of TGFβ-related genes, regulated in murine OA, between 
transient embryonic cartilage (EC) and the outer interzone (OI) or intermediate interzone (II). 
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Figure 2: Overview of TGFβ-related genes in murine OA and chondrocyte hypertrophy. First, 
TGFβ-related genes were defined. Second, a microarray dataset was used to determine which 
TGFβ-related genes were upregulated or downregulated in murine OA 
42
. Third, which of these 
genes were similarly regulated during chondrocyte hypertrophy in the growth plate or in 
embryonic joint development was determined using published microarray data 
11,50
. Of the 580 
TGFβ-related genes, a total of 10 genes were downregulated (left) and 33 genes were 
upregulated (right) in murine OA and chondrocyte hypertrophy (fold change ≥ 3 and P ≤ 0.01). 
Identification of novel genes implicated in OA 
Since 43 TGFβ-related genes were regulated in both DMM-induced OA and either of 
the chondrocyte hypertrophy datasets, these might be novel candidates implicated in 
OA development and hypertrophy of chondrocytes. To determine whether these genes 
have previously been associated with OA, a literature search was performed. We 
found that 18 of the 43 genes (Table 3) are known to be regulated in cartilage of OA 
animal models (early-stage OA) or human OA patients (late-stage OA). Since the 
remaining 25 genes (Table 4) have not been associated with OA, we considered these 
as novel candidates involved in early onset of OA. An overview of the regulation of 
these 25 genes in the DMM model is presented in Supplementary Figure S1. 
Deficiency of genes may cause skeletal abnormalities and OA-like features as, for 
instance, observed in Smad3 knockout mice 
25,26
. Therefore, we next investigated 
whether the 25 novel candidates have a potential role in development and/or 
maintenance of skeletal tissue. To investigate this, we used the Mouse Genome 
110 
Informatics database to evaluate whether mice deficient for any of the 25 genes have 
a skeletal phenotype 
52,53
. There was no data available for 8 out of 25 genes, because 
no knockout mice have been generated (Table 4). No abnormal skeletal phenotype 
was reported for knockout mice of 13 of the 25 genes, while mice deficient for Ltbp1, 
Nr2f2, Pdgfra or Prkg2 do have a skeletal phenotype (Table 4) 
54-57
. From the 25 novel 
candidates we found that Ltbp1, Nr2f2, Pdgfra or Prkg2 are involved in the 
development of skeletal tissue. 
In addition to the phenotype of knockout mice, we searched in the supplementary 
data of published human OA microarray studies for our 25 candidate genes. Studies in 
which human cartilage from OA patients was compared to that of healthy individuals 
58-61
, and damaged to intact cartilage of OA joints were used 
61-64
. We found that 15 of 
the 25 novel candidate genes were indeed significantly regulated in human OA 
cartilage (Table 4). Thus, besides regulation in early OA (DMM model, Supplementary 
Figure S1), these genes were regulated in late/end-stage OA (human OA). Importantly, 
these 15 genes have not been previously proposed or validated to be involved in OA 
development. 
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Gene symbol Gene name 
Knockout mice 
have a skeletal 
phenotype? 
Regulated in 
human  
OA cartilage? 
Ltbp1  
Latent transforming growth factor beta 
binding protein 1  
Yes 54  Yes 58, 63 
Nr2f2  
Nuclear receptor subfamily 2 group F member 
2  
Yes 55  Yes 61, 62 
Pdgfra  Platelet derived growth factor receptor alpha  Yes 56  Yes 64 
Prkg2  Protein kinase, cGMP-dependent, type II  Yes 57  Yes 62 
Pmepa1  
Prostate transmembrane protein, androgen 
induced 1  
No data available  Yes 59-61 
Ddit4l  DNA damage inducible transcript 4 like  No data available  Yes 58, 60 
Scara3  Scavenger receptor class A member 3  No data available  Yes 58, 60 
Ncapg  Non-SMC condensin I complex subunit G  No data available  Yes 62 
Thbs4  Thrombospondin 4  No  Yes 59, 61, 62  
Map1b  Microtubule associated protein 1B  No  Yes 58, 62 
Agpat9  Glycerol-3-phosphate acyltransferase 3  No  Yes 62 
Arhgap24  Rho GTPase activating protein 24  No  Yes 62 
Cdkn2b  Cyclin dependent kinase inhibitor 2B  No  Yes 62 
Dnajb9  
DnaJ heat shock protein family (Hsp40) 
member B9  
No  Yes 61 
Gas6  Growth arrest specific 6  No  Yes 61 
Ccnjl  Cyclin J like  No data available  No 
Myrip  Myosin VIIA and Rab interacting protein  No data available  No  
6330415B21Rik  -  No data available  No  
Gna14  G protein subunit alpha 14  No data available  No  
Asb4  Ankyrin repeat and SOCS box containing 4  No  No  
Dtna  Dystrobrevin alpha  No  No  
Pcdh17  Protocadherin 17  No  No  
Slit2  Slit guidance ligand 2  No  No  
Tnnt2  Troponin T2, cardiac type  No  No  
Wipf3  
WAS/WASL interacting protein family 
member 3  
No  No  
Table 4: TGFβ-related genes that have not been previously implicated in OA. The 25 TGFβ-
related genes that have not been previously associated with OA were further studied in 
literature to obtain indications for a potential role in skeletal tissue development and 
homeostasis. Moreover, it was evaluated whether these genes were regulated in human OA 
cartilage using the (supplementary) data of published microarray studies.   
 113 
Discussion 
The objective of this study was to identify novel candidate genes related to TGFβ 
signaling that are implicated in OA and chondrocyte hypertrophy. As aberrant TGFβ 
signaling has been associated with enhanced chondrocyte hypertrophy and OA, we 
compiled a list of 580 TGFβ-related genes and found that 106 of these genes were 
regulated in murine OA. Subsequently, the regulation of the 106 genes was evaluated 
in two independent microarray datasets on chondrocyte hypertrophy: the murine 
growth plate and embryonic limb joint development. With this approach we identified 
43 genes that were similarly regulated in both murine OA and chondrocyte 
hypertrophy. We found that 18 of these 43 genes have been previously identified as 
relevant for OA pathology, indicating that the present study identified 25 new 
candidate genes potentially implicated in OA. 
For this study we combined gene expression data available from several previously 
published experiments. This setup allowed us to further investigate the link between 
TGFβ signaling, chondrocyte hypertrophy and OA. Since TGFβ signaling associates with 
the onset of OA as well as chondrocyte hypertrophy 
12-14,65,66
, the present study 
focused on genes related to and/or regulated by TGFβ signaling. The KEGG pathway 
database contains a list of genes that constitute the TGFβ signaling pathway 
46
. 
Importantly, this pathway has been shown to be enriched in cartilage from DMM-
operated mice 
42-44
. In addition to members of the TGFβ pathway (e.g. ligands, 
receptors, transcription factors), the cellular response to TGFβ may be mediated by 
regulation of specific target genes. As the transcriptional program initiated by TGFβ is 
highly cell type and context dependent 
67
, we included TGFβ-target genes in multiple 
types of chondrogenic cells to generate a more comprehensive list of TGFβ-related 
genes. The genes were derived from three microarray studies in which cells were 
stimulated in vitro with TGFβ 
47-49
. Moreover, genes were included based on in vivo 
data in mice with and without TGFβ signaling via Tgfbr2 
48
. Besides investigating which 
of these TGFβ-related genes were regulated during development of OA in mice, we 
determined whether the identified genes were regulated during hypertrophic 
differentiation of chondrocytes. This novel approach, by combining multiple 
microarray datasets based on current knowledge of OA pathobiology, resulted in the 
identification of new candidate genes that might play a role in OA pathogenesis. 
In our study, 106 genes were regulated in murine OA cartilage following DMM. Of 
these regulated genes, a higher number of TGFβ-related genes were similarly 
regulated during chondrocyte hypertrophy in growth plate cartilage than in transient 
embryonic cartilage. This could indicate that the gene expression profile of OA 
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chondrocytes is more similar to hypertrophy in the postnatal growth plate than in 
transient embryonic cartilage. Provided this is the case, the regulation of chondrocyte 
differentiation by TGFβ signaling should be different in postnatal animals versus 
embryos. In fact, there are indications that such a difference truly exists. For example, 
mice deficient for Tgfbr2, Tgfbr1, Smad3 or Smad4 exhibit normal joint development 
and the TGFβ signaling pathway is not enriched during embryonic joint development 
25-
27,38-40,50,68-70
. These observations suggest that the TGFβ signaling pathway is not 
required for chondrocyte differentiation during embryonic articular cartilage 
development. On the other hand, the TGFβ pathway does seem to be essential for 
maintenance of postnatal cartilage by preventing hypertrophic differentiation of 
articular chondrocytes 
26,34-40
. This is supported by studies showing that loss of TGFβ 
signaling leads to chondrocyte hypertrophy 
30,32,71
. The maintenance of the 
chondrocyte phenotype by TGFβ might also be regulated by a shift in the balance 
between the two TGFβ receptors ALK5 and ALK1. The expression of ALK5 in 
chondrocytes protects the cartilage from degradation, while ALK1 might be involved in 
cartilage destruction 
15,31,32,72
. Overall, these findings indicate an age-dependent 
regulation of chondrocyte differentiation by the TGFβ signaling pathway. 
Upon further examination of the literature we observed that most of the identified 
TGFβ-related genes (33 out of 43) were upregulated in OA. This can be explained by 
the release of TGFβ from the cartilage matrix upon damage 
14
. Some of the TGFβ 
signaling pathway members, however, have been reported to be reduced in OA 
cartilage 
28,29,32
. For example, while we found that Bmp7 is upregulated in murine OA 
cartilage, others have shown that this gene is downregulated in OA 
73,74
. A possible 
explanation for differences in regulation of TGFβ-related genes might be that 
expression is differentially regulated in late versus early stages of OA 
42
. It is 
conceivable that TGFβ-related genes have a distinct role during different stages of OA, 
but this requires further investigation. 
The genes of thrombospondin-4 (Thbs4), hedgehog-interacting protein (Hhip) and 
cyclin-dependent kinase inhibitor 2B (Cdkn2b) were regulated in all three microarray 
datasets, indicating these genes may be involved in both chondrocyte maturation and 
OA. Mice lacking Thbs4, Hhip or Cdkn2b have a normal skeleton and body size at birth 
75-77
, indicating that these three genes have a redundant role in embryonic joint 
development. Thrombospondin-4 has been identified as a marker of articular cartilage 
78
. Moreover, articular cartilage from knee joints of 26 week old Thbs4 knockout mice 
is thinner than that of wild-type mice 
77
. This suggests that Thbs4 has a protective 
function in articular cartilage, which is supported by our finding that Thbs4 was 
downregulated in DMM-induced OA. Furthermore, Thbs4 has been shown to interact 
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with various cartilage matrix molecules to exert its protective function 
79
. It would be 
interesting to determine the role of Thbs4 in OA. Similar to Thbs4, Hhip was also 
downregulated in murine DMM-induced OA cartilage and hypertrophic chondrocytes. 
Previously, hedgehog-interacting protein was shown to antagonize Indian Hedgehog 
(Ihh) signaling 
75,80
. Ihh signaling is known to induce chondrocyte maturation during 
endochondral ossification 
81
. Therefore, suppression of Ihh signaling by Hhip might be 
crucial to prevent chondrocyte hypertrophy. In line with this, Hhip was downregulated 
in the two chondrocyte hypertrophy datasets. Contrary to our observation, HHIP 
expression is enhanced in human OA cartilage and positively correlates with the OARSI 
cartilage damage score 
82,83
. This discrepancy may be explained by a difference in the 
disease stage between studies with human OA samples (end-stage disease) and 
material obtained from mice with DMM-induced OA (early onset, trauma-induced). 
Additional studies are required to determine whether the expression of Hhip differs at 
different stages of OA. Cdkn2b was the only gene upregulated in cartilage of DMM-
operated mice and in both chondrocyte hypertrophy datasets. In the literature we did 
not find a link between Cdkn2b and OA or chondrocyte maturation. Thus, we propose 
that Cdkn2b is a novel candidate gene for both chondrocyte hypertrophy and OA. 
In addition to Cdkn2b and Thbs4, we identified 23 other potential novel candidate 
genes involved in OA. As the interplay between skeletal tissues has an important role 
in cartilage homeostasis 
84
, we evaluated whether deficiency of these genes results in a 
skeletal phenotype. To the best of our knowledge, no knockout mice have been 
generated for 6330415B21Rik, Ccnjl, Ddit4l, Gna14, Myrip, Ncapg, Pmepa1 and Scara3. 
Although mice deficient for Agpat9, Arhgap24, Asb4, Cdkn2b, Dnajb9, Dtna, Gas6, 
Map1b, Pcdh17, Slit2, Thbs4, Tnnt2 or Wipf3 have been generated, there are no 
indications that these mice have a skeletal phenotype. Our results indicate that these 
genes may be important for early OA, which could be evaluated by experimentally 
inducing OA in these knockout mice. According to literature, deletion of Ltbp1, Nr2f2, 
Prkg2 or Pdgfra results in skeletal abnormalities 
54-57
. In line with this, these four genes 
are involved in chondrogenesis and homeostasis of cartilage 
85-91
. Conditional or tissue-
specific knockout mice may be used to elucidate the role of these genes in OA. 
Although Gas6-knockout mice do not have a skeletal phenotype, Gas6 is involved in 
survival of articular chondrocytes and regulation of the growth plate 
92,93
. Overall, 
these findings suggest that Gas6, Ltbp1, Nr2f2, Prkg2 and Pdgfra play a direct role in 
skeletal development and cartilage homeostasis. Research on their involvement in OA 
would be interesting.  
A limitation of our study is that we investigated only mRNA expression. In the future, 
protein expression should be evaluated in order to verify our results. Furthermore, our 
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selection criterium (fold change ≥3) for differentially expressed genes was rather strict. 
Therefore, we might have missed less strongly regulated genes. Nevertheless, we 
identified 43 candidate genes. Importantly, 18 out of these 43 candidate genes have 
already been implicated in OA, which indicates that our approach is able to identify 
relevant target genes. The data on murine OA used in this study are based only on the 
DMM model. However, the DMM model is a well-characterized, reproducible and 
validated model that has been recommended as first choice to identify potential 
targets in OA and is considered to represent characteristics of both age-related as well 
as trauma-induced OA 
94,95
. Bateman et al. have shown that markers for chondrocyte 
hypertrophy are expressed in this model 
42
. Moreover, 18 of the 43 identified genes 
have already been associated with early and/or late-stage OA, confirming DMM 
represents aspects of human OA. Furthermore, our data have revealed that these 18 
genes (Table 3) are regulated by TGFβ and are similarly regulated during endochondral 
bone formation and embryonic joint development.  
From the 25 novel identified candidates, we found evidence for significant regulation 
of Ltbp1, Nr2f2, Pdgfra, Prkg2, Pmepa1, DDIT4L, SCARA3, ncapg, THBS4, map1b, 
AGPAT9, ARHGAP24, Cdkn2b, DNAJB9 and Gas6 in human OA cartilage in the 
supplementary data provided in previous publications 
58-64
, indicating that these genes 
are of particular interest for further study in OA pathophysiology. It would be of 
interest to determine whether manipulation of these 15 genes in articular 
chondrocytes leads to phenotypic changes as observed during OA development, for 
example hypertrophy, in vitro and/or in vivo. 
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Supplementary tables and figure 
Gene symbol Gene name Gene ID 
1500015O10Rik RIKEN cDNA 1500015O10 gene 78896 
4930544G11Rik RIKEN cDNA 4930544G11 gene 67653 
5530601H04Rik RIKEN cDNA 5530601H04 gene 71445 
5730478J17Rik RIKEN cDNA 5730478J17 gene 70580 
5830408B19Rik RIKEN cDNA 5830408B19 gene 74756 
5930405F01Rik RIKEN cDNA 5930405F01 gene 320550 
6330415B21Rik RIKEN cDNA 6330415B21 gene 70753 
9330177L23Rik RIKEN cDNA 9330177L23 gene 77246 
9430085L16Rik RIKEN cDNA 9430085L16 gene 77375 
9530059O14Rik RIKEN cDNA 9530059O14 gene 319626 
9630021D06Rik RIKEN cDNA 9630021D06 gene 319926 
9630023C09Rik RIKEN cDNA 9630023C09 gene 320378 
Aard alanine and arginine rich domain containing protein 239435 
Abca9 ATP-binding cassette, sub-family A (ABC1), member 9 217262 
Abi3bp ABI gene family, member 3 (NESH) binding protein 320712 
Acox2 acyl-Coenzyme A oxidase 2, branched chain 93732 
Actb actin, beta 11461 
Actr2 ARP2 actin-related protein 2 66713 
Acvr1 activin A receptor, type 1 11477 
Acvr1b activin A receptor, type 1B 11479 
Acvr1c activin A receptor, type IC 269275 
Acvr2a activin receptor IIA 11480 
Acvr2b activin receptor IIB 11481 
Adam12 a disintegrin and metallopeptidase domain 12 (meltrin alpha) 11489 
Adamts1 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 
motif, 1 
11504 
Adamts20 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 
motif, 20 
223838 
Adamts6 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 
motif, 6 
108154 
Adamtsl2 ADAMTS-like 2 77794 
Adarb1 adenosine deaminase, RNA-specific, B1 110532 
Adgrb3 adhesion G protein-coupled receptor B3 210933 
Adh5 alcohol dehydrogenase 5 (class III), chi polypeptide 11532 
Adm adrenomedullin 11535 
Adra2a adrenergic receptor, alpha 2a 11551 
Adss adenylosuccinate synthetase, non muscle 11566 
Agpat9 1-acylglycerol-3-phosphate O-acyltransferase 9 231510 
Agtr1a angiotensin II receptor, type 1a 11607 
Agtr2 angiotensin II receptor, type 2 11609 
AI448005 expressed sequence AI448005 98965 
AI504432 expressed sequence AI504432 229694 
Ak1 adenylate kinase 1 11636 
Ak5 adenylate kinase 5 229949 
Ak6 adenylate kinase 6 102216272 
Alcam activated leukocyte cell adhesion molecule 11658 
Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 11668 
Alg5 asparagine-linked glycosylation 5 (dolichyl-phosphate beta-glucosyltransferase) 66248 
Amh anti-Mullerian hormone 11705 
Amhr2 anti-Mullerian hormone type 2 receptor 110542 
Ampd3 adenosine monophosphate deaminase 3 11717 
Angptl4 angiopoietin-like 4 57875 
Ank progressive ankylosis 11732 
Anp32a acidic (leucine-rich) nuclear phosphoprotein 32 family, member A 11737 
Anxa11 annexin A11 11744 
Anxa8 annexin A8 11752 
Apc adenomatosis polyposis coli 11789 
Aplnr apelin receptor 23796 
Apod apolipoprotein D 11815 
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Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 212285 
Arhgap20 Rho GTPase activating protein 20 244867 
Arhgap24 Rho GTPase activating protein 24 231532 
Arhgef5 Rho guanine nucleotide exchange factor (GEF) 5 54324 
Arsi arylsulfatase i 545260 
Asb4 ankyrin repeat and SOCS box-containing 4 65255 
Aspn asporin 66695 
Ass1 argininosuccinate synthetase 1 11898 
Asxl3 additional sex combs like 3 (Drosophila) 211961 
AU015680 expressed sequence AU015680 552875 
Avpr1a arginine vasopressin receptor 1A 54140 
Axin2 axin 2 12006 
B3galnt2 UDP-GalNAc:betaGlcNAc beta 1,3-galactosaminyltransferase, polypeptide 2 97884 
B3galt2 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 26878 
Bach1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 12013 
Bag6 BCL2-associated athanogene 6 224727 
Bambi BMP and activin membrane-bound inhibitor 68010 
Barx1 BarH-like homeobox 1 12022 
Bhlhe40 basic helix-loop-helix family, member e40 20893 
Bmp2 bone morphogenetic protein 2 12156 
Bmp4 bone morphogenetic protein 4 12159 
Bmp5 bone morphogenetic protein 5 12160 
Bmp6 bone morphogenetic protein 6 12161 
Bmp7 bone morphogenetic protein 7 12162 
Bmp8a bone morphogenetic protein 8a 12163 
Bmp8b bone morphogenetic protein 8b 12164 
Bmper BMP-binding endothelial regulator 73230 
Bmpr1a bone morphogenetic protein receptor, type 1A 12166 
Bmpr1b bone morphogenetic protein receptor, type 1B 12167 
Bmpr2 bone morphogenetic protein receptor, type II (serine/threonine kinase) 12168 
C030026M15Rik RIKEN cDNA C030026M15 gene 77378 
C1qtnf3 C1q and tumor necrosis factor related protein 3 81799 
C4a complement component 4A (Rodgers blood group) 625018 
C4b complement component 4B (Chido blood group) 12268 
Cadps2 Ca2+-dependent activator protein for secretion 2 320405 
Calml3 calmodulin-like 3 70405 
Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 66259 
Car5b carbonic anhydrase 5b, mitochondrial 56078 
Cav1 caveolin 1, caveolae protein 12389 
Cav2 caveolin 2 12390 
Cbx6 chromobox 6 494448 
Ccdc142 coiled-coil domain containing 142 243510 
Ccdc28b coiled coil domain containing 28B 66264 
Ccdc58 coiled-coil domain containing 58 381045 
Ccl21a chemokine (C-C motif) ligand 21A (serine) 18829 
Ccl21b chemokine (C-C motif) ligand 21B (leucine) 100042493 
Ccl21c chemokine (C-C motif) ligand 21C (leucine) 65956 
Ccnjl cyclin J-like 380694 
Cd40 CD40 antigen 21939 
Cd44 CD44 antigen 12505 
Cd59b CD59b antigen 333883 
Cda cytidine deaminase 72269 
Cdc42ep3 CDC42 effector protein (Rho GTPase binding) 3 260409 
Cdca5 cell division cycle associated 5 67849 
Cdh10 cadherin 10 320873 
Cdh2 cadherin 2 12558 
Cdkn2b cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 12579 
Cgref1 cell growth regulator with EF hand domain 1 68567 
Chac1 ChaC, cation transport regulator 1 69065 
Chad chondroadherin 12643 
Chdh choline dehydrogenase 218865 
Chek1 checkpoint kinase 1 12649 
Chrd chordin 12667 
Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 214425 
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Cldn1 claudin 1 12737 
Clu clusterin 12759 
Cmklr1 chemokine-like receptor 1 14747 
Cntn3 contactin 3 18488 
Col14a1 collagen, type XIV, alpha 1 12818 
Col6a1 collagen, type VI, alpha 1 12833 
Col8a2 collagen, type VIII, alpha 2 329941 
Cotl1 coactosin-like 1 (Dictyostelium) 72042 
Cplx2 complexin 2 12890 
Crebbp CREB binding protein 12914 
Csrp2 cysteine and glycine-rich protein 2 13008 
Ctdspl CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-
like 
69274 
Ctgf connective tissue growth factor 14219 
Ctsw cathepsin W 13041 
Cul1 cullin 1 26965 
Cux2 cut-like homeobox 2 13048 
Cxcl5 chemokine (C-X-C motif) ligand 5 20311 
D18Ertd232e DNA segment, Chr 18, ERATO Doi 232, expressed 52492 
D430019H16Rik RIKEN cDNA D430019H16 gene 268595 
D5Ertd505e DNA segment, Chr 5, ERATO Doi 505, expressed 52485 
Dab1 disabled 1 13131 
Dancr differentiation antagonizing non-protein coding RNA 70036 
Dcn decorin 13179 
Dctpp1 dCTP pyrophosphatase 1 66422 
Ddah1 dimethylarginine dimethylaminohydrolase 1 69219 
Ddit4 DNA-damage-inducible transcript 4 74747 
Ddit4l DNA-damage-inducible transcript 4-like 73284 
Ddx18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 66942 
Ddx3y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked 26900 
Ddx6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 13209 
Dio2 deiodinase, iodothyronine, type II 13371 
Dkk2 dickkopf WNT signaling pathway inhibitor 2 56811 
Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 27362 
Dock4 dedicator of cytokinesis 4 238130 
Dok1 docking protein 1 13448 
Dpysl2 dihydropyrimidinase-like 2 12934 
Dtna dystrobrevin alpha 13527 
Dubr Dppa2 upstream binding RNA 68190 
Dusp26 dual specificity phosphatase 26 (putative) 66959 
Dyrk1b dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1b 13549 
E2f4 E2F transcription factor 4 104394 
E2f5 E2F transcription factor 5 13559 
Ebf1 early B cell factor 1 13591 
Ebf3 early B cell factor 3 13593 
Edil3 EGF-like repeats and discoidin I-like domains 3 13612 
Efemp1 epidermal growth factor-containing fibulin-like extracellular matrix protein 1 216616 
Eif2s3y eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked 26908 
Emp3 epithelial membrane protein 3 13732 
Enc1 ectodermal-neural cortex 1 13803 
Endod1 endonuclease domain containing 1 71946 
Enpep glutamyl aminopeptidase 13809 
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 18605 
Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 18606 
Ep300 E1A binding protein p300 328572 
Epas1 endothelial PAS domain protein 1 13819 
Erg avian erythroblastosis virus E-26 (v-ets) oncogene related 13876 
Esrrg estrogen-related receptor gamma 26381 
F3 coagulation factor III 14066 
Fam134b family with sequence similarity 134, member B 66270 
Fam13c family with sequence similarity 13, member C 71721 
Fam199x family with sequence similarity 199, X-linked 245622 
Fam32a family with sequence similarity 32, member A 67922 
Fat3 FAT atypical cadherin 3 270120 
 125 
Fat4 FAT atypical cadherin 4 329628 
Fbln5 fibulin 5 23876 
Fbp1 fructose bisphosphatase 1 14121 
Fcf1 FCF1 rRNA processing protein 73736 
Fgf18 fibroblast growth factor 18 14172 
Fgf21 fibroblast growth factor 21 56636 
Fgfr1op2 FGFR1 oncogene partner 2 67529 
Fgfr2 fibroblast growth factor receptor 2 14183 
Fgfr3 fibroblast growth factor receptor 3 14184 
Fjx1 four jointed box 1 (Drosophila) 14221 
Flnb filamin, beta 286940 
Flt4 FMS-like tyrosine kinase 4 14257 
Fmod fibromodulin 14264 
Fn1 fibronectin 1 14268 
Fndc3a fibronectin type III domain containing 3A 319448 
Foxp1 forkhead box P1 108655 
Foxq1 forkhead box Q1 15220 
Frmd5 FERM domain containing 5 228564 
Frmd6 FERM domain containing 6 319710 
Fst follistatin 14313 
Fstl3 follistatin-like 3 83554 
G0s2 G0/G1 switch gene 2 14373 
Gabrg3 gamma-aminobutyric acid (GABA) A receptor, subunit gamma 3 14407 
Gadd45b growth arrest and DNA-damage-inducible 45 beta 17873 
Gadd45g growth arrest and DNA-damage-inducible 45 gamma 23882 
Gal galanin 14419 
Galc galactosylceramidase 14420 
Gas6 growth arrest specific 6 14456 
Gdf10 growth differentiation factor 10 14560 
Gdf5 growth differentiation factor 5 14563 
Gdf6 growth differentiation factor 6 242316 
Gdf7 growth differentiation factor 7 238057 
Gfpt2 glutamine fructose-6-phosphate transaminase 2 14584 
Ggps1 geranylgeranyl diphosphate synthase 1 14593 
Gjb3 gap junction protein, beta 3 14620 
Gm10591 predicted gene 10591 100504239 
Gm13304 predicted gene 13304 100504346 
Gm13552 predicted gene 13552 100038999 
Gm15421 predicted gene 15421 100042049 
Gm1987 predicted gene 1987 100504362 
Gm21541 predicted gene, 21541 100862177 
Gm21949 predicted gene, 21949 100505386 
Gm2260 predicted gene 2260 100039484 
Gm2274 predicted gene 2274 100039503 
Gm5424 predicted gene 5424 432466 
Gm9840 predicted gene 9840 100043674 
Gna14 guanine nucleotide binding protein, alpha 14 14675 
Gng2 guanine nucleotide binding protein (G protein), gamma 2 14702 
Gpc2 glypican 2 (cerebroglycan) 71951 
Gprc5b G protein-coupled receptor, family C, group 5, member B 64297 
Gprin2 G protein regulated inducer of neurite outgrowth 2 432839 
Gpsm2 G-protein signalling modulator 2 (AGS3-like, C. elegans) 76123 
Grb10 growth factor receptor bound protein 10 14783 
Grid2 glutamate receptor, ionotropic, delta 2 14804 
Grin2c glutamate receptor, ionotropic, NMDA2C (epsilon 3) 14813 
Gsg1l GSG1-like 269994 
Gt(ROSA)26Sor gene trap ROSA 26, Philippe Soriano 14910 
Hacd3 3-hydroxyacyl-CoA dehydratase 3 57874 
Hand2 heart and neural crest derivatives expressed transcript 2 15111 
Has2 hyaluronan synthase 2 15117 
Hes1 hairy and enhancer of split 1 (Drosophila) 15205 
Hhip Hedgehog-interacting protein 15245 
Higd1c HIG1 domain family, member 1C 380975 
Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 15357 
 126 
Hook1 hook microtubule tethering protein 1 77963 
Hoxa10 homeobox A10 15395 
Hoxa9 homeobox A9 15405 
Hoxc10 homeobox C10 209448 
Hoxd10 homeobox D10 15430 
Hoxd3os1 homeobox D3, opposite strand 1 73429 
Hoxd9 homeobox D9 15438 
Hpgd hydroxyprostaglandin dehydrogenase 15 (NAD) 15446 
Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 15484 
Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 114664 
Hspb2 heat shock protein 2 69253 
Hspb8 heat shock protein 8 80888 
Htra1 HtrA serine peptidase 1 56213 
Htra3 HtrA serine peptidase 3 78558 
Ibsp integrin binding sialoprotein 15891 
Id1 inhibitor of DNA binding 1 15901 
Id2 inhibitor of DNA binding 2 15902 
Id3 inhibitor of DNA binding 3 15903 
Id4 inhibitor of DNA binding 4 15904 
Ifng interferon gamma 15978 
Il1rap interleukin 1 receptor accessory protein 16180 
Inhba inhibin beta-A 16323 
Inhbb inhibin beta-B 16324 
Inhbc inhibin beta-C 16325 
Inhbe inhibin beta-E 16326 
Itgbl1 integrin, beta-like 1 223272 
Itih5 inter-alpha (globulin) inhibitor H5 209378 
Jag1 jagged 1 16449 
Kank4 KN motif and ankyrin repeat domains 4 242553 
Kcnd3 potassium voltage-gated channel, Shal-related family, member 3 56543 
Kcnk1 potassium channel, subfamily K, member 1 16525 
Kcnk6 potassium inwardly-rectifying channel, subfamily K, member 6 52150 
Kcnmb4 potassium large conductance calcium-activated channel, subfamily M, beta member 4 58802 
Kdm5d lysine (K)-specific demethylase 5D 20592 
Kif11 kinesin family member 11 16551 
Kif5c kinesin family member 5C 16574 
Kitl kit ligand 17311 
Krt19 keratin 19 16669 
Lamp2 lysosomal-associated membrane protein 2 16784 
Lcat lecithin cholesterol acyltransferase 16816 
Ldb2 LIM domain binding 2 16826 
Ldlrad4 low density lipoprotein receptor class A domain containing 4 52662 
Lefty1 left right determination factor 1 13590 
Lefty2 left-right determination factor 2 320202 
Limk2 LIM motif-containing protein kinase 2 16886 
LOC100041504  100041504 
LOC100041593  100041593 
LOC552873  552873 
LOC552911  552911 
Lox lysyl oxidase 16948 
Lpl lipoprotein lipase 16956 
Lrp1b low density lipoprotein-related protein 1B (deleted in tumors) 94217 
Lrp8 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor 16975 
Lrr1 leucine rich repeat protein 1 69706 
Lrrtm1 leucine rich repeat transmembrane neuronal 1 74342 
Lsamp limbic system-associated membrane protein 268890 
Ltbp1 latent transforming growth factor beta binding protein 1 268977 
Ltbp2 latent transforming growth factor beta binding protein 2 16997 
Lypd6 LY6/PLAUR domain containing 6 320343 
Maf avian musculoaponeurotic fibrosarcoma oncogene homolog 17132 
Mafb v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) 16658 
Map1b microtubule-associated protein 1B 17755 
Map2k6 mitogen-activated protein kinase kinase 6 26399 
Map3k5 mitogen-activated protein kinase kinase kinase 5 26408 
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Mapk1 mitogen-activated protein kinase 1 26413 
Mapk3 mitogen-activated protein kinase 3 26417 
Matn2 matrilin 2 17181 
Mbnl3 muscleblind-like 3 (Drosophila) 171170 
Mbp myelin basic protein 17196 
Mcm5 minichromosome maintenance complex component 5 17218 
Methig1 methyltransferase hypoxia inducible domain containing 1 554292 
Mettl7a1 methyltransferase like 7A1 70152 
Mettl7a2 methyltransferase like 7A2 393082 
Mettl7a3 methyltransferase like 7A3 668178 
Mfsd2a major facilitator superfamily domain containing 2A 76574 
Mgll monoglyceride lipase 23945 
Mgp matrix Gla protein 17313 
Mgst1 microsomal glutathione S-transferase 1 56615 
Mir22hg Mir22 host gene (non-protein coding) 100042498 
Mkx mohawk homeobox 210719 
Mlph melanophilin 171531 
Mrpl50 mitochondrial ribosomal protein L50 28028 
Mrpl53 mitochondrial ribosomal protein L53 68499 
Mrps18b mitochondrial ribosomal protein S18B 66973 
Mtus1 mitochondrial tumor suppressor 1 102103 
Myc myelocytomatosis oncogene 17869 
Myo18a myosin XVIIIA 360013 
Myo1d myosin ID 338367 
Myocd myocardin 214384 
Myrip myosin VIIA and Rab interacting protein 245049 
Nbl1 neuroblastoma, suppression of tumorigenicity 1 17965 
Ncam1 neural cell adhesion molecule 1 17967 
Ncapg non-SMC condensin I complex, subunit G 54392 
Ndnf neuron-derived neurotrophic factor 68169 
Ndp Norrie disease (pseudoglioma) (human) 17986 
Nedd4l neural precursor cell expressed, developmentally down-regulated gene 4-like 83814 
Nedd9 neural precursor cell expressed, developmentally down-regulated gene 9 18003 
Nefl neurofilament, light polypeptide 18039 
Nfatc1 nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 18018 
Nfatc2 nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2 18019 
Ngf nerve growth factor 18049 
Nkd2 naked cuticle 2 homolog (Drosophila) 72293 
Nme1 NME/NM23 nucleoside diphosphate kinase 1 18102 
Nodal nodal 18119 
Nog noggin 18121 
Nov nephroblastoma overexpressed gene 18133 
Nptx1 neuronal pentraxin 1 18164 
Nr2f2 nuclear receptor subfamily 2, group F, member 2 11819 
Nrip3 nuclear receptor interacting protein 3 78593 
Nrp1 neuropilin 1 18186 
Nrp2 neuropilin 2 18187 
Nrxn1 neurexin I 18189 
Nsg2 neuron specific gene family member 2 18197 
Nt5e 5' nucleotidase, ecto 23959 
Ntf5 neurotrophin 5 78405 
Ntm neurotrimin 235106 
Nuak1 NUAK family, SNF1-like kinase, 1 77976 
Nucks1 nuclear casein kinase and cyclin-dependent kinase substrate 1 98415 
Nupr1 nuclear protein transcription regulator 1 56312 
Ogn osteoglycin 18295 
Olfm2 olfactomedin 2 244723 
Orc5 origin recognition complex, subunit 5 26429 
Osr1 odd-skipped related 1 (Drosophila) 23967 
Otor otoraplin 57329 
Palld palladin, cytoskeletal associated protein 72333 
Palm2 paralemmin 2 242481 
Pamr1 peptidase domain containing associated with muscle regeneration 1 210622 
Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 23972 
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Pcdh17 protocadherin 17 219228 
Pcdh9 protocadherin 9 211712 
Pcgf5 polycomb group ring finger 5 76073 
Pclo piccolo (presynaptic cytomatrix protein) 26875 
Pcnp PEST proteolytic signal containing nuclear protein 76302 
Pcp4 Purkinje cell protein 4 18546 
Pcsk5 proprotein convertase subtilisin/kexin type 5 18552 
Pde7a phosphodiesterase 7A 18583 
Pde7b phosphodiesterase 7B 29863 
Pdgfra platelet derived growth factor receptor, alpha polypeptide 18595 
Pdgfrl platelet-derived growth factor receptor-like 68797 
Pdia6 protein disulfide isomerase associated 6 71853 
Pdk3 pyruvate dehydrogenase kinase, isoenzyme 3 236900 
Pdxdc1 pyridoxal-dependent decarboxylase domain containing 1 94184 
Penk preproenkephalin 18619 
Phex phosphate regulating endopeptidase homolog, X-linked 18675 
Pik3r1 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) 18708 
Pim1 proviral integration site 1 18712 
Pitpnb phosphatidylinositol transfer protein, beta 56305 
Pitx2 paired-like homeodomain transcription factor 2 18741 
Pkp1 plakophilin 1 18772 
Plek2 pleckstrin 2 27260 
Plekha4 pleckstrin homology domain containing, family A (phosphoinositide binding specific) 
member 4 
69217 
Plod2 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 26432 
Plscr2 phospholipid scramblase 2 18828 
Plxnc1 plexin C1 54712 
Plxnd1 plexin D1 67784 
Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 58801 
Pmepa1 prostate transmembrane protein, androgen induced 1 65112 
Polr3k polymerase (RNA) III (DNA directed) polypeptide K 67005 
Postn periostin, osteoblast specific factor 50706 
Ppa1 pyrophosphatase (inorganic) 1 67895 
Ppp1r3b protein phosphatase 1, regulatory (inhibitor) subunit 3B 244416 
Ppp2ca protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 19052 
Ppp2cb protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform 19053 
Ppp2r1a protein phosphatase 2, regulatory subunit A, alpha 51792 
Ppp2r1b protein phosphatase 2, regulatory subunit A, beta 73699 
Prg4 proteoglycan 4 (megakaryocyte stimulating factor, articular superficial zone protein) 96875 
Prkcdbp protein kinase C, delta binding protein 109042 
Prkg2 protein kinase, cGMP-dependent, type II 19092 
Prm1 protamine 1 19118 
Prom1 prominin 1 19126 
Prpf39 pre-mRNA processing factor 39 328110 
Prps1 phosphoribosyl pyrophosphate synthetase 1 19139 
Prps1l3 phosphoribosyl pyrophosphate synthetase 1-like 3 328099 
Prss12 protease, serine 12 neurotrypsin (motopsin) 19142 
Prss35 protease, serine 35 244954 
Psap prosaposin 19156 
Psmd10 proteasome (prosome, macropain) 26S subunit, non-ATPase, 10 53380 
Pstpip2 proline-serine-threonine phosphatase-interacting protein 2 19201 
Ptgs2 prostaglandin-endoperoxide synthase 2 19225 
Pth1r parathyroid hormone 1 receptor 19228 
Pthlh parathyroid hormone-like peptide 19227 
Ptprd protein tyrosine phosphatase, receptor type, D 19266 
Ptprr protein tyrosine phosphatase, receptor type, R 19279 
Pxylp1 2-phosphoxylose phosphatase 1 235534 
Pygl liver glycogen phosphorylase 110095 
Rab10 RAB10, member RAS oncogene family 19325 
Rasal2 RAS protein activator like 2 226525 
Rasl11b RAS-like, family 11, member B 68939 
Rbl1 retinoblastoma-like 1 (p107) 19650 
Rbx1 ring-box 1 56438 
Reps2 RALBP1 associated Eps domain containing protein 2 194590 
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Rgcc regulator of cell cycle 66214 
Rgs10 regulator of G-protein signalling 10 67865 
Rgs2 regulator of G-protein signaling 2 19735 
Rhoa ras homolog family member A 11848 
Rhob ras homolog family member B 11852 
Rnf144b ring finger protein 144B 218215 
Rnf19b ring finger protein 19B 75234 
Rock1 Rho-associated coiled-coil containing protein kinase 1 19877 
Rpl22l1 ribosomal protein L22 like 1 68028 
Rps6ka3 ribosomal protein S6 kinase polypeptide 3 110651 
Rps6kb1 ribosomal protein S6 kinase, polypeptide 1 72508 
Rps6kb2 ribosomal protein S6 kinase, polypeptide 2 58988 
Rspo2 R-spondin 2 239405 
Runx1 runt related transcription factor 1 12394 
Runx1t1 runt-related transcription factor 1; translocated to, 1 (cyclin D-related) 12395 
Runx2 runt related transcription factor 2 12393 
Ryr3 ryanodine receptor 3 20192 
S100a6 S100 calcium binding protein A6 (calcyclin) 20200 
Saa1 serum amyloid A 1 20208 
Sar1b secretion associated Ras related GTPase 1B 66397 
Scara3 scavenger receptor class A, member 3 219151 
Scara5 scavenger receptor class A, member 5 71145 
Scd1 stearoyl-Coenzyme A desaturase 1 20249 
Schip1 schwannomin interacting protein 1 30953 
Scx scleraxis 20289 
Sdpr serum deprivation response 20324 
Sdr39u1 short chain dehydrogenase/reductase family 39U, member 1 654795 
Sec22b SEC22 homolog B, vesicle trafficking protein 20333 
Selenbp1 selenium binding protein 1 20341 
Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 18787 
Sesn3 sestrin 3 75747 
Sfrp2 secreted frizzled-related protein 2 20319 
Sfxn3 sideroflexin 3 94280 
Shisa3 shisa family member 3 330096 
Skap2 src family associated phosphoprotein 2 54353 
Skp1a S-phase kinase-associated protein 1A 21402 
Slc17a1 solute carrier family 17 (sodium phosphate), member 1 20504 
Slc20a1 solute carrier family 20, member 1 20515 
Slc29a1 solute carrier family 29 (nucleoside transporters), member 1 63959 
Slc4a7 solute carrier family 4, sodium bicarbonate cotransporter, member 7 218756 
Slco3a1 solute carrier organic anion transporter family, member 3a1 108116 
Slit2 slit homolog 2 (Drosophila) 20563 
Slitrk1 SLIT and NTRK-like family, member 1 76965 
Smad1 SMAD family member 1 17125 
Smad2 SMAD family member 2 17126 
Smad3 SMAD family member 3 17127 
Smad4 SMAD family member 4 17128 
Smad5 SMAD family member 5 17129 
Smad6 SMAD family member 6 17130 
Smad7 SMAD family member 7 17131 
Smad9 SMAD family member 9 55994 
Smarca4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 4 
20586 
Smoc2 SPARC related modular calcium binding 2 64074 
Smurf1 SMAD specific E3 ubiquitin protein ligase 1 75788 
Smurf2 SMAD specific E3 ubiquitin protein ligase 2 66313 
Snai2 snail family zinc finger 2 20583 
Sned1 sushi, nidogen and EGF-like domains 1 208777 
Sox11 SRY (sex determining region Y)-box 11 20666 
Sox4 SRY (sex determining region Y)-box 4 20677 
Sp1 trans-acting transcription factor 1 20683 
Spp1 secreted phosphoprotein 1 20750 
Spsb1 splA/ryanodine receptor domain and SOCS box containing 1 74646 
Srl sarcalumenin 106393 
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Ssr3 signal sequence receptor, gamma 67437 
St8sia1 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 20449 
St8sia4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 20452 
Stc2 stanniocalcin 2 20856 
Steap3 STEAP family member 3 68428 
Syt1 synaptotagmin I 20979 
Taf9 TATA-box binding protein associated factor 9 108143 
Tasp1 taspase, threonine aspartase 1 75812 
Tbx1 T-box 1 21380 
Tenm2 teneurin transmembrane protein 2 23964 
Tesc tescalcin 57816 
Tet1 tet methylcytosine dioxygenase 1 52463 
Tfdp1 transcription factor Dp 1 21781 
Tfrc transferrin receptor 22042 
Tgfb1 transforming growth factor, beta 1 21803 
Tgfb2 transforming growth factor, beta 2 21808 
Tgfb3 transforming growth factor, beta 3 21809 
Tgfbi transforming growth factor, beta induced 21810 
Tgfbr1 transforming growth factor, beta receptor I 21812 
Tgfbr2 transforming growth factor, beta receptor II 21813 
Tgfbr3 transforming growth factor, beta receptor III 21814 
Tgif1 TGFB-induced factor homeobox 1 21815 
Tgif2 TGFB-induced factor homeobox 2 228839 
Thbs1 thrombospondin 1 21825 
Thbs4 thrombospondin 4 21828 
Thsd7a thrombospondin, type I, domain containing 7A 330267 
Timp3 tissue inhibitor of metalloproteinase 3 21859 
Tle2 transducin-like enhancer of split 2 21886 
Tle3 transducin-like enhancer of split 3 21887 
Tmeff1 transmembrane protein with EGF-like and two follistatin-like domains 1 230157 
Tmem2 transmembrane protein 2 83921 
Tmem204 transmembrane protein 204 407831 
Tmem26 transmembrane protein 26 327766 
Tmem27 transmembrane protein 27 57394 
Tmem30a transmembrane protein 30A 69981 
Tnf tumor necrosis factor 21926 
Tnfaip6 tumor necrosis factor alpha induced protein 6 21930 
Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) 18383 
Tnk2 tyrosine kinase, non-receptor, 2 51789 
Tnnt2 troponin T2, cardiac 21956 
Tns2 tensin 2 209039 
Tomm70a translocase of outer mitochondrial membrane 70 homolog A (yeast) 28185 
Tpr translocated promoter region, nuclear basket protein 108989 
Trim47 tripartite motif-containing 47 217333 
Trpc3 transient receptor potential cation channel, subfamily C, member 3 22065 
Trps1 trichorhinophalangeal syndrome I (human) 83925 
Tspan12 tetraspanin 12 269831 
Tspan2 tetraspanin 2 70747 
Ttc30b tetratricopeptide repeat domain 30B 72421 
Ttyh1 tweety family member 1 57776 
Tulp1 tubby like protein 1 22157 
Ucma upper zone of growth plate and cartilage matrix associated 68527 
Ugcg UDP-glucose ceramide glucosyltransferase 22234 
Ugdh UDP-glucose dehydrogenase 22235 
Unc5d unc-5 netrin receptor D 210801 
Upf1 UPF1 regulator of nonsense transcripts homolog (yeast) 19704 
Utp18 UTP18 small subunit processome component 217109 
Uty ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome 22290 
Vamp7 vesicle-associated membrane protein 7 20955 
Vegfa vascular endothelial growth factor A 22339 
Vegfc vascular endothelial growth factor C 22341 
Vstm2a V-set and transmembrane domain containing 2A 211739 
Wif1 Wnt inhibitory factor 1 24117 
Wipf3 WAS/WASL interacting protein family, member 3 330319 
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Wisp1 WNT1 inducible signaling pathway protein 1 22402 
Wls wntless homolog (Drosophila) 68151 
Wnt5a wingless-type MMTV integration site family, member 5A 22418 
Xiap X-linked inhibitor of apoptosis 11798 
Xist inactive X specific transcripts 213742 
Yipf5 Yip1 domain family, member 5 67180 
Zfa-ps zinc finger protein, autosomal, pseudogene 22639 
Zfhx3 zinc finger homeobox 3 11906 
Zfp185 zinc finger protein 185 22673 
Zfp800 zinc finger protein 800 627049 
Zfp811 zinc finger protein 811 240063 
Zfx zinc finger protein X-linked 22764 
Zfyve16 zinc finger, FYVE domain containing 16 218441 
Zfyve9 zinc finger, FYVE domain containing 9 230597 
Zic1 zinc finger protein of the cerebellum 1 22771 
Supplementary Table 1. List of TGFβ-related genes. 
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Week 1 
Gene Symbol 
 
Fold change (abs) 
 
Regulation 
(DMM vs. sham) 
 
P-value 
6330415B21Rik 6.740 up 6.65E-03 
Ank 5.835 up 7.46E-06 
Arhgap24 5.275 up 2.45E-04 
Asb4 4.776 up 6.28E-03 
Bmp2 7.795 up 3.10E-03 
Bmp6 3.871 up 9.38E-03 
Bmp7 5.545 up 2.06E-04 
Cd44 3.557 up 7.15E-03 
Cda 3.358 up 1.72E-03 
Col6a1 3.052 up 7.21E-04 
Dcn 15.311 up 8.30E-03 
Ddit4l 4.082 up 1.36E-05 
Dtna 4.092 up 2.81E-04 
Enpep 11.362 up 5.56E-03 
F3 13.534 up 8.58E-08 
Fn1 9.771 up 3.49E-05 
Gna14 18.098 up 8.86E-08 
Gt(ROSA)26Sor 3.472 up 1.69E-03 
Hspb8 3.468 up 4.70E-03 
Inhba 11.650 up 1.93E-05 
Ltbp1 3.952 up 1.35E-04 
Ltbp2 4.995 up 2.22E-04 
Nbl1 3.621 up 8.07E-04 
Nefl 4.402 up 4.24E-04 
Ngf 5.696 up 5.09E-04 
Nov 5.620 up 6.23E-06 
Nt5e 15.131 up 9.37E-05 
Papss2 4.089 up 5.21E-03 
Pcdh17 3.965 up 2.03E-03 
Penk 7.451 up 2.10E-04 
Pmepa1 3.388 up 1.34E-03 
Ptgs2 53.168 up 3.13E-06 
Rgcc 3.071 up 8.70E-04 
Sar1b 3.572 up 6.31E-04 
Timp3 4.315 up 2.64E-05 
Tnfrsf11b 6.628 up 4.10E-04 
Adamtsl2 8.499 down 5.28E-04 
Agtr1a 3.617 down 1.19E-03 
Ccnjl 3.120 down 4.82E-03 
Col8a2 5.208 down 2.01E-04 
Gas6 4.033 down 7.81E-03 
Hhip 9.704 down 9.32E-04 
Mgll 3.554 down 1.20E-04 
Ndnf 4.543 down 5.88E-03 
Scara3 3.108 down 9.35E-04 
Selenbp1 5.704 down 1.29E-04 
 
Week 2 
Gene Symbol 
 
Fold change (abs) 
 
Regulation 
(DMM vs. sham) 
 
P-value 
Acvr1 3.015 up 5.87E-05 
Adamts6 3.028 up 8.74E-04 
Agpat9 3.029 up 7.04E-05 
Agtr2 3.688 up 6.44E-03 
Ank 8.336 up 1.06E-07 
Arhgap24 8.050 up 3.31E-11 
Bmp2 9.044 up 3.20E-04 
Bmp6 5.891 up 9.94E-05 
Bmp7 6.863 up 2.79E-06 
Cd44 5.009 up 1.44E-06 
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Cilp 4.251 up 2.57E-03 
Col14a1 4.239 up 3.89E-03 
Dcn 58.593 up 4.40E-05 
Dpysl2 3.401 up 3.84E-08 
Efemp1 8.485 up 4.38E-06 
Enpep 12.170 up 4.06E-06 
F3 8.186 up 2.20E-03 
Fcf1 3.167 up 1.07E-04 
Fn1 6.073 up 2.90E-08 
Gdf6 6.175 up 6.44E-05 
Gjb3 26.314 up 3.65E-08 
Gna14 19.907 up 4.59E-08 
Hoxd10 3.011 up 2.54E-03 
Hspb8 3.180 up 3.63E-05 
Htra1 4.459 up 1.72E-05 
Id2 4.061 up 6.73E-08 
Inhba 15.564 up 5.08E-06 
Jag1 4.501 up 4.31E-05 
Kitl 3.367 up 3.19E-03 
Ltbp1 3.566 up 1.25E-05 
Ltbp2 8.714 up 2.09E-07 
Map1b 6.478 up 1.25E-04 
Nbl1 4.872 up 4.37E-06 
Nedd4l 4.955 up 1.06E-03 
Nedd9 3.226 up 6.44E-04 
Nfatc1 3.651 up 1.18E-04 
Ngf 4.944 up 8.36E-05 
Nov 13.164 up 2.75E-06 
Nt5e 17.635 up 1.63E-08 
Pcsk5 5.079 up 1.76E-05 
Penk 19.513 up 8.16E-08 
Pmepa1 4.285 up 1.16E-07 
Ppp2cb 4.537 up 1.05E-04 
Prkg2 3.700 up 1.06E-03 
Ptgs2 50.611 up 7.73E-11 
Rgcc 5.544 up 1.36E-08 
Rps6ka3 3.950 up 8.33E-04 
Scd1 5.096 up 1.09E-07 
Serpine1 4.069 up 5.22E-03 
Slit2 3.379 up 5.53E-03 
Smad7 6.654 up 3.03E-06 
Smurf2 4.703 up 3.26E-06 
Tgfbi 8.747 up 8.39E-09 
Tgif1 3.744 up 1.40E-04 
Timp3 3.239 up 7.91E-05 
Tmem204 3.748 up 1.49E-06 
Tnfaip6 12.220 up 1.26E-05 
Tnfrsf11b 6.333 up 2.18E-06 
Tnnt2 6.566 up 1.52E-03 
Tspan2 3.865 up 1.62E-04 
Adamtsl2 5.274 down 3.46E-04 
Ccnjl 10.018 down 8.21E-06 
Col8a2 7.032 down 7.78E-09 
Hhip 10.383 down 7.53E-04 
Ibsp 9.333 down 8.29E-08 
Map2k6 3.012 down 4.66E-05 
Myrip 12.545 down 1.68E-06 
Ogn 3.762 down 4.61E-04 
Scara3 3.515 down 6.48E-06 
Selenbp1 10.249 down 2.76E-08 
Thbs4 3.174 down 2.94E-03 
Wif1 3.586 down 4.74E-06 
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Week 6 
Gene Symbol 
 
Fold change (abs) 
 
Regulation 
(DMM vs. sham) 
 
P-value 
Acvr2a 4.477 up 1.03E-04 
Adss 3.422 up 3.38E-03 
Agtr2 5.179 up 6.59E-03 
Ank 5.615 up 1.99E-04 
Arhgap24 5.961 up 1.57E-05 
Bhlhe40 3.389 up 7.28E-05 
Bmpr1b 4.309 up 2.62E-03 
Cd44 3.641 up 2.11E-04 
Cdkn2b 3.599 up 4.16E-03 
Ddah1 3.103 up 3.95E-05 
Dnajb9 3.942 up 3.80E-03 
Dpysl2 3.250 up 7.82E-04 
Enpep 6.167 up 1.97E-03 
Gdf6 21.734 up 4.19E-07 
Gjb3 15.345 up 7.54E-04 
Gna14 33.466 up 7.56E-09 
Gprc5b 3.371 up 6.99E-05 
Hoxd10 3.035 up 7.69E-03 
Inhba 5.547 up 1.40E-04 
Jag1 5.027 up 3.91E-04 
Kif5c 7.399 up 1.04E-06 
Nedd9 3.286 up 1.41E-03 
Ngf 3.082 up 5.20E-04 
Nov 10.575 up 9.41E-05 
Nr2f2 4.450 up 7.97E-05 
Nrip3 3.189 up 2.42E-04 
Nt5e 6.519 up 3.46E-05 
Pdgfra 6.624 up 4.48E-07 
Pkp1 5.452 up 2.79E-05 
Ppa1 3.022 up 2.19E-03 
Ptgs2 124.771 up 2.84E-12 
Rgcc 3.055 up 9.92E-05 
Sar1b 3.134 up 3.54E-04 
Scd1 4.356 up 9.22E-06 
Tgfbi 4.401 up 4.14E-05 
Tmem27 3.482 up 3.52E-03 
Tnfaip6 3.349 up 1.51E-03 
Tnfrsf11b 3.137 up 5.92E-03 
Tnnt2 5.009 up 1.63E-03 
Adamtsl2 5.282 down 2.27E-05 
Amhr2 3.663 down 9.45E-05 
Chac1 5.335 down 4.17E-04 
Col8a2 3.779 down 4.48E-04 
Mgll 3.447 down 5.15E-05 
Ncapg 6.095 down 5.21E-04 
Selenbp1 5.224 down 1.26E-05 
Wipf3 3.229 down 6.67E-05 
Analyses based on Moderated T-test: Fold change ≥ 3 and P ≤ 0.01 
Supplementary Table 2. TGFβ-related genes upregulated or downregulated in DMM compared 
to sham at 1, 2 and 6 weeks post-surgery. 
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Supplementary Figure S1. Regulation of the 25 identified candidate genes in murine OA. 
Relative expression levels of the 25 new candidate genes for OA were determined in 
microdissected murine articular cartilage after sham operation and after OA was induced by 
destabilization of the medial meniscus (DMM). Bars represent gene expression (mean + S.D) in 
sham and DMM at 1, 2 and 6 weeks post-surgery (n=4 mice per timepoint).  
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Articular cartilage has limited regenerative capacity. Lesions in articular cartilage do 
not heal sufficiently and may lead to the degenerative joint disease osteoarthritis (OA). 
A promising treatment is to regenerate cartilage using MSCs. TGFβ can potently induce 
chondrogenic differentiation of MSCs and is known to control the phenotype of 
chondrocytes.
1,2
 It has been suggested that TGFβ-releasing biomaterials could prove 
critical for in vivo cartilage tissue engineering applications in the future.
3
 However, 
cartilage tissue obtained by TGFβ-induced chondrogenesis of MSCs does not resemble 
native articular cartilage, because MSC-derived chondrocytes express genes related to 
chondrocyte hypertrophy.
4-11
 Hypertrophic differentiation of chondrocytes is not only 
an issue in cartilage tissue engineering, but can also strongly influence the integrity of 
articular cartilage as hypertrophy is recognized in OA.
12,13
 The principal components of 
TGFβ signaling are the active form of the TGFβ ligand, the membrane-bound TGFβ 
receptors (or activin receptor-like kinases; ALKs) and the intracellular SMAD proteins. 
As reviewed in chapter 1, these signaling components have an important role in 
chondrogenesis and a loss of or imbalance between them has been associated with 
chondrocyte hypertrophy and the onset of OA. Therefore, TGFβ signaling components 
may be potential therapeutic targets for improvement of MSC chondrogenesis and 
modification of OA pathogenesis. In this thesis we aimed to define the contribution of 
TGFβ receptors and SMAD proteins during TGFβ-induced chondrogenic differentiation 
of bone marrow-derived MSCs. Moreover, the link between TGFβ signaling, 
hypertrophic differentiation of chondrocytes and the onset of OA was investigated in 
order to identify genes involved in both chondrocyte hypertrophy and OA. 
TGFβ seems to be the most efficient ligand to induce chondrogenesis 
Only mimicking the condensation stage of natural chondrogenesis by culturing MSCs in 
3D pellets is not sufficient to induce chondrogenic differentiation of MSCs. MSCs also 
require appropriate stimulation factors to differentiate into chondrocytes. Learning 
from embryonic cartilage development, TGFβ  is commonly used to induce 
chondrogenic differentiation of MSCs. In chapters 2 and 4 we confirmed that TGFβ can 
activate the SMAD2/3 and SMAD1/5/9 signaling pathway in human bone marrow-
derived MSCs. Importantly, the SMAD1/5/9 pathway is highly involved in 
endochondral bone formation; a process wherein chondrocytes undergo hypertrophic 
differentiation after which they transform into bone cells.
14,15
 Next to TGFβ, there are 
other ligands that signal via the SMAD2/3 pathway, such as activin and nodal, and 
ligands that signal via the SMAD1/5/9 pathway, such as bone morphogenetic proteins 
(BMPs) and growth and differentiation factors (GDFs). We have demonstrated in 
chapter 2 that activin can activate the SMAD2/3 pathway without activating the 
SMAD1/5/9 pathway in human MSCs. However, unlike TGFβ, activin did not induce 
chondrogenic differentiation of MSCs, suggesting that activation of only the SMAD2/3 
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pathway is not sufficient to induce chondrogenesis. Moreover, ligands that only 
activate the SMAD1/5/9 pathway, BMPs and GDFs, do not induce chondrogenesis as 
efficiently as TGFβ does.
1,16
 These findings indicate that ligands that activate only the 
SMAD2/3 or SMAD1/5/9 pathway are not suitable alternatives for TGFβ to efficiently 
induce chondrogenic differentiation of MSCs. This is supported by results from chapter 
3 showing that overexpression of single constitutively active (ca) TGFβ receptors 
(either caALK5 or caALK1) does not induce chondrogenesis. Apparently, both the 
SMAD2/3 pathway and the SMAD1/5/9 pathway need to be activated to efficiently 
induce chondrogenic differentiation of MSCs. Since TGFβ does that, it is up until now 
the most efficient ligand to induce chondrogenesis. 
Extra stimulation of TGFβ signaling pathways may enhance chondrogenesis 
In chapters 3 and 4 we found that blocking either ALK5, ALK1, SMAD3 or SMAD4 
during the onset of chondrogenesis strongly inhibited chondrogenic differentiation of 
MSCs. Our results are in line with those of previous studies showing that inhibition of 
activation of the ALK5–SMAD2/3 or the ALK1–SMAD1/5/9 pathway with chemical 
inhibitors blocked chondrogenesis.
6,17-23
 This suggests that SMAD2/3 and SMAD1/5/9 
pathways are both required for TGFβ-induced chondrogenesis. Therefore, extra 
stimulation of both pathways could enhance chondrogenesis. We and others have 
attempted this by stimulating MSCs simultaneously with TGFβ and BMP(s) or GDF(s). 
Despite the combination of TGFβ and a BMP or GDF leads to higher expression of 
markers for chondrogenesis as compared to TGFβ alone, it also results in enhanced 
expression of chondrocyte hypertrophy markers.
16,24-33
 Another option to enhance 
chondrogenesis is to overexpress TGFβ, but high doses of TGFβ might have detrimental 
effects, such as chondrocyte hypertrophy and fibrosis.
34-38
 Therefore, this is not a 
preferential option. Moreover, there are ethical and safety concerns with the use of 
genetic manipulation for clinical application.
39,40
 
TGFβ signaling components have a different role during different stages of 
chondrogenesis 
TGFβ signaling appears to have a distinct role during different stages of natural 
chondrogenesis.
2,14
 The same seems to hold true for in vitro chondrogenesis. As 
described above, from chapters 2 to 4 we learned that the SMAD2/3 and SMAD1/5/9 
pathways are highly important during in vitro induction of chondrogenic differentiation 
of MSCs. However, after chondrogenesis, the SMAD1/5/9 pathway enhances 
hypertrophic differentiation of MSC-derived chondrocytes in vitro, while the SMAD2/3 
pathway inhibits chondrocyte hypertrophy.
6,17
 This suggests a stage-specific role of the 
two TGFβ signaling pathways. As activin activates the SMAD2/3 pathway, but not the 
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SMAD1/5/9 pathway (chapter 2), it would be interesting to investigate in the future 
whether activin can prevent hypertrophic differentiation of MSCs that are already 
induced to chondrogenically differentiate. Perhaps by adding activin or replacing TGFβ 
by activin in the culture medium at later time points after induction of chondrogenic 
differentiation.  
The data demonstrating the stage-specific role of the two TGFβ signaling pathways 
during in vitro chondrogenesis are based on the use of small molecule inhibitors.
6,17
 
However, these small molecules inhibit the phosphorylation of multiple SMAD proteins 
and have off-target effects.
41
 Therefore, additional research should be undertaken to 
further investigate the spatiotemporal role of the specific TGFβ receptors and the 
different SMADs. For example, by employing (cell type-specific; COL2-Cre or agent-
specific; LacO) inducible constructs to knockdown or overexpress one (or a 
combination) of these TGFβ signaling components. This approach is especially desired 
to further determine the specific role of TGFβ signaling components in the induction of 
hypertrophic differentiation as our studies were focused on determining their role 
during the onset of chondrogenesis. 
Targeting mediators of chondrocyte hypertrophy may improve TGFβ-induced 
chondrogenesis and prevent cartilage degeneration in OA 
Hypertrophic differentiation of MSC-derived chondrocytes is a major issue in TGFβ-
induced chondrogenesis. A possible strategy to improve the outcome of MSC 
chondrogenesis is to inhibit hypertrophic differentiation by targeting mediators that 
are directly involved in this process. Such a strategy might also be of interest to block 
cartilage degeneration in OA, because chondrocyte hypertrophy is a hallmark of OA.
13
 
To target mediators of hypertrophy, there are various methods available, such as 
inhibition of indian hedgehog by parathyroid hormone-related protein (PTHrP), 
inhibition of matrix metalloproteinases (MMPs) or inhibition of BMP signaling 
(reviewed elsewhere).
10,42,43
 Additionally, we recently demonstrated that inhibition of 
Wingless/Int (Wnt) signaling during chondrogenic induction of human MSCs leads to 
reduced hypertrophic maturation.
44
 Since the aforementioned strategies all 
suppressed chondrocyte hypertrophy, they seem promising for clinical application. 
However, data on long-term outcome is lacking and hypertrophy was not completely 
absent, while it is absent in primary articular chondrocytes.
10,13,42,44
 Whether inhibition 
of chondrocyte hypertrophy is the most optimal strategy to improve TGFβ-induced 
chondrogenesis and block cartilage degeneration during OA needs to be further 
studied in long-term in vivo experiments. It could also be that the ideal target(s) to 
inhibit chondrocyte hypertrophy has (have) not yet been identified. The genes 
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identified in chapter 5 may be interesting novel targets, because they are regulated 
during OA development as well as during hypertrophic differentiation in the growth 
plate and/or transient embryonic cartilage. Whether these genes are suitable 
therapeutic targets to inhibit chondrocyte hypertrophy during MSC chondrogenesis 
and OA warrants further investigation.  
A possible problem with targeting mediators of hypertrophy during TGFβ-induced 
chondrogenesis is that once in vitro-cultured MSCs start to express markers of 
chondrogenesis, they also start to express markers of hypertrophy. In line with this, in 
chapter 4 we observed that modulation of SMAD2, SMAD3 or SMAD4 did not have an 
effect specifically on hypertrophic differentiation without effects on chondrogenic 
maturation. This supports the need of time/stage-dependent modulation, but this may 
be challenging, especially in a clinical setting. For example, since the speed of 
chondrogenesis varies between donors, it is uncertain when to start or stop the 
modulation. Imperfect timing may affect successful chondrogenic differentiation or 
may be too late to prevent hypertrophic differentiation. This raises the question 
whether it will be possible to obtain stable cartilage by targeting mediators of 
hypertrophy during TGFβ-induced chondrogenesis. 
Options to improve chondrogenesis without targeting the TGFβ signaling pathway 
As the use of TGFβ to induce chondrogenesis is accompanied with undesired off-target 
effects and TGFβ signaling appears to be a difficult therapeutic target to improve 
chondrogenesis, there is a need for suitable alternatives. Recently, our group has 
introduced a novel strategy based on the removal of an anti-chondrogenic factor. 
Knockdown of anti-chondrogenic microRNA-221 successfully induced chondrogenic 
differentiation of human MSCs in the absence of TGFβ. Importantly, the obtained 
cartilage did not show signs of hypertrophic maturation.
45,46
 As is the case for TGFβ, 
also microRNAs may regulate chondrogenesis in a stage-specific manner. By 
characterizing microRNA regulation during in vitro chondrogenic differentiation of 
human MSCs, a recent study has identified differentiation-dependent and 
hypertrophy-related microRNA clusters. These microRNAs may be interesting novel 
targets for controlling the chondrocyte phenotype.
47
 Despite targeting of microRNAs 
may be a promising strategy, there are still several hurdles, such as off-target effects 
and targeted delivery method, that need to be overcome prior to clinical application.
48
 
Another strategy to induce chondrogenesis without exogenous addition of growth 
factors, such as TGFβ, is to apply mechanical compression of MSCs seeded in a 
scaffold.
49-53
 Similarly, this seem to work with low-intensity ultrasound stimulation.
54
 
However, none of these studies provide data on hypertrophic differentiation. Instead 
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of mechanical compression, it may be interesting to overexpress transcription factors 
that are essential for chondrogenesis, such as the SOX trio (SOX5, SOX6, and SOX9). Im 
et al. have developed a scaffold in which particles can be incorporated that deliver 
plasmid DNA containing the SOX trio genes. These particles are slowly released to 
transfect adipose tissue-derived MSCs seeded in the scaffold. They found that this 
scaffold enhances chondrogenic differentiation, while it suppresses hypertrophy in 
vitro. Moreover, it promotes the healing of osteochondral defects in vivo in rabbits.
55
 
This type of gene delivery to control stem cell fate seem interesting for future 
application. Due ethical and safety concerns, it may be very difficult to translate these 
results to human clinical practice.
56
  
Are MSCs as promising for cartilage tissue engineering as they seem? 
Apart from focusing on the TGFβ signaling pathway to improve MSC chondrogenesis, 
the question remains whether MSCs are suitable for the formation of stable articular 
cartilage. MSCs offer several advantages for cartilage regeneration strategies. Besides 
MSC-derived chondrocytes deposit cartilage-like tissue (as shown by deposition of 
collagen type II and proteoglycans in this thesis), MSCs are rather easy to obtain from 
multiple adult tissues, including bone marrow, adipose tissue and synovium, can be 
expanded in vitro whilst retaining their capacity to differentiate into cells of 
mesenchymal tissues and have immunosuppressive properties by secreting trophic 
factors.
57
 In addition, the secretion of trophic factors by MSCs in combination with 
direct cell to cell contact between MSCs and articular chondrocytes (ACs) has been 
shown to improve cartilage formation by ACs and reduce hypertrophy and 
mineralization both in vitro and in vivo.
58-61
  
The advantages of adult MSCs have emerged their application in the clinic to 
regenerate cartilage or treat symptoms of OA.
62
 However, the outcome does not meet 
the clinical expectations.
63,64
 MSCs obtained from adult tissues are a heterogeneous 
population of cells that, depending on the tissue source and age of the patient, have 
variable capacity to differentiate into the chondrogenic lineage.
65-68
 As an alternative, 
fetal MSCs have been introduced, which appear to be an intermediate cell type 
between adult MSCs and embryonic stem cells.
24,69
 In the experiments described in this 
thesis we have predominantly used fetal MSCs, because a high number of cells was 
available from one donor, which differentiated into chondrocytes within 7 days. This 
was preferred in our experiments to reliably test the effect of viral transductions as 
adenoviruses cannot integrate into the cell’s genome. However, as is the case for MSCs 
obtained from adult tissues, chondrogenic differentiation of fetal MSCs is directly 
followed by hypertrophic differentiation (chapter 4).
24
 Collectively, MSC-derived 
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chondrocytes seem to be prone to undergo hypertrophy leading to the development 
of transient cartilage with inferior biomechanical properties compared to native 
articular cartilage.
63
 Despite research findings, including those described in this thesis, 
have provided a better understanding of the molecular and cellular control of 
chondrogenesis, it is not completely understood why fetal and adult MSCs fail to adopt 
the phenotype of articular chondrocytes forming stable cartilage. In chapter 5 we 
generated a list of genes that are regulated by TGFβ in chondrogenic cells based on the 
results of three microarray studies. Interestingly, in this list there are no typical 
markers for chondrocyte hypertrophy, such as expression of COL10, MMP13 and ALP, 
suggesting that TGFβ does not directly regulate expression of these markers in 
chondrogenic cells. If TGFβ is not the direct cause of hypertrophy, it is possible that 
MSCs are predisposed to undergo hypertrophic maturation.  
Next to hypertrophy is the variable outcome of MSC chondrogenesis a major issue for 
cartilage tissue engineering using MSCs. The chondrogenic differentiation capacity of 
MSCs and phenotype of MSC-derived chondrocytes depend on many factors. One of 
these factors is age, as the chondrogenic potential of MSCs declines with age.
70-72
 In 
this thesis, we demonstrated that both TGFβ receptors and the downstream SMAD3 
and SMAD4 proteins are highly important for chondrogenic induction. Interestingly, 
previous work from our group has shown an age-related loss of TGFβ receptors and 
(phosphorylated) SMAD2/3 proteins in cartilage and this coincided with the onset of 
chondrocyte hypertrophy and OA.
73-76
 Based on these findings, it would be interesting 
to determine the effect of aging on the expression of TGFβ signaling components in 
MSCs and whether this negatively affects the chondrogenic potential of MSCs or 
influences the rate of hypertrophic differentiation. Also the tissue source is an 
important factor, as MSCs obtained from different tissue sources show variable 
capacity to differentiate into the chondrogenic lineage. This might be explained by the 
finding that MSCs from different tissues express distinct ranges of growth factors and 
receptors that are involved in chondrogenesis, such as those of TGFβ.
24,77
 For example, 
adipose tissue-derived MSCs have reduced chondrogenic potential due to a lack of 
ALK5 expression, which can be overcome by treatment of these cells with BMP6.
77
 
Additionally, these variations may be caused by differences in the epigenetic 
signature.
78
 The impact of epigenetics, defined as heritable changes in gene expression 
without alterations in the underlying DNA sequence
79
, on MSC chondrogenesis is a 
rather new area of research and deserves more attention in future studies.  
MSCs, although differences exist depending on tissue source, they all seem incapable 
of producing stable hyaline cartilage and their chondrogenic differentiation capacity is 
highly variable between donors.
80
 These disadvantages need to be solved to achieve 
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successful clinical application. A way to overcome the variability is to select 
subpopulation of cells with the highest chondrogenic potential
81
, for example by 
selection of internal
82,83
 or surface
84,85
 markers.  Although this may lead to enhanced 
chondrogenesis, it does not provide information on stable cartilage formation. In fact, 
it still remains to be elucidated why MSCs fail to generate stable cartilage. A possible 
explanation could be a difference in the developmental origin of MSCs and articular 
chondrocytes. If so, then the use of pluripotent stem cells, either embryonic (ESCs) or 
induced (iPSCs), may circumvent this issue.
86
 Because pluripotent stem cells have 
unlimited capacity for self-renewal while maintaining the capacity for chondrogenic 
differentiation, they are of interest as a source for consistently uniform cells with high 
chondrogenic capacity.
87
 Recently, protocols have been developed to generate 
chondrogenic cells from human ESCs
88
 and iPSCs
89
 with high efficiency and purity. 
However, whether the obtained chondrocytes can form functional articular cartilage 
with the same biomechanical properties as native tissue remains to be determined.
90
 
There are also still concerns about the genome integrity of differentiated iPSCs and 
their safety with respect to potential teratoma formation by undifferentiated 
pluripotent stem cells.
87,91
 
Chondrogenesis is regulated by complex interactions between several pathways 
From the studies on embryonic joint formation it has become clear that development 
of articular cartilage is tightly regulated by many distinct molecular regulators that 
induce or inhibit differentiation of MSCs to chondroprogenitors to chondrocytes.
92,93
 
Indeed, members of the TGFβ superfamily, including TGFβ, BMPs and GDFs, are 
essential regulators, but the Wnt and FGF (fibroblast growth factor) signaling pathways 
are important as well.
94-97
 Besides these pathways regulate each other, they regulate 
embryonic chondrogenesis in a spatiotemporal manner. Recent findings have revealed 
that this also holds true during in vitro chondrogenesis. Supplementation of FGF2 
during expansion of MSCs enhances proliferation and chondrogenic potential.
98-101
 In 
contrast, exposure to FGF2, FGF9 or FGF18 during (induction of) chondrogenic 
differentiation inhibits chondrogenesis.
102-104
 When FGF9 or FGF18 are supplemented 
during late chondrogenic differentiation, they delay hypertrophic differentiation.
103,104
 
Also stage-dependent modulation of Wnt signals directs chondrogenic differentiation 
toward a more stable cartilage phenotype. Combining FGF2 with WNT3a during 
expansion promotes proliferation and enhances the chondrogenic potential even 
further than with FGF2 alone. Furthermore, inhibiting Wnt signaling during 
chondrogenic differentiation enhances chondrogenesis and prevents endochondral 
ossification in an in vivo model.
44
 The spatiotemporal role of signaling pathways in 
chondrogenesis and effects on chondrocyte differentiation could explain why in our 
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studies (chapter 3 and 4) continuous knockdown or overexpression of TGFβ signaling 
components had a major impact on chondrogenesis.  
TGFβ activates intracellularly the SMAD2/3 and SMAD1/5/9 pathways. Besides these 
pathways control chondrogenesis in a stage-specific manner, the balance between the 
two pathways regulates the chondrogenic phenotype.
6,105,106
 This is further supporter 
by our finding that continuously enhanced expression levels of SMAD3 and SMAD4 did 
not lead to enhanced chondrogenesis. In fact, overexpression of SMAD3 even inhibited 
chondrogenic differentiation (chapter 4). A possible approach to improve cartilage 
formation by MSCs, as well as to control the altered phenotype of articular 
chondrocytes during OA, is to modulate the balance between the two pathways. 
However, determining the optimal balance to prevent hypertrophic differentiation 
may be difficult as our studies have revealed that TGFβ and its downstream signaling 
components regulate each other’s expression during chondrogenic differentiation. 
Namely, in chapter 3, we found that TGFβ regulates expression of ALK5 and ALK1, and 
ALK5 regulates ALK1 expression. Furthermore, in chapter 4, we showed that 
modulating the expression of SMAD2 affects expression of SMAD3 and SMAD4, and 
knockdown of SMAD4 leads to altered expression of SMAD2 and SMAD3. We also 
demonstrated that TGFβ-activated phosphorylation of SMAD2 and SMAD1/5/9 are 
strongly reduced by SMAD4 knockdown. Our results are consistent with other studies 
which have reported auto-modulation of TGFβ signaling.
107-111
 These findings suggest 
that targeting one component of TGFβ signaling leads to altered expression or 
activation of one or multiple other signaling component(s). Therefore, therapeutic 
targeting of TGFβ signaling to control the chondrocyte phenotype may be a challenge. 
Moreover, the balance between both TGFβ pathways can be altered by other signaling 
pathways that are involved in chondrogenesis, such as Wnt, FGF and MAPK (mitogen-
activated protein kinases).
95,106,112,113
 This adds another level of complexity. These 
signaling pathways can affect the balance between the SMAD2/3 and SMAD1/5/9 
pathways by regulating the expression or activation of SMADs.
95
 This interaction seems 
to be predominantly mediated by phosphorylation of the linker region of SMADs.
106,114
 
However, much remains unknown regarding the relative importance of these linker 
modifications during chondrogenesis and in the development of OA.  
Various external factors influence chondrogenesis 
Since MSCs express markers of hypertrophy simultaneously with markers of 
chondrogenesis, they seem to be predisposed to undergo endochondral ossification 
rather than becoming a stable articular chondrocyte. This predisposition may be 
induced by the currently applied in vitro models to study cartilage tissue engineering, 
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like the 3D pellet model used in the experiments described in this thesis. These in vitro 
models were developed based on chondrogenesis during embryonic endochondral 
bone formation.
115
 However, the past decade it has become clear that cells which 
contribute to endochondral bone formation are derived from a distinct cohort of 
progenitors than cells that will form articular cartilage.
116-118
 Apparently, more 
sophisticated models will be needed, which more closely resemble embryonic 
development of articular cartilage.
63,119
 Such models can be developed in the near 
future, because novel genetic cell lineage tracing techniques and microarray analyses 
have provided new insights into the morphogenesis of articular cartilage during 
embryonic joint development. 
92,93,120
  
Joint formation becomes evident when cells at putative joint sites within the 
uninterrupted cartilaginous anlagen of developing embryonic limbs start to flatten and 
condense, forming an interzone. The interzone consists of two outer zone layers 
adjacent to the epiphyseal end of the future bones and an intermediate zone.
92,93,118,121
 
By selectively isolating cells of the outer interzone and intermediate interzone, a 
recent study has shown that the outer interzone undergoes endochondral ossification, 
forming the subchondral bone, whereas the intermediate interzone will form articular 
cartilage.
93
 While we used the microarray dataset on the interzone layers
93
 to identify 
genes regulated during hypertrophic differentiation in chapter 5, this dataset can also 
be used to identify genes involved in the differentiation of MSCs into articular 
chondrocytes. Future studies should explore whether and how cells from the 
intermediate interzone can form stable hyaline cartilage. To study this in vitro, the 
optimal culture conditions need to be established. 
Chondrogenesis appears to be highly influenced by the cellular microenvironment, 
which involves contacts with surrounding cells and the extracellular matrix, oxygen 
concentration and mechanical stimulation.
92,97
 Apart from a direct effect on the cell, 
these environmental factors have an impact on the molecular signaling pathways in 
the cell. For example, mechanical loading promotes chondrogenic differentiation of 
MSCs
122
 and activates TGFβ signaling in chondrocytes.
123,124
 Moreover, culturing 
chondrocytes under hypoxic conditions leads to enhanced expression of ALK5 and 
ALK1.
125
 Currently, the 3D pellet culture model is the most frequently used model to 
study chondrogenesis. Despite this model allows one to investigate chondrogenic 
differentiation using standard laboratory techniques, it does not take into account all 
the aforementioned microenvironmetal factors.
126,127
 As an alternative, our recently 
introduced osteochondral model can be applied, which appears to provide a favorable 
microenvironment for chondrogenic differentiation of MSCs as chondrogenesis is 
induced without supplementation of TGFβ.
128,129
 Importantly, the most optimal model 
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to induce chondrogenic differentiation of MSCs in such a way that stable cartilage is 
formed and maintained remains to be elucidated.  
Future perspectives  
This thesis has provided novel insights into the contribution of specific TGFβ signaling 
components during chondrogenesis using different ligands and by knockdown and 
overexpression of TGFβ receptors and SMAD proteins. Moreover, by combining several 
microarray databases in an innovative manner, we have identified novel genes 
potentially implicated in chondrocyte hypertrophy and OA. Although direct translation 
of the outcome of our studies towards clinical application is not yet feasible, several 
important clues at the cellular and molecular level for future directions have been 
provided throughout this discussion. An overview is given below. 
Up to now, TGFβ appears to be the most efficient ligand to induce chondrogenic 
differentiation. Importantly, chondrogenesis seems to depend on a delicate balance 
between TGFβ signaling components. Our data have revealed that when modulating 
any of these components, one should take into account that other components of the 
TGFβSMAD pathways can be affected as well. Moreover, the expression of TGFβ 
signaling components are regulated by other signaling pathways, such as Wnt, FGF and 
MAPK.
95,106,112,113
 To better predict the consequences of modulation with signaling 
molecules, more research should be performed on the interactions between these 
molecular pathways.  
Recent studies have shown that the Wnt and FGF signaling pathways regulate 
chondrogenesis in a spatio-temporal manner.
44,99-104
 This holds true for TGFβ signaling 
as well. In our studies continuous interference with TGFβ signaling components had 
predominantly detrimental effects on chondrogenesis. Future studies should 
determine the effects of temporal interference with TGFβ signaling. These 
investigations could lead to more sophisticated culture regimes in which cartilage is 
formed that does not undergo hypertrophy upon implantation. 
As indicated in the introduction, the “joint problem” in MSC chondrogenesis and OA 
pathogenesis is hypertrophic differentiation of chondrocytes. Since TGFβ and its 
downstream signaling components are highly involved in chondrocyte differentiation, 
it is an attractive pathway for intervention. However, the results of this thesis show 
that the mechanism by which TGFβ regulates chondrocyte differentiation is regulated 
at the level of ligand, receptor and intracellular SMAD proteins. In addition, TGFβ 
signaling has beneficial and detrimental effects on chondrogenesis, which highly 
depends on the cellular context. As a result of the complexity that is associated with 
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TGFβ-mediated chondrocyte differentiation, we believe that targeting the TGFβ 
signaling pathway for improvement of MSC chondrogenesis and modification of OA 
pathogenesis is not feasible with our current knowledge. More detailed information is 
needed to determine how the TGFβ signaling components regulate genes that control 
cellular differentiation and maintain the chondrogenic phenotype. Triggered by this 
convention, we think that the candidate genes identified in chapter 5 are potentially a 
good starting point for further investigation. Namely, the proteins encoded by these 
candidate genes could be useful for the manipulation of hypertrophic differentiation of 
MSC-derived chondrocytes and articular chondrocytes in cartilage of OA patients.  
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Summary and conclusions 
Damaged articular cartilage does not heal spontaneously and may lead to 
osteoarthritis 
Articular cartilage covers the surface of bones in joints. This tissue is crucial for the 
reduction of friction between bone ends and the distribution of forces during 
movement. Cartilage mainly consists of extracellular matrix, which is produced and 
maintained by cartilage cells, also called chondrocytes. Damage to this tissue, for 
example as a result of trauma, does not heal and may lead to the degenerative joint 
disease osteoarthritis (OA). The clinical symptoms of OA are joint pain and joint 
stiffness, which are associated with functional impairment and have a major impact on 
quality of life. The exact cause of OA remains unknown. Moreover, no treatment is 
currently available that inhibits or halts the degeneration of cartilage or completely 
repairs damaged cartilage. 
Cartilage regeneration using stem cells is promising, but needs to be improved 
Tissue engineering has emerged as a potential technique to regenerate damaged 
articular cartilage. In a laboratory, cells are induced to form cartilage, which can then 
be implanted in a patient. Mesenchymal stem cells (MSCs) are promising for tissue 
engineering applications, because they are relatively easy to isolate and expand 
compared to articular cartilage-derived chondrocytes, and MSCs can differentiate into 
chondrocytes. 
A problem with the use of MSCs is large variation in the chondrogenic differentiation 
capacity between donors. Another problem is that cartilage tissue formed by MSC-
derived chondrocytes does not have the same composition and properties as native 
articular cartilage. Contrary to articular chondrocytes, MSC-derived chondrocytes 
undergo hypertrophic differentiation. This results in the formation of cartilage that 
resembles growth plate cartilage. In the growth plate, transient cartilage is formed, 
which mineralizes and transforms into bone. This process is needed for the formation 
and longitudinal growth of long bones and is called endochondral ossification. The 
exact cause of hypertrophic differentiation of MSC-derived chondrocytes is not 
completely understood. 
TGFβ has an important role in the differentiation of stem cells and chondrocytes 
To induce chondrogenic differentiation of MSCs, growth factors (also called ligands) 
are needed. A commonly used ligand is Transforming Growth Factor β (TGFβ). It is also 
known that TGFβ is involved in hypertrophic differentiation of chondrocytes. 
Hypertrophic differentiation not only negatively influences the outcome of cartilage 
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tissue engineering, but also the integrity of articular cartilage as it occurs in cartilage of 
OA patients. To improve cartilage regeneration using MSCs and to prevent further 
degeneration of articular cartilage during OA, it is important to better understand the 
factors that govern these processes. The current knowledge on the role of TGFβ 
signaling in chondrogenesis, chondrocyte hypertrophy and the development of OA has 
been reviewed in chapter 1. 
TGFβ signaling is initiated when a TGFβ ligand binds to and activates receptors (Activin 
receptor-Like Kinases; ALKs) on the cell membrane. Subsequently, the receptors 
activate intracellular SMAD proteins. This way, TGFβ can activate two distinct SMAD 
signaling pathways: the SMAD2/3 pathway and SMAD1/5/9 pathway. Activated SMAD 
proteins form a complex with cofactor SMAD4 after which they transduce the signal 
from the cell membrane to the nucleus. In the nucleus, SMAD complexes regulate the 
transcription of specific genes.  
In this thesis, the role of TGFβ signaling during chondrogenic and 
hypertrophic differentiation is investigated  
Previously, it has been shown that the SMAD2/3 pathway induces chondrogenic 
differentiation and inhibits chondrocyte hypertrophy, while the SMAD1/5/9 pathway 
induces hypertrophic differentiation. We wondered whether it would be possible to 
induce chondrogenic differentiation without hypertrophic differentiation when using 
ligands that only activate the SMAD2/3 pathway. The ligands activin and nodal are 
known to activate SMAD2/3 signaling in multiple cell types, but are incapable of 
activating SMAD1/5/9 signaling. In chapter 2, we verified whether activin and nodal 
have a similar effect on SMAD signaling in MSCs and we determined whether these 
ligands can induce chondrogenesis, like TGFβ. Activin did activate SMAD2/3 signaling. 
However, unlike TGFβ, activin did not induce chondrogenesis. Nodal neither activated 
the SMAD2/3 pathway nor induced chondrogenic differentiation of MSCs. These data 
indicate that activin and nodal are not interesting alternative candidates for TGFβ to 
induce chondrogenesis without terminal differentiation. 
The observation that activin does not induce chondrogenic differentiation of MSCs 
suggests that activation of the SMAD2/3 pathway only is not sufficient to induce 
chondrogenesis. Possibly both SMAD pathways are required. TGFβ is known to activate 
the SMAD2/3 pathway via the ALK5 receptor and the SMAD1/5/9 pathway via the 
ALK1 receptor. In chapter 3 it was investigated whether ALK5 and ALK1 are both 
required for chondrogenic differentiation of MSCs. The expression levels of ALK5 and 
ALK1 did not clearly associate with the chondrogenic differentiation capacity of MSCs. 
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We also observed that TGFβ regulated the expression of ALK5 and ALK1 in MSCs, by 
increasing ALK5 and decreasing ALK1 expression. To determine whether TGFβ induces 
chondrogenesis through activation of ALK5 or ALK1, viruses were used to overexpress 
constitutively active (ca) receptors. Overexpression of either caALK5 or caALK1 did not 
induce chondrogenic differentiation as efficient as TGFβ did. Moreover, knockdown of 
either ALK5 or ALK1 expression in MSCs inhibited TGFβ-induced chondrogenesis. Thus, 
both ALK5 and ALK1 are required to induce chondrogenic differentiation of MSCs.  
The above mentioned SMAD2/3 pathway is activated by the ALK5 receptor. 
Importantly, SMAD2 and SMAD3 are two different proteins. A remarkable difference is 
that SMAD2 cannot bind DNA without forming a complex with SMAD4, while SMAD3 
can. It has been shown that SMAD2, SMAD3 and SMAD4 have distinct functions during 
embryonic cartilage development and in cartilage homeostasis. Whether these SMADs 
also have specific functions during chondrogenic differentiation of MSCs was studied in 
chapter 4. We demonstrated that modulating SMAD2 expression only mildly affected 
TGFβ-induced chondrogenesis. Remarkably, both knockdown and overexpression of 
SMAD3 strongly inhibited chondrogenic differentiation of MSCs. While chondrogenesis 
was completely blocked by SMAD4 knockdown, it was not affected by SMAD4 
overexpression. Thus, as chondrogenic differentiation was not enhanced by 
overexpression of SMAD4 and even inhibited by SMAD3 overexpression, induction of 
chondrogenic differentiation of MSCs seems to rely on a delicate balance in the 
amount of SMAD3 and SMAD4 proteins. We concluded that SMAD3 and SMAD4 have a 
more dominant role than SMAD2 during TGFβ-induced chondrogenesis. In addition, 
our findings have revealed that activation of TGFβ signaling is not only limited by 
receptor activity, but also by the abundance of SMADs. 
The studies of chapter 3 and 4 demonstrated that modulation TGFβ signaling 
predominantly disturbs chondrogenic differentiation. Since hypertrophic 
differentiation follows directly after chondrogenic differentiation, it will be difficult to 
specifically manipulate hypertrophy by modulating TGFβ signaling. In chapter 5 we 
introduced a sophisticated approach with which potential therapeutic targets for 
chondrocyte hypertrophy and OA pathology were identified. First, we compiled a list of 
TGFβ-related genes. Then, we determined which of these TGFβ-related genes were 
regulated in a murine model for OA as well as during chondrocyte hypertrophy in 
murine growth plates and/or embryonic cartilage during endochondral ossification. 
This was determined by using datasets from microarrays (a technique in which the 
expression of thousands of genes can be measured in one sample) that were 
performed in previous studies. A total of 106 TGFβ-related genes were regulated in 
articular cartilage of mice in which OA was induced. From the 106 genes regulated in 
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murine OA, 43 genes were similarly regulated during chondrocyte hypertrophy in the 
growth plate and/or in embryonic cartilage undergoing endochondral ossification. 
These 43 genes were further studied in the literature and we found that 18 genes were 
already associated with OA. Therefore, the remaining 25 genes are novel candidate 
genes that are regulated during OA and chondrocyte hypertrophy. In addition, in the 
supplementary data of available microarray datasets we found that 15 of these 25 
genes were regulated in articular cartilage of OA patients compared to intact articular 
cartilage. This makes these genes of particular interest for further study their role in 
OA pathology. Modulation of these genes may be a novel therapeutic strategy to 
inhibit hypertrophic differentiation of chondrocytes.  
The conclusions of this thesis 
Since TGFβ signaling has an important role during differentiation of MSCs and 
chondrocytes, it is an potential therapeutic target for improvement of chondrogenic 
differentiation of MSCs and treatment of cartilage degeneration in OA patients. The 
results described in this thesis have shown that continuous modulation (knockdown or 
overexpression) of TGFβ signaling in MSCs has predominantly negative effects on 
chondrogenesis. Perhaps temporal modulation is required instead of continuous 
modulation. However, it will be difficult to determine the exact timing of modulation, 
because the timing of chondrogenic differentiation of MSCs is variable between 
donors. Moreover, our data has demonstrated that the signaling mechanism by which 
TGFβ regulates chondrogenesis is regulated at the levels of ligand, receptor and SMAD 
proteins. When modulating a component of TGFβ signaling at one of these levels, it 
may lead to altered expression of other components. After discussing the findings in 
chapter 6, I conclude that the current knowledge on improving chondrogenesis, 
preventing hypertrophy and maintaining the articular chondrocyte phenotype by 
modulation of TGFβ signaling is not sufficient. In the future, focusing on the regulation 
of TGFβ-related genes may lead to the identification of interesting novel targets to 
improve cartilage regeneration using MSCs and halt degeneration of cartilage during 
osteoarthritis.  
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Samenvatting en conclusies 
Schade aan het gewrichtskraakbeen herstelt niet en kan leiden tot artrose 
Articulair kraakbeen (alias gewrichtskraakbeen) bedekt het uiteinde van botten in 
gewrichten. Dit weefsel is belangrijk voor vermindering van wrijving tussen 
botuiteinden en verdeling van de drukkrachten die ontstaan tijdens bewegen. 
Kraakbeen bestaat vooral uit extracellulaire matrix. Dit wordt geproduceerd en 
onderhouden door kraakbeencellen, ook wel chondrocyten genoemd. Als het 
kraakbeen beschadigd raakt, bijvoorbeeld door trauma, herstelt het zich slecht. 
Hierdoor kan de schade over tijd verergeren en zelfs leiden tot degeneratie van het 
kraakbeen, oftewel artrose of osteoartritis (afgekort OA) genoemd. Deze 
gewrichtsziekte gaat gepaard met pijn, stijfheid en belemmering van beweging welke 
een behoorlijke impact op de kwaliteit van leven hebben. Hoe OA precies ontstaat is 
nog onbekend. Bovendien is er momenteel nog geen ideale behandelmethode om 
degeneratie van kraakbeen te remmen of te stoppen of om beschadigd kraakbeen te 
herstellen.  
Kraakbeenregeneratie met stamcellen is veelbelovend, maar moet verbeterd worden 
Een potentiële techniek om degeneratie tegen te gaan, is het herstellen van de 
kraakbeenschade door kraakbeen te regenereren met tissue engineering. Hierbij 
worden cellen in een laboratorium aangezet tot het maken van kraakbeen (ook wel 
chondrogenese genoemd) en het gevormde weefsel kan worden geïmplanteerd in een 
patiënt. Mesenchymale stamcellen (MSC) zijn veelbelovend om te gebruiken voor 
kraakbeen tissue engineering, omdat ze relatief makkelijker te isoleren en te 
vermenigvuldigen zijn dan chondrocyten uit articulair kraakbeen en MSC kunnen 
differentiëren tot chondrocyten. 
Een probleem met het gebruik van MSC is de grote variatie in de chondrogene 
differentiatie capaciteit tussen donoren. Een ander groot probleem is dat het 
kraakbeen van MSC-afkomstige chondrocyten niet exact dezelfde samenstelling en 
eigenschappen heeft als articulair kraakbeen. In tegenstelling tot articulaire 
chondrocyten ondergaan MSC-afkomstige chondrocyten hypertrofe differentiatie. 
Hierdoor wordt kraakbeen gevormd dat lijkt op het kraakbeen van de groeischijf. De 
groeischijf bestaat uit ‘tijdelijk kraakbeen’ dat verkalkt/mineraliseert en wordt 
omgezet in bot. Dit proces heet endochondrale ossificatie (verbening) en is nodig voor 
de vorming en lengtegroei van de lange beenderen. De precieze oorzaak van 
hypertrofe differentiatie van MSC-afkomstige chondrocyten is nog onduidelijk. 
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TGFβ heeft een belangrijke rol in de differentiatie van stamcellen en chondrocyten  
Om chondrogene differentiatie van MSC te induceren, zijn groeifactoren (ook wel 
liganden genoemd) nodig. Het meest gebruikte ligand hiervoor is Transforming Growth 
Factor β (TGFβ). Ook is bekend dat TGFβ betrokken is bij hypertrofe differentiatie van 
chondrocyten. Hypertrofe differentiatie is niet alleen een probleem tijdens kraakbeen 
tissue engineering, maar ook voor het behoud van articulair kraakbeen. Het is namelijk 
geobserveerd in kraakbeen van patiënten met OA. Om kraakbeenregeneratie door 
MSC te verbeteren en verdere degeneratie van het articulair kraakbeen tijdens OA te 
voorkomen, is het van belang om de factoren die deze processen beheren beter te 
begrijpen. In hoofdstuk 1 is een overzicht gegeven van de huidige kennis over de 
betrokkenheid van TGFβ signalering tijdens zowel chondrogene als hypertrofe 
differentiatie en het ontstaan van OA. 
TGFβ signalering wordt geïnitieerd wanneer een TGFβ ligand aan receptoren (Activin 
receptor-Like Kinases of afgekort ALKs) op het celmembraan bindt. Hierdoor worden 
de receptoren actief, waardoor ze vervolgens intracellulaire SMAD eiwitten activeren. 
Op deze manier kan TGFβ twee verschillende SMAD signaal routes activeren: de 
SMAD2/3 route en de SMAD1/5/9 route. Na activatie vormen deze SMAD eiwitten een 
complex met cofactor SMAD4, waarna ze het signaal van het celmembraan naar de 
celkern brengen. In de celkern reguleren de SMAD complexen de transcriptie van 
specifieke genen. 
In dit proefschrift is de rol van TGFβ signalering tijdens chondrogene en 
hypertrofe differentiatie onderzocht 
Eerder is aangetoond dat de SMAD2/3 route belangrijk is voor chondrogene 
differentiatie en hypertrofie van chondrocyten remt, terwijl de SMAD1/5/9 route juist 
hypertrofe differentiatie induceert. Hierdoor vroegen wij ons af of het mogelijk is om 
met liganden die specifiek de SMAD2/3 route activeren chondrogene differentiatie van 
MSC te induceren zonder hypertrofe differentiatie. Activine en nodal zijn liganden 
waarvan bekend is dat ze in verschillende celtypes wel de SMAD2/3 route activeren, 
maar niet de SMAD1/5/9 route. In hoofdstuk 2 hebben we geverifieerd of dit ook het 
geval is voor MSC en we hebben onderzocht of activine en nodal chondrogenese 
konden induceren. Activine activeerde inderdaad alleen de SMAD2/3 route. Echter, in 
tegenstelling tot TGFβ, kon activine geen chondrogenese induceren. Nodal kon noch 
SMAD2/3 signalering activeren noch chondrogene differentiatie van MSC induceren. 
Deze data tonen aan dat activine en nodal geen interessante alternatieve liganden zijn 
voor TGFβ om chondrogenese te induceren. 
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Dat activine geen chondrogene differentiatie van MSC induceerde, suggereert dat 
enkel activatie van de SMAD2/3 route niet voldoende is om chondrogenese te 
induceren. Mogelijk zijn beide SMAD routes nodig. Het is bekend dat TGFβ de 
SMAD2/3 route activeert via de ALK5 receptor en de SMAD1/5/9 route via de ALK1 
receptor. In hoofdstuk 3 is onderzocht of beide TGFβ receptoren, ALK5 en ALK1, nodig 
zijn voor chondrogene differentiatie van MSC. De mate van expressie van ALK5 en 
ALK1 was niet geassocieerd met de chondrogene differentiatie capaciteit van MSC. 
Ook viel het ons op dat TGFβ de expressie van ALK5 en ALK1 reguleerde in MSC, 
waarbij de expressie van ALK5 verhoogd werd en de expressie van ALK1 verlaagd. Om 
te bepalen of TGFβ chondrogene differentiatie van MSC induceert via ALK5 of via ALK1 
is gebruik gemaakt van virussen die constant actieve (ca) receptoren tot overexpressie 
brachten. Alleen caALK5 overexpressie of alleen caALK1 overexpressie leidde in beide 
gevallen niet tot chondrogene differentiatie zoals dat geïnduceerd werd door TGFβ. 
Bovendien resulteerde verlaging van de expressie van ALK5 of ALK1 in sterk 
verminderde TGFβ-geïnduceerde chondrogene differentiatie van MSC. Zowel ALK5 als 
ALK1 zijn dus nodig om chondrogenese in MSC te induceren. 
De eerder genoemde SMAD2/3 route wordt door de ALK5 receptor geactiveerd. Een 
belangrijk gegeven hierbij is dat SMAD2 en SMAD3 verschillende eiwitten zijn. Een 
opvallend verschil is dat SMAD2 niet aan DNA kan binden zonder een complex te 
hebben gevormd met SMAD4, terwijl SMAD3 dit wel kan. Het is bekend dat SMAD2, 
SMAD3 en SMAD4 verschillende functies hebben tijdens embryonale kraakbeen 
ontwikkeling en in kraakbeen homeostase. Of deze SMAD eiwitten ook specifieke 
functies hebben tijdens chondrogene differentiatie van MSC is bestudeerd in 
hoofdstuk 4. We laten zien dat het moduleren van SMAD2 expressie nauwelijks een 
effect had op TGFβ-geïnduceerde chondrogenese. Zowel knockdown als overexpressie 
van SMAD3 resulteerden in sterk verminderde chondrogene differentiatie van MSC. 
Hoewel chondrogenese volledig was geblokkeerd door knockdown van SMAD4, was 
het niet verstoord door overexpressie van SMAD4. Gezien chondrogene differentiatie 
niet verbeterde door overexpressie van SMAD4 en zelfs geremd werd door 
overexpressie van SMAD3, hangt het dus af van een balans tussen de hoeveelheid 
SMAD3 en SMAD4 eiwitten. Ook concluderen we dat SMAD3 en SMAD4 een 
belangrijkere rol hebben dan SMAD2 tijdens TGFβ-geïnduceerde chondrogenese. 
Tevens bleek uit onze experimenten dat de activatie van TGFβ signalering mogelijk niet 
alleen beperkt wordt door de hoeveelheid receptor activiteit, maar ook door de 
hoeveelheid SMAD eiwitten.  
Uit de studies van hoofdstuk 3 en 4 bleek dat het moduleren van TGFβ signalering de 
chondrogene differentiatie verstoorde. Omdat hypertrofe differentiatie volgt na 
 169 
chondrogene differentiatie, zal het lastig zijn om specifiek hypertrofie te manipuleren 
door modulatie van TGFβ signalering. In hoofdstuk 5 hebben we een geavanceerde 
manier beschreven waarmee mogelijke therapeutische targets voor hypertrofie en OA 
pathologie werden geïdentificeerd. Eerst is een lijst van TGFβ-gerelateerde genen 
opgesteld. Vervolgens is bepaald welke TGFβ-gerelateerde genen zowel gereguleerd 
werden tijdens ontwikkeling van OA in een muismodel als tijdens hypertrofe 
differentiatie van chondrocyten in de groeischijf van jonge muizen en/of in embryonaal 
kraakbeen tijdens endochondrale ossificatie. Hierbij hebben we gebruik gemaakt van 
microarray datasets (een techniek waarbij de expressie van duizenden genen 
tegelijkertijd in een sample gemeten wordt) met gegevens die waren verzameld in 
vorige studies. In totaal werden 106 TGFβ-gerelateerde genen gereguleerd in articulair 
kraakbeen van muizen waarin OA was geïnduceerd. Van de 106 genen werden 43 
genen ook gereguleerd tijdens hypertrofe differentiatie van chondrocyten in de 
groeischijf en/of in embryonaal kraakbeen tijdens endochondrale ossificatie. 
Vervolgens hebben we in de literatuur gevonden dat 18 van deze 43 genen al 
beschreven zijn in relatie met OA. De overige 25 zijn nieuwe kandidaat genen die 
gereguleerd worden bij zowel OA als hypertrofie van chondrocyten. Verder hebben we 
in online beschikbare microarray datasets gevonden dat 15 van deze 25 genen 
gereguleerd worden in articulair kraakbeen van OA patiënten vergeleken met intact 
articulair kraakbeen. Dit maakt het extra interessant om de rol van deze genen in OA 
pathologie verder te bestuderen. Modulatie van deze genen zou een nieuwe 
therapeutische strategie kunnen zijn om hypertrofie van chondrocyten tegen te gaan. 
De conclusies van dit proefschrift  
Gezien TGFβ signalering een belangrijke rol heeft bij zowel de differentiatie van 
stamcellen als van chondrocyten is het een potentiële target voor verbetering van 
chondrogene differentiatie van MSC en voor het behandelen van 
kraakbeendegeneratie in OA patiënten. De resultaten beschreven in dit proefschrift 
tonen aan dat continue modulatie (knockdown of overexpressie) van TGFβ signalering 
in MSC vooral gepaard gaat met negatieve effecten op chondrogenese. In plaats van 
continue modulatie zou tijdelijke modulatie mogelijk wel een positieve werking op 
chondrogenese kunnen hebben. Echter de juiste timing van tijdelijke modulatie is 
moeilijk vast te stellen, omdat het tijdsverloop van chondrogene differentiatie van 
MSC variabel is tussen donoren. Tevens laten we zien dat het signaleringsmechanisme 
waarmee TGFβ chondrogenese aanstuurt, gereguleerd wordt op het niveau van ligand, 
receptor én SMAD eiwitten. Wanneer op één van deze niveaus een component 
gemoduleerd wordt, kan dit leiden tot veranderde expressie van andere 
componenten. Na de bevindingen bediscussieerd te hebben in hoofdstuk 6 is mijn 
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conclusie dat er momenteel nog niet voldoende kennis is om met modulatie van TGFβ 
signalering chondrogenese te verbeteren, hypertrofie te voorkomen en het fenotype 
van articulaire chondrocyten te behouden. Focussen op regulatie van TGFβ-
gerelateerde genen zou in toekomstige studies interessante targets kunnen opleveren 
om kraakbeenregeneratie met MSC te verbeteren en de degeneratie van kraakbeen 
tijdens OA te stoppen. 
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Award 
A. van den Hooff award for best debater (Annual meeting of the NVMB, May 2015) 
 
Scholarship 
Travel grant (€500) to attend the World Congress of the ICRS (May 2015) 
 
Attended workshop 
Thermo Fisher Scientific Basic Real-Time PCR training tour (18 September 2014) 
 
Courses 
Entrepreneurship and Innovation for PhD students (3 ECTS) 
Scientific Writing for PhD candidates (3 ECTS) 
Management voor Promovendi (2 ECTS) 
Opfriscursus Statistiek met SPSS (2 ECTS) 
Presenteren Eigen Onderzoek (1.5 ECTS) 
Perfecting your Academic Writing Skills (1.5 ECTS) 
Achieving your goals and performing more successfully in your PhD (1.5 ECTS) 
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Research data management 
Findable 
The (meta)data of the results described in this thesis can be identified as 
deKroon_ALKproject and is stored at the department of Experimental Rheumatology of 
the Radboud university medical center.  
Accessible 
The (meta)data are available according to a standardized communications protocol, 
which can be obtained upon request from the department of Experimental 
Rheumatology of the Radboud university medical center. 
Interoperable 
The (meta)data are documented in English according to the FAIR principles and include 
qualified references to other (meta)data. 
Reusable 
The (meta)data are sufficiently documented to be reusable. 
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